

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

---



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 367 566 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**14.05.1997 Bulletin 1997/20**

(51) Int Cl.<sup>6</sup>: **C12N 15/12, C12N 15/62,  
C12P 21/02, A61K 38/37,  
C07K 14/435, C12P 21/08**

(21) Application number: **89311244.1**

(22) Date of filing: **31.10.1989**

### (54) Interleukin-4 receptors

Interleukin-4-Rezeptoren

Récepteurs d'interleukine-4

(84) Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**

(30) Priority: **31.10.1988 US 265047  
02.03.1989 US 319438  
20.03.1989 US 326156  
23.06.1989 US 370924**

(43) Date of publication of application:  
**09.05.1990 Bulletin 1990/19**

(73) Proprietor: **IMMUNEX CORPORATION  
Seattle Washington 98101 (US)**

(72) Inventors:

- **Cosman, David J.**  
**Bainbridge Island WA 98110 (US)**
- **Park, Linda**  
**Seattle Washington 98107 (US)**
- **Mosley, Bruce**  
**Seattle Washington 98125 (US)**
- **Beckmann, Patricia**  
**Poulsbo Washington 98370 (US)**
- **March, Carl J.**  
**Seattle Washington 98106 (US)**
- **Idzerda, Rejean**  
**Seattle Washington 98125 (US)**

(74) Representative: **Sheard, Andrew Gregory et al  
Kilburn & Strode  
30, John Street  
London WC1N 2DD (GB)**

(56) References cited:  
**WO-A-89/09621**

- **IMMUNOLOGY**, vol. 54, 1985, pages 745-754;  
**R.A. DE MAAGD et al.**: "The human thymus  
microenvironment: heterogeneity detected by  
monoclonal anti-epithelial cell antibodies"
- **IMMUNOLOGY**, vol. 65, 1988, pages 617-622; **M.  
LARCHE et al.**: "functional evidence for a  
monoclonal antibody that binds to the human  
IL-4 receptor"
- **IMMUNOLOGY**, vol. 64, 1988, pages 101-105; **M.  
LARCHE et al.**
- **PROC. NATL. ACAD. SCI. USA**, vol. 84, March  
1987, pages 1669-1673; **L.S. PARK et al.**:  
"Characterization of the high-affinity  
cell-surface receptor for murine B-  
cell-stimulating factor I"
- **NATURE**, vol. 325, 5th February 1987, pages  
537-540; **J. OHARA et al.**: "Receptors for B-cell  
stimulatory factor-1 expressed on cells of  
haematopoietic lineage"
- **Inami et al. (1994)**, *Int. Immunol.*, 6(10),  
p.1575-1584.
- **Kaklamanis et al. (1992)**, *British J. Cancer*, 66,  
p.711-716.

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 367 566 B1**

## Description

The present invention relates generally to cytokine receptors and, more specifically, to Interleukin-4 receptors.

Interleukin-4 (IL-4, also known as B cell stimulating factor, or BSF-1) was originally characterized by its ability to stimulate the proliferation of B cells in response to low concentrations of antibodies directed to surface immunoglobulin. More recently, IL-4 has been shown to possess a far broader spectrum of biological activities, including growth co-stimulation of T cells, mast cells, granulocytes, megakaryocytes, and erythrocytes. In addition, IL-4 stimulates the proliferation of several IL-2- and IL-3-dependent cell lines, induces the expression of class II major histocompatibility complex molecules on resting B cells, and enhances the secretion of IgE and IgG1 isotypes by stimulated B cells. Both murine and human IL-4 have been definitively characterized by recombinant DNA technology and by purification to homogeneity of the natural murine protein (Yokota et al., *Proc. Natl. Acad. Sci. USA* 83:5894, 1986; Noma et al., *Nature* 319:640, and Grabstein et al., *J. Exp. Med.* 163:1405, 1986).

The biological activities of IL-4 are mediated by specific cell surface receptors for IL-4 which are expressed on primary cells and *in vitro* cell lines of mammalian origin. IL-4 binds to the receptor, which then transduces a biological signal to various immune effector cells. Purified IL-4 receptor (IL-4R) compositions will therefore be useful in diagnostic assays for IL-4 or IL-4 receptor, and in raising antibodies to IL-4 receptor for use in diagnosis or therapy. In addition, purified IL-4 receptor compositions may be used directly in therapy to bind or scavenge IL-4, providing a means for regulating the biological activities of this cytokine.

Although IL-4 has been extensively characterized, little progress has been made in characterizing its receptor. Numerous studies documenting the existence of an IL-4 receptor on a wide range of cell types have been published; however, structural characterization has been limited to estimates of the molecular weight of the protein as determined by SDS-PAGE analysis of covalent complexes formed by chemical cross-linking between the receptor and radiolabeled IL-4 molecules. Ohara et al. (*Nature* 325:537, 1987) and Park et al. (*Proc. Natl. Acad. Sci. USA* 84:1669, 1987) first established the presence of an IL-4 receptor using radioiodinated recombinant murine IL-4 to bind a high affinity receptor expressed in low numbers on B and T lymphocytes and a wide range of cells of the hematopoietic lineage. By affinity cross-linking  $^{125}\text{I}$ -IL-4 to IL-4R, Ohara et al. and Park et al. identified receptor proteins having apparent molecular weights of 60,000 and 75,000 daltons, respectively. It is possible that the small receptor size observed on the murine cells represents a proteolytically cleaved fragment of the native receptor. Subsequent experiments by Park et al. (*J. Exp. Med.* 166:476, 1987) using yeast-derived recombinant human IL-4 radiolabeled with  $^{125}\text{I}$  showed that human IL-4 receptor is present not only on cell lines of B, T, and hematopoietic cell lineages, but is also found on human fibroblasts and cells of epithelial and endothelial origin. IL-4 receptors have since been shown to be present on other cell lines, including CBA/N splenic B cells (Nakajima et al., *J. Immunol.* 139:774, 1987), Burkitt lymphoma Jijoye cells (Cabrillat et al., *Biochem. & Biophys. Res. Commun.* 149:995, 1987), a wide variety of hemopoietic and nonhemopoietic cells (Lowenthal et al., *J. Immunol.* 140:456, 1988), and murine Lyt-2<sup>+</sup>/L3T4<sup>+</sup> thymocytes. More recently, Park et al. (UCLA Symposia, *J. Cell Biol.*, Suppl. 12A, 1988) reported that, in the presence of sufficient protease inhibitors,  $^{125}\text{I}$ -IL-4-binding plasma membrane receptors of 138-145 kDa could be identified on several murine cell lines. Considerable controversy thus remains regarding the actual size and structure of IL-4 receptors.

Further study of the structure and biological characteristics of IL-4 receptors and the role played by IL-4 receptors in the responses of various cell populations to IL-4 or other cytokine stimulation, or of the methods of using IL-4 receptors effectively in therapy, diagnosis, or assay, has not been possible because of the difficulty in obtaining sufficient quantities of purified IL-4 receptor. No cell lines have previously been known to express high levels of IL-4 receptors constitutively and continuously, and in cell lines known to express detectable levels of IL-4 receptor, the level of expression is generally limited to less than about 2000 receptors per cell. Thus, efforts to purify the IL-4 receptor molecule for use in biochemical analysis or to clone and express mammalian genes encoding IL-4 receptor have been impeded by lack of purified receptor and a suitable source of receptor mRNA.

The present invention provides DNA sequences encoding polypeptides capable of binding mammalian interleukin-4 as described in claims 1 to 9 (apart from the claims for Spain, where processes comprising the step of isolating such DNA sequences are described in claims 1 to 9). The present invention also provides recombinant expression vectors comprising the DNA sequences defined above, host cells transfected with the recombinant expression vectors, recombinant IL-4R molecules produced using the recombinant expression vectors, and processes for producing the recombinant IL-4R molecules using the expression vectors.

The present invention also provides a purified polypeptide capable of binding mammalian interleukin-4 protein as described in claims 13 to 23 (apart from the claims for Spain and Greece, where processes for preparing such a polypeptide are described in claims 11 to 23). The full length murine IL-4R molecule is a glycoprotein having a molecular weight of about 130,000 to about 140,000 M<sub>r</sub> by SDS-PAGE. The apparent binding affinity ( $K_a$ ) for COS cells transfected with murine IL-4 receptor clones 16 and 18 from the CTLL 19.4 library is 1 to 8 x 10<sup>9</sup> M<sup>-1</sup>. The  $K_a$  for COS cells transfected with murine IL-4 receptor clones 7B9-2 and 7B9-4 from the murine 7B9 library is 2 x 10<sup>9</sup> to 1 x 10<sup>10</sup> M<sup>-1</sup>. The mature murine IL-4 receptor molecule has an N-terminal amino acid sequence as follows:

IKVLGEPTCFSDYIRTSCEW.

The human IL-4R molecule is believed to have a molecular weight of between about 110,000 and 150,000 M<sub>r</sub>, and has an N-terminal amino acid sequence, predicted from the cDNA sequence and by analogy to the biochemically determined N-terminal sequence of the mature murine protein, as follows: MKVLQEPTCVSDYMSISTCEW.

The present invention also provides compositions for use in therapy, diagnosis, assay of IL-4 receptor, or in raising antibodies to IL-4 receptors, comprising effective quantities of soluble receptor proteins prepared according to the foregoing processes. Such soluble recombinant receptor molecules include truncated proteins wherein regions of the receptor molecule not required for IL-4 binding have been deleted. These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. The invention will now be described by way of example with reference to the accompanying drawings, in which:

Figure 1 shows restriction maps of cDNA clones containing the coding regions (denoted by a bar) of the murine and human IL-4R cDNAs. The restriction sites *EcoRI*, *PvuII*, *HincII* and *SstI* are represented by the letters R, P, H and S, respectively.

Figures 2A-C depict the cDNA sequence and the derived amino acid sequence of the coding region of a murine IL-4 receptor, as derived from clone 7B9-2 of the 7B9 library. The N-terminal isoleucine of the mature protein is designated amino acid number 1. The coding region of the full-length membrane-bound protein from clone 7B9-2 is defined by amino acids 1-785. The ATC codon specifying the isoleucine residue constituting the mature N-terminus is underlined at position 1 of the protein sequence; the putative transmembrane region at amino acids 209-232 is also underlined. The sequences of the coding regions of clones 7B9-4 and clones CTLL-18 and CTLL-16 of the CTLL 19.4 library are identical to that of 7B9-2 except as follows. The coding region of CTLL-16 encodes a membrane-bound IL-4-binding receptor defined by amino acids -25 through 233 (including the putative 25 amino acid signal peptide sequence), but is followed by a TAG terminator codon (not shown) which ends the open reading frame. The nucleic acid sequence indicates the presence of a splice donor site at this position (indicated by an arrow in Figure 1) and a splice acceptor site near the 3' end (indicated by a second arrow), suggesting that CTLL-16 was derived from an unspliced mRNA intermediate. Clones 7B9-4 and CTLL-18 encode amino acids 23 through 199 and -25 through 199, respectively. After amino acid 199, a 114-base pair insert (identical in both clones and shown by an open box in Figure 1) introduces six new amino acids, followed by a termination codon. This form of the receptor is soluble.

Figure 3 is a schematic illustration of the mammalian high expression plasmid pCAV/NOT, which is described in greater detail in Example 8.

Figures 4A-C depict the coding sequence of a human IL-4 receptor cDNA from clone T22-8, which was obtained from a cDNA library derived from the T cell line T22. The predicted N-terminal methionine of the mature protein and the transmembrane region are underlined.

Figures 5A-B are a comparison of the predicted amino acid sequences of human (top line) and murine (bottom line) IL-4 receptor cDNA clones.

### Definitions

As used herein, the terms "IL-4 receptor" and "IL-4R" refer to proteins having amino acid sequences which are substantially similar to the native mammalian Interleukin-4 receptor amino acid sequences disclosed in Figures 2 and 4, and which are biologically active as defined below, in that they are capable of binding Interleukin-4 (IL-4) molecules or transducing a biological signal initiated by an IL-4 molecule binding to a cell, or cross-reacting with anti-IL-4R antibodies raised against IL-4R from natural (i.e., nonrecombinant) sources. The native murine IL-4 receptor molecule is thought to have an apparent molecular weight by SDS-PAGE of about 140 kilodaltons (kDa). The terms "IL-4 receptor" or "IL-4R" include, but are not limited to, analogs or subunits of native proteins having at least 20 amino acids and which exhibit at least some biological activity in common with IL-4R. As used throughout the specification, the term "mature" means a protein expressed in a form lacking a leader sequence as may be present in full-length transcripts of a native gene. Various bioequivalent protein and amino acid analogs are described in detail below.

The term "substantially similar," when used to define either amino acid or nucleic acid sequences, means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which is to retain biological activity of the IL-4R protein. Alternatively, nucleic acid subunits and analogs are "substantially similar" to the specific DNA sequences disclosed herein if: (a) the DNA sequence is derived from the coding region of a native mammalian IL-4R gene; (b) the DNA sequence is capable of hybridization to DNA sequences of (a) under moderately stringent conditions and which encode biologically active IL-4R molecules; or DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b) and which encode biologically active IL-4R molecules. Substantially similar analog proteins may be greater than about 30 percent similar to the corresponding sequence of the native IL-4R. Sequences having lesser degrees of similarity but comparable biological activity are considered to be equivalents. More preferably, the analog proteins will be greater than about 80 percent similar to the corresponding sequence of the native IL-4R, in which case

they are defined as being "substantially identical." In defining nucleic acid sequences, all subject nucleic acid sequences capable of encoding substantially similar amino acid sequences are considered substantially similar to a reference nucleic acid sequence. Percent similarity may be determined, for example, by comparing sequence information using the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443, 1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482, 1981). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted comparison matrix of Gribkov and Burgess, *Nucl. Acids Res.* 14:6745, 1986, as described by Schwartz and Dayhoff, ed., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, pp. 353-358, 1979; (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

"Recombinant," as used herein, means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems. "Microbial" refers to recombinant proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a protein produced in a microbial expression system which is essentially free of native endogenous substances. Protein expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycan. Protein expressed in yeast may have a glycosylation pattern different from that expressed in mammalian cells.

"Biologically active," as used throughout the specification as a characteristic of IL-4 receptors, means that a particular molecule shares sufficient amino acid sequence similarity with the embodiments of the present invention disclosed herein to be capable of binding detectable quantities of IL-4, transmitting an IL-4 stimulus to a cell, for example, as a component of a hybrid receptor construct, or cross-reacting with anti-IL-4R antibodies raised against IL-4R from natural (i.e., nonrecombinant) sources. Preferably, biologically active IL-4 receptors within the scope of the present invention are capable of binding greater than 0.1 nmoles IL-4 per nmole receptor, and most preferably, greater than 0.5 nmole IL-4 per nmole receptor in standard binding assays (see below).

"DNA sequence" refers to a DNA molecule, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the sequence and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such sequences are preferably provided in the form of an open reading frame uninterrupted by internal non-translated sequences, or introns, which are typically present in eukaryotic genes. Genomic DNA containing the relevant sequences could also be used. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions. The sequences are preferably at least 60 bases long.

"Nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. DNA sequences encoding the proteins provided by this invention can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit.

"Recombinant expression vector" refers to a replicable DNA construct used either to amplify or to express DNA which encodes IL-4R and which includes a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences. Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.

"Recombinant microbial expression system" means a substantially homogeneous monoculture of suitable host microorganisms, for example, bacteria such as *E. coli* or yeast such as *S. cerevisiae*, which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid. Generally, cells constituting the system are the progeny of a single ancestral transformant. Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA sequence or synthetic gene to be expressed.

## Proteins and Analogs

The present invention provides substantially homogeneous recombinant mammalian IL-4R polypeptides substantially free of contaminating endogenous materials and, optionally, without associated native-pattern glycosylation. The

native murine and human IL-4 receptor molecules are recovered from cell lysates as glycoproteins having an apparent molecular weight by SDS-PAGE of about 130-145 kilodaltons (kDa). Mammalian IL-4R of the present invention includes, by way of example, primate, human, murine, canine, feline, bovine, ovine, equine and porcine IL-4R. Derivatives of IL-4R within the scope of the invention also include various structural forms of the primary protein which retain biological activity. Due to the presence of ionizable amino and carboxyl groups, for example, an IL-4R protein may be in the form of acidic or basic salts, or in neutral form. Individual amino acid residues may also be modified by oxidation or reduction.

The primary amino acid structure may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid sequence mutants. Covalent derivatives are prepared by linking particular functional groups to IL-4R amino acid side chains or at the N- or C-termini. Other derivatives of IL-4R within the scope of this invention include covalent or aggregative conjugates of IL-4R or its fragments with other proteins or polypeptides, such as by synthesis in recombinant culture as N-terminal or C-terminal fusions. For example, the conjugated peptide may be a signal (or leader) polypeptide sequence at the N-terminal region of the protein which co-translationally or post-translationally directs transfer of the protein from its site of synthesis to its site of function inside or outside of the cell membrane or wall (e.g., the yeast  $\alpha$ -factor leader). IL-4R protein fusions can comprise peptides added to facilitate purification or identification of IL-4R (e.g., poly-His). The amino acid sequence of IL-4 receptor can also be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp-Lys (DYKDDDDK) (Hopp et al., *Bio/Technology* 6:1204, 1988.) The latter sequence is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid assay and facile purification of expressed recombinant protein. This sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in *E. coli*.

IL-4R derivatives may also be used as immunogens, reagents in receptor-based immunoassays, or as binding agents for affinity purification procedures of IL-4 or other binding ligands. IL-4R derivatives may also be obtained by cross-linking agents, such as M-maleimidobenzoyl succinimide ester and N-hydroxysuccinimide, at cysteine and lysine residues. IL-4R proteins may also be covalently bound through reactive side groups to various insoluble substrates, such as cyanogen bromide-activated, bisoxirane-activated, carbonyldiimidazole-activated or tosyl-activated agarose structures, or by adsorbing to polyolefin surfaces (with or without glutaraldehyde cross-linking). Once bound to a substrate, IL-4R may be used to selectively bind (for purposes of assay or purification) anti-IL-4R antibodies or IL-4.

The present invention also includes IL-4R with or without associated native-pattern glycosylation. IL-4R expressed in yeast or mammalian expression systems, e.g., COS-7 cells, may be similar or significantly different in molecular weight and glycosylation pattern than the native molecules, depending upon the expression system. Expression of IL-4R DNAs in bacteria such as *E. coli* provides non-glycosylated molecules. Functional mutant analogs of mammalian IL-4R having inactivated N-glycosylation sites can be produced by oligonucleotide synthesis and ligation or by site-specific mutagenesis techniques. These analog proteins can be produced in a homogeneous, reduced-carbohydrate form in good yield using yeast expression systems. N-glycosylation sites in eukaryotic proteins are characterized by the amino acid triplet Asn-A<sub>1</sub>-Z, where A<sub>1</sub> is any amino acid except Pro, and Z is Ser or Thr. In this sequence, asparagine provides a side chain amino group for covalent attachment of carbohydrate. Such a site can be eliminated by substituting another amino acid for Asn or for residue Z, deleting Asn or Z, or inserting a non-Z amino acid between A<sub>1</sub> and Z, or an amino acid other than Asn between Asn and A<sub>1</sub>.

IL-4R derivatives may also be obtained by mutations of IL-4R or its subunits. An IL-4R mutant, as referred to herein, is a polypeptide homologous to IL-4R but which has an amino acid sequence different from native IL-4R because of a deletion, insertion or substitution. Like most mammalian genes, mammalian IL-4 receptors are presumably encoded by multi-exon genes. Alternative mRNA constructs which can be attributed to different mRNA splicing events following transcription, and which share large regions of identity or similarity with the cDNAs claimed herein, are considered to be within the scope of the present invention.

Bioequivalent analogs of IL-4R proteins may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity. For example, cysteine residues can be deleted or replaced with other amino acids to prevent formation of incorrect intramolecular disulfide bridges upon renaturation. Other approaches to mutagenesis involve modification of adjacent dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present. Generally, substitutions should be made conservatively; i.e., the most preferred substitute amino acids are those having physicochemical characteristics resembling those of the residue to be replaced. Similarly, when a deletion or insertion strategy is adopted, the potential effect of the deletion or insertion on biological activity should be considered.

Subunits of IL-4R may be constructed by deleting terminal or internal residues or sequences. Particularly preferred subunits include those in which the transmembrane region and intracellular domain of IL-4R are deleted or substituted with hydrophilic residues to facilitate secretion of the receptor into the cell culture medium. The resulting protein is a soluble IL-4R molecule which may retain its ability to bind IL-4. Particular examples of soluble IL-4R include polypep-

tides having substantial identity to the sequence of amino acid residues 1-208 in Figure 2A, and residues 1-207 in Figure 4A.

Mutations in nucleotide sequences constructed for expression of analog IL-4Rs must, of course, preserve the reading frame phase of the coding sequences and preferably will not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, which would adversely affect translation of the receptor mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed IL-4R mutants screened for the desired activity.

Not all mutations in the nucleotide sequence which encodes IL-4R will be expressed in the final product, for example, nucleotide substitutions may be made to enhance expression, primarily to avoid secondary structure loops in the transcribed mRNA (see EPA 75,444A, incorporated herein by reference), or to provide codons that are more readily translated by the selected host, e.g., the well-known *E. coli* preference codons for *E. coli* expression.

Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting re-constructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (*Gene* 42:133, 1986); Bauer et al. (*Gene* 37: 73, 1985); Craik (*BioTechniques*, January 1985, 12-19); Smith et al. (*Genetic Engineering: Principles and Methods*, Plenum Press, 1981); and U.S. Patent Nos. 4,518,584 and 4,737,462, which are incorporated by reference herein.

#### Expression of Recombinant IL-4R

The present invention provides recombinant expression vectors which include synthetic or cDNA-derived DNA fragments encoding mammalian IL-4R or bioequivalent analogs operably linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect genes. Such regulatory elements include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and translation, as described in detail below. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated. DNA regions are operably linked when they are functionally related to each other. For example, DNA for a signal peptide (secretory leader) is operably linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operably linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Generally, operably linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame.

DNA sequences encoding mammalian IL-4 receptors which are to be expressed in a microorganism will preferably contain no introns that could prematurely terminate transcription of DNA into mRNA; however, premature termination of transcription may be desirable, for example, where it would result in mutants having advantageous C-terminal truncations, for example, deletion of a transmembrane region to yield a soluble receptor not bound to the cell membrane. Due to code degeneracy, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence; exemplary DNA embodiments are those corresponding to the nucleotide sequences shown in the Figures. Other embodiments include sequences capable of hybridizing to the sequences of the Figures under moderately stringent conditions (50°C, 2 X SSC) and other sequences hybridizing or degenerate to those described above, which encode biologically active IL-4 receptor polypeptides.

Transformed host cells are cells which have been transformed or transfected with IL-4R vectors constructed using recombinant DNA techniques. Transformed host cells ordinarily express IL-4R, but host cells transformed for purposes of cloning or amplifying IL-4R DNA do not need to express IL-4R. Expressed IL-4R will be deposited in the cell membrane or secreted into the culture supernatant, depending on the IL-4R DNA selected. Suitable host cells for expression of mammalian IL-4R include prokaryotes, yeast or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example *E. coli* or bacilli. Higher eukaryotic cells include established cell lines of mammalian origin as described below. Cell-free translation systems could also be employed to produce mammalian IL-4R using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al. (*Cloning Vectors: A Laboratory Manual*, Elsevier, New York, 1985), the relevant disclosure of which is hereby incorporated by reference.

Prokaryotic expression hosts may be used for expression of IL-4Rs that do not require extensive proteolytic and disulfide processing. Prokaryotic expression vectors generally comprise one or more phenotypic selectable markers, for example a gene encoding proteins conferring antibiotic resistance or supplying an autotrophic requirement, and an



origin of replication recognized by the host to ensure amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium*, and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

Useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. *E. coli* is typically transformed using derivatives of pBR322, a plasmid derived from an *E. coli* species (Bolivar et al., *Gene* 2:95, 1977). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells.

Promoters commonly used in recombinant microbial expression vectors include the  $\beta$ -lactamase (penicillinase) and lactose promoter system (Chang et al., *Nature* 275:615, 1978; and Goeddel et al., *Nature* 281:544, 1979), the tryptophan (trp) promoter system (Goeddel et al., *Nucl. Acids Res.* 8:4057, 1980; and EPA 36,776) and tac promoter (Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful bacterial expression system employs the phage  $\lambda$  P<sub>L</sub> promoter and c1857ts thermolabile repressor. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the  $\lambda$  P<sub>L</sub> promoter include plasmid pHUB2, resident in *E. coli* strain JMB9 (ATCC 37092) and pPLc28, resident in *E. coli* RR1 (ATCC 53082).

Recombinant IL-4R proteins may also be expressed in yeast hosts, preferably from the *Saccharomyces* genus, such as *S. cerevisiae*. Yeast of other genera, such as *Pichia* or *Kluyveromyces* may also be employed. Yeast vectors will generally contain an origin of replication from the 2 $\mu$  yeast plasmid or an autonomously replicating sequence (ARS), promoter, DNA encoding IL-4R, sequences for polyadenylation and transcription termination and a selection gene. Preferably, yeast vectors will include an origin of replication and selectable marker permitting transformation of both yeast and *E. coli*, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* trp1 gene, which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, and a promoter derived from a highly expressed yeast gene to induce transcription of a structural sequence downstream. The presence of the trp1 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

Suitable promoter sequences in yeast vectors include the promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem.* 255:2073, 1980) or other glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg.* 7:149, 1968; and Holland et al., *Biochem.* 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EPA 73,657.

Preferred yeast vectors can be assembled using DNA sequences from pBR322 for selection and replication in *E. coli* (Amp<sup>r</sup> gene and origin of replication) and yeast DNA sequences including a glucose-repressible ADH2 promoter and  $\alpha$ -factor secretion leader. The ADH2 promoter has been described by Russell et al. (*J. Biol. Chem.* 258:2674, 1982) and Beier et al. (*Nature* 300:724, 1982). The yeast  $\alpha$ -factor leader, which directs secretion of heterologous proteins, can be inserted between the promoter and the structural gene to be expressed. See, e.g., Kurjan et al., *Cell* 30:933, 1982; and Bitter et al., *Proc. Natl. Acad. Sci. USA* 81:5330, 1984. The leader sequence may be modified to contain, near its 3' end, one or more useful restriction sites to facilitate fusion of the leader sequence to foreign genes.

Suitable yeast transformation protocols are known to those of skill in the art; an exemplary technique is described by Hinnen et al., *Proc. Natl. Acad. Sci. USA* 75:1929, 1978, selecting for Trp<sup>+</sup> transformants in a selective medium consisting of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10  $\mu$ g/ml adenine and 20  $\mu$ g/ml uracil.

Host strains transformed by vectors comprising the ADH2 promoter may be grown for expression in a rich medium consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80  $\mu$ g/ml adenine and 80  $\mu$ g/ml uracil. Derepression of the ADH2 promoter occurs upon exhaustion of medium glucose. Crude yeast supernatants are harvested by filtration and held at 4°C prior to further purification.

Various mammalian or insect cell culture systems can be employed to express recombinant protein. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, *Bio/Technology* 6:47 (1988). Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells, described by Gluzman (*Cell* 23:175, 1981), and other cell lines capable of expressing an appropriate vector including, for example, L cells, C127, 3T3, Chinese hamster ovary (CHO), HeLa and BHK cell lines. Mammalian expression vectors may comprise nontranscribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.

The transcriptional and translational control sequences in expression vectors to be used in transforming vertebrate cells may be provided by viral sources. For example, commonly used promoters and enhancers are derived from



Polyoma, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a heterologous DNA sequence. The early and late promoters are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers et al., *Nature* 273:113, 1978). Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the viral origin of replication is included. Further, mammalian genomic IL-4R promoter, control and/or signal sequences may be utilized, provided such control sequences are compatible with the host cell chosen. Additional details regarding the use of a mammalian high expression vectors to produce a recombinant mammalian IL-4 receptor are provided in Example 8 below. Exemplary vectors can be constructed as disclosed by Okayama and Berg (*Mol. Cell. Biol.* 3:280, 1983).

A useful system for stable high level expression of mammalian receptor cDNAs in C127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. (*Mol. Immunol.* 23:935, 1986).

A particularly preferred eukaryotic vector for expression of IL-4R DNA is disclosed below in Example 2. This vector, referred to as pCAV/NOT, was derived from the mammalian high expression vector pDC201 and contains regulatory sequences from SV40, adenovirus-2, and human cytomegalovirus. pCAV/NOT containing a human IL-7 receptor insert has been deposited with the American Type Culture Collection (ATCC) under deposit accession number 68014.

Purified mammalian IL-4 receptors or analogs are prepared by culturing suitable host/vector systems to express the recombinant translation products of the DNAs of the present invention, which are then purified from culture media or cell extracts.

For example, supernatants from systems which secrete recombinant protein into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix. For example, a suitable affinity matrix can comprise an IL-4 or lectin or antibody molecule bound to a suitable support. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred.

Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify an IL-4R composition. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein.

Recombinant protein produced in bacterial culture is usually isolated by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of recombinant mammalian IL-4R can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

Fermentation of yeast which express mammalian IL-4R as a secreted protein greatly simplifies purification. Secreted recombinant protein resulting from a large-scale fermentation can be purified by methods analogous to those disclosed by Urdal et al. (*J. Chromatog.* 296:171, 1984). This reference describes two sequential, reversed-phase HPLC steps for purification of recombinant human IL-2 on a preparative HPLC column.

Human IL-4R synthesized in recombinant culture is characterized by the presence of non-human cell components, including proteins, in amounts and of a character which depend upon the purification steps taken to recover human IL-4R from the culture. These components ordinarily will be of yeast, prokaryotic or non-human higher eukaryotic origin and preferably are present in innocuous contaminant quantities, on the order of less than about 1 percent by weight. Further, recombinant cell culture enables the production of IL-4R free of proteins which may be normally associated with IL-4R as it is found in nature in its species of origin, e.g. in cells, cell exudates or body fluids.

IL-4R compositions are prepared for administration by mixing IL-4R having the desired degree of purity with physiologically acceptable carriers. Such carriers will be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the IL-4R with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients.

IL-4R compositions may be used to regulate the function of B cells. For example, soluble IL-4R (sIL-4R) inhibits the proliferation of B cell cultures induced by IL-4 in the presence of anti-1g. sIL-4R also inhibits IL-4 induced IgG1 secretion by LPS-activated B cells as determined by isotype specific ELISA and inhibits IL-4 induced 1a expression on murine B cells as determined by EPICS analysis. sIL-4R also inhibits IL-4 induced IgE synthesis and may accordingly be used to treat IgE-induced immediate hypersensitivity reactions, such as allergic rhinitis (common hay fever), bronchial asthma, atopic dermatitis and gastrointestinal food allergy.

IL-4R compositions may also be used to regulate the function of T cells. For example, IL-4R inhibits IL-4 induced proliferation of T cell lines, such as the CTLL T cell line. sIL-4R also inhibits functional activity mediated by endogenously produced IL-4. For example, sIL-4R inhibits the generation of alloreactive cytolytic T lymphocytes (CTL) in secondary mixed leukocyte culture when present in culture concomitantly with a monoclonal antibody against IL-2, such as S4B6.

Neutralizing agents for both IL-2 and IL-4 are used to inhibit endogenous IL-2 and IL-4, both of which regulate CTL generation and are produced in such cultures.

In therapeutic applications, a therapeutically effective quantity of an IL-4 receptor composition is administered to a mammal, preferably a human, in association with a pharmaceutical carrier or diluent.

The following examples are offered by way of illustration, and not by way of limitation.

## EXAMPLES

### Example 1

#### Binding assays for IL-4 receptor

**A. Radiolabeling of IL-4.** Recombinant murine and human IL-4 were expressed in yeast and purified to homogeneity as described by Park, et al., *Proc. Natl. Acad. Sci. USA* 84:5267(1987) and Park et al., *J. Exp. Med.* 166:476(1987), respectively. The purified protein was radiolabeled using a commercially available enzymebead radioiodination reagent (BioRad). In this procedure 2.5 µg rIL-4 in 50 µl 0.2 M sodium phosphate, pH 7.2 are combined with 50 µl enzymebead reagent, 2 MCl of sodium iodide in 20 µl of 0.05 M sodium phosphate pH 7.0 and 10 µl of 2.5% b-D-glucose. After 10 min at 25°C, sodium azide (10 µl of 50 mM) and sodium metabisulfite (10 µl of 5 mg/ml) were added and incubation continued for 5 min. at 25°C. The reaction mixture was fractionated by gel filtration on a 2 ml bed volume of Sephadex® G-25 (Sigma) equilibrated in Roswell Park Memorial Institute (RPMI) 1640 medium containing 2.5% (w/v) bovine serum albumin (BSA), 0.2% (w/v) sodium azide and 20 mM Hepes pH 7.4 (binding medium). The final pool of <sup>125</sup>I-IL-4 was diluted to a working stock solution of  $2 \times 10^{-8}$  M in binding medium and stored for up to one month at 4°C without detectable loss of receptor binding activity. The specific activity is routinely in the range of  $1-2 \times 10^{16}$  cpm/mmol IL-4.

**B. Binding to Adherent Cells.** Binding assays done with cells grown in suspension culture (i.e., CTLL and CTLL-19.4) were performed by a phthalate oil separation method (Dower et al., *J. Immunol.* 132:751, 1984) essentially as described by Park et al., *J. Biol. Chem.* 261:4177, 1986 and Park et al., *supra*. Binding assays were also done on COS cells transfected with a mammalian expression vector containing cDNA encoding an IL-4 receptor molecule. For Scatchard analysis of binding to adherent cells, COS cells were transfected with plasmid DNA by the method of Luthman et al., *Nucl. Acids. Res.* 11:1295, 1983, and McCutchan et al., *J. Natl. Cancer Inst.* 41:351, 1968. Eight hours following transfection, cells were trypsinized, and reseeded in six well plates (Costar, Cambridge, MA) at a density of  $1 \times 10^4$  COS-IL-4 receptor transfectants/well mixed with  $5 \times 10^5$  COS control transfectected cells as carriers. Two days later monolayers were assayed for <sup>125</sup>I-IL-4 binding at 4°C essentially by the method described by Park et al., *J. Exp. Med.* 166:476, 1987. Nonspecific binding of <sup>125</sup>I-IL-4 was measured in the presence of a 200-fold or greater molar excess of unlabeled IL-4. Sodium azide (0.2%) was included in all binding assays to inhibit internalization of <sup>125</sup>I-IL-4 by cells at 37°C.

For analysis of inhibition of binding by soluble IL-4R, supernatants from COS cells transfected with recombinant IL-4R constructs were harvested three days after transfection. Serial two-fold dilutions of conditioned media were pre-incubated with  $3 \times 10^{-10}$  M <sup>125</sup>I-IL-4 (having a specific activity of about  $1 \times 10^{16}$  cpm/mmol) for one hour at 37°C prior to the addition of  $2 \times 10^6$  CTLL cells. Incubation was continued for 30 minutes at 37°C prior to separation of free and cell-bound murine <sup>125</sup>I-IL-4.

**C. Solid Phase Binding Assays.** The ability of IL-4 receptor to be stably adsorbed to nitrocellulose from detergent extracts of CTLL 19.4 cells yet retain IL-4 binding activity provided a means of monitoring purification. One ml aliquots of cell extracts (see Example 3), IL-4 affinity column fractions (see Example 4) or other samples are placed on dry BA85/21 nitrocellulose membranes (Schleicher and Schuell, Keene, NH) and allowed to dry. The membranes are incubated in tissue culture dishes for 30 minutes in Tris (0.05 M) buffered saline (0.15 M) pH 7.5 containing 3% w/v BSA to block nonspecific binding sites. The membrane is then covered with  $4 \times 10^{-11}$  M <sup>125</sup>I-IL-4 in PBS + 3% BSA with or without a 200 fold molar excess of unlabeled IL-4 and incubated for 2 hr at 4°C with shaking. At the end of this time, the membranes are washed 3 times in PBS, dried and placed on Kodak X-Omat™ AR film for 18 hr at -70°C.

**Example 2****Selection of CTLL cells with high IL-4 receptor expression by fluorescence activated cell sorting (FACS)**

The preferred cell line for obtaining high IL-4 receptor selection is CTLL, a murine IL-2 dependent cytotoxic T cell line (ATCC TIB 214). To obtain higher levels of IL-4 receptor expression, CTLL cells (parent cells) were sorted using fluorescence-activated cell sorting and fluorescein-conjugated recombinant murine IL-4 (rmIL-4) in which the extensive carbohydrate attached to rmIL-4 by the yeast host is used to advantage by coupling fluorescein hydrazide to periodate oxidized sugar moieties. The fluorescein-conjugated IL-4 was prepared by combining aliquots of hyperglycosylated rmIL-4 (300 µg in 300 µl of 0.1 M citrate-phosphate buffer, pH 5.5) with 30 µl of 10 mM sodium m-periodate (Sigma), freshly prepared in 0.1 M citrate-phosphate, pH 5.5 and the mixture incubated at 4°C for 30 minutes in the dark. The reaction was quenched with 30 µl of 0.1 M glycerol and dialyzed for 18 hours at 4°C against 0.1 M citrate-phosphate pH 5.5. Following dialysis, a 1/10 volume of 100 mM 5-(((2-(carbohydrazino)methyl)thio)acetyl)-aminofluorescein (Molecular Probes, Eugene OR) dissolved in DMSO was added to the sample and incubated at 25°C for 30 minutes. The IL-4-fluorescein was then exhaustively dialyzed at 4°C against PBS, pH 7.4 and protein concentration determined by amino acid analysis. The final product was stored at 4°C following the addition of 1% (w/v) BSA and sterile filtration.

In order to sort, CTLL cells ( $5 \times 10^6$ ) were incubated for 30 min at 37°C in 150 µl PBS + 1% BSA containing  $1 \times 10^{-9}$  M IL-4-fluorescein under sterile conditions. The mixture was then chilled to 4°C, washed once in a large volume of PBS + 1% BSA and sorted using an EPICS® C flow cytometer (Coulter Instruments). The cells providing the highest level fluorescence signal (top 1.0%) were collected in bulk and the population expanded in liquid cell culture. Alternatively, for single cell cloning, cells exhibiting a fluorescence signal in the top 1.0% were sorted into 96 well tissue culture microtiter plates at 1 cell per well.

Progress was monitored by doing binding assays with  $^{125}$ I-IL-4 following each round of FACS selection. Unsorted CTLL cells (CTLL parent) typically exhibited 1000-2000 IL-4 receptors per cell. CTLL cells were subjected to 19 rounds of FACS selection. The final CTLL cells selected (CTLL-19) exhibited  $5 \times 10^5$  to  $1 \times 10^6$  IL-4 receptors per cell. At this point the CTLL-19 population was subjected to EPICS® C-assisted single cell cloning and individual clonal populations were expanded and tested for  $^{125}$ I-IL-4 binding. A single clone, designated CTLL-19.4, exhibited  $1 \times 10^6$  IL-4 receptors per cell and was selected for purification and cloning studies. While the calculated apparent  $K_a$  values are similar for the two lines, CTLL-19.4 expresses approximately 400-fold more receptors on its surface than does the CTLL parent.

**Example 3****Detergent extraction of CTLL cells**

CTLL 19.4 cells were maintained in RPMI 1640 containing 10% fetal bovine serum, 50 U/ml penicillin, 50 µg/ml streptomycin and 10 ng/ml of recombinant human IL-2. Cells were grown to  $5 \times 10^5$  cells/ml in roller bottles, harvested by centrifugation, washed twice in serum free DMEM and sedimented at 2000 x g for 10 minutes to form a packed pellet (about  $2 \times 10^8$  cells/ml). To the pellet was added an equal volume of PBS containing 1% Triton® X-100 and a cocktail of protease inhibitors (2 mM phenylmethylsulfonylfluoride, 10 µM pepstatin, 10 µM leupeptin, 2 mM o-phenanthroline and 2 mM EGTA). The cells were mixed with the extraction buffer by vigorous vortexing and the mixture incubated on ice for 20 minutes after which the mixture was centrifuged at 12,000 x g for 20 minutes at 8°C to remove nuclei and other debris. The supernatant was either used immediately or stored at -70°C until use.

**Example 4****IL-4 receptor purification by IL-4 affinity chromatography**

In order to obtain sufficient quantities of murine IL-4R to determine its N-terminal sequence or to further characterize human IL-4R, protein obtained from the detergent extraction of cells was further purified by affinity chromatography. Recombinant murine or human IL-4 was coupled to Affigel®-10 (BioRad) according to the manufacturer's suggestions. For example, to a solution of IL-4 (3.4 mg/ml in 0.4 ml of 0.1 M Hepes pH 7.4) was added 1.0 ml of washed Affigel®-10. The solution was rocked overnight at 4°C and an aliquot of the supernatant tested for protein by a BioRad protein assay per the manufacturer's instructions using BSA as a standard. Greater than 95% of the protein had coupled to the gel, suggesting that the column had a final load of 1.3 mg IL-4 per ml gel. Glycine ethyl ester was added to a final concentration of 0.05 M to block any unreacted sites on the gel. The gel was washed extensively with PBS-1% Triton® followed by 0.1 Glycine-HCl, pH 3.0. A 0.8 x 4.0 cm column was prepared with IL-4-coupled Affigel® prepared as described (4.0 ml bed volume) and washed with PBS containing 1% Triton® X-100 for purification of murine IL-4R. Alternatively, 50 µl aliquots of 20% suspension of IL-4-coupled Affigel® were incubated with  $^{35}$ S-cysteine/methionine-

labeled cell extracts for small-scale affinity purifications and gel electrophoresis.

Aliquots (25 ml) of detergent extracted IL-4 receptor bearing CTLL 19.4 cells were slowly applied to the murine IL-4 affinity column at 4°C (flow rate of 3.0 ml/hr). The column was then washed sequentially with PBS containing 1% Triton® X-100, RIPA buffer (0.05 M Tris, 0.15 M NaCl, 1% NP-40, 1% deoxycholate and 0.1% SDS), PBS containing 0.1% Triton® X-100 and 10 mM ATP, and PBS with 1% Triton® X-100 to remove all contaminating material except the mIL-4R. The column was then eluted with pH 3.0 glycine HCl buffer containing 0.1% Triton® X-100 to remove the IL-4R and washed subsequently with PBS containing 0.1% Triton® X-100. One ml fractions were collected for the elution and 2 ml fractions collected during the wash. Immediately following elution, samples were neutralized with 80 µl of 1 M Hepes, pH 7.4. The presence of receptor in the fractions was detected by the solid phase binding assay as described above, using <sup>125</sup>I-labeled IL-4. Aliquots were removed from each fraction for analysis by SDS-PAGE and the remainder frozen at -70°C until use. For SDS-PAGE, 40 µl of each column fraction was added to 40 µl of 2 X SDS sample buffer (0.125 M Tris HCl pH 6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol). The samples were placed in a boiling water bath for 3 minutes and 80 µl aliquots applied to sample wells of a 10% polyacrylamide gel which was set up and run according to the method of Laemmli (*Nature* 227:680, 1970). Following electrophoresis, gels were silver stained as previously described by Urdal et al. (*Proc. Natl. Acad. Sci. USA* 81: 6481, 1984).

Purification by the foregoing process permitted identification by silver staining of polyacrylamide gels of two mIL-4R protein bands averaging 45 - 55 kDa and 30 - 40 kDa that were present in fractions exhibiting IL-4 binding activity. Experiments in which the cell surface proteins of CTLL-19.4 cells were radiolabeled and <sup>125</sup>I-labeled receptor was purified by affinity chromatography suggested that these two proteins were expressed on the cell surface. The ratio of the lower to higher molecular weight bands increased upon storage of fractions at 4°C, suggesting a precursor product relationship, possibly due to slow proteolytic degradation. The mIL-4 receptor protein purified by the foregoing process remains capable of binding IL-4, both in solution and when adsorbed to nitrocellulose.

## Example 5

### Sequencing of IL-4 receptor protein

CTLL 19.4 mIL-4 receptor containing fractions from the mIL-4 affinity column purification were prepared for amino terminal protein sequence analysis by fractionating on an SDS-PAGE gel and then transferred to a PVDF membrane. Prior to running the protein fractions on polyacrylamide gels, it was first necessary to remove residual detergent from the affinity purification process. Fractions containing proteins bound to the mIL-4 affinity column from three preparations were thawed and concentrated individually in a speed vac under vacuum to a final volume of 1 ml. The concentrated fractions were then adjusted to pH 2 by the addition of 50% (v/v) TFA and injected onto a Brownlee RP-300 reversed-phase HPLC column (2.1 x 30 mm) equilibrated with 0.1% (v/v) TFA in H<sub>2</sub>O at a flow rate of 200 µl/min running on a Hewlett Packard Model 1090M HPLC. The column was washed with 0.1% TFA in H<sub>2</sub>O for 20 minutes post injection. The HPLC column containing the bound protein was then developed with a gradient as follows:

| Time | % Acetonitrile in 0.1% TFA |
|------|----------------------------|
| 0    | 0                          |
| 5    | 30                         |
| 15   | 30                         |
| 25   | 70                         |
| 30   | 70                         |
| 35   | 100                        |
| 40   | 0                          |

1 ml fractions were collected every five minutes and analyzed for the presence of protein by SDS PAGE followed by silver staining.

Each fraction from the HPLC run was evaporated to dryness in a speed vac and then resuspended in Laemmli reducing sample buffer, prepared as described by Laemmli, *U.K. Nature* 227:680, 1970. Samples were applied to a 5-20% gradient Laemmli SDS gel and run at 45 mA until the dye front reached the bottom of the gel. The gel was then transferred to PVDF paper and stained as described by Matsudaira, *J. Biol. Chem.* 262:10035, 1987. Staining bands were clearly identified in fractions from each of the three preparations at approximately 30,000 to 40,000 M<sub>r</sub>.

The bands from the previous PVDF blotting were excised and subjected to automated Edman degradation on an Applied Biosystems Model 477A Protein Sequencer essentially as described by March et al. (*Nature* 315:641, 1985), except that PTH amino acids were automatically injected and analyzed on line with an Applied Biosystems Model 120A

HPLC using a gradient and detection system supplied by the manufacturer. The following amino terminal sequence was determined from the results of sequencing: NH<sub>2</sub>-Ile-Lys-Val-Leu-Gly-Glu-Pro-Thr-Cys/Asn-Phe-Ser-Asp-Tyr-Ile. The bands from the second preparation used for amino terminal sequencing were treated with CNBr using the *in situ* technique described by March et al. (*Nature* 315: 641, 1985) to cleave the protein after internal methionine residues. Sequencing of the resulting cleavage products yielded the following data, indicating that the CNBr cleaved the protein after two internal methionine residues:

| Cycle | Residues Observed |
|-------|-------------------|
| 1     | Val, Ser          |
| 2     | Gly, Leu          |
| 3     | Ile, Val          |
| 4     | Tyr, Ser          |
| 5     | Arg, Tyr          |
| 6     | Glu, Thr          |
| 7     | Asp, Ala          |
| 8     | Asn, Leu          |
| 9     | Pro, Val          |
| 10    | Ala               |
| 11    | Glu, Val          |
| 12    | Phe, Gly          |
| 13    | Ile, Asn          |
| 14    | Val, Gln          |
| 15    | Tyr, Ile          |
| 16    | Lys, Asn          |
| 17    | Val, Thr          |
| 18    | Thr, Gly          |

When compared with the protein sequences derived from clones 16 and 18 (see Figure 2), the sequences matched as follows:

Sequence 1: (Met)-Val-Asn-Ile-Ser-Arg-Glu-Asp-Asn-Pro-Ala-Glu-Phe-Ile-Val-Tyr-Asn-Val-Thr

Sequence 2: (Met)-Ser-Gly-Val-Tyr-Tyr-Thr-Ala-Arg-Val-Arg-Val-Arg-Ser-Gln-Ile-Leu-Thr-Gly

Identical matches were found for all positions of sequence 1 except Asn(2) and sequence 2, except Arg at positions 8, 10, and 12, Ser at position 13, and Leu at position 16. The above sequences correspond to amino acid residues 137-154 and 169-187 of Figure 2.

In addition, the amino terminal sequence matched a sequence derived from the clone with position 9 being defined as a Cys.

The above data support the conclusion that clones 16 and 18 are derived from the message for the IL-4 receptor.

## Example 6

### Synthesis of hybrid-subtracted cDNA probe

In order to screen a library for clones encoding a murine IL-4 receptor, a highly enriched IL-4 receptor cDNA probe was obtained using a subtractive hybridization strategy. Polyadenylated (polyA<sup>+</sup>) mRNA was isolated from two similar cell lines, the parent cell line CTLL (which expresses approximately 2,000 receptors per cell) and the sorted cell line CTLL 19.4 (which expresses 1 x 10<sup>6</sup> receptors per cell). The mRNA content of these two cell lines is expected to be identical except for the relative level of IL-4 receptor mRNA. A radiolabeled single-stranded cDNA preparation was

then made from the mRNA of the sorted cell line CTLL 19.4 by reverse transcription of polyadenylated mRNA from CTLL 19.4 cells by a procedure similar to that described by Maniatis et al., *Molecular Cloning, A Laboratory Manual* (Cold Spring Harbor Laboratory, New York, 1982). Briefly, polyA<sup>+</sup> mRNA was purified as described by March et al. (*Nature* 315:641-647, 1985) and copied into cDNA by reverse transcriptase using oligo dT as a primer. To obtain a high level of <sup>32</sup>P-labeling of the cDNA, 100 µCi of <sup>32</sup>P-dCTP (s.a.=3000 Ci/mmol) was used in a 50 µl reaction with non-radioactive dCTP at 10 µM. After reverse transcription at 42°C for 2 hours, EDTA was added to 20 mM and the RNA was hydrolyzed by adding NaOH to 0.2 M and incubating the cDNA mixture at 68°C for 20 minutes. The single-stranded cDNA was extracted with a phenol/chloroform (50/50) mixture previously equilibrated with 10 mM Tris-Cl, 1 mM EDTA. The aqueous phase was removed to a clean tube and made alkaline again by the addition of NaOH to 0.5 M. The cDNA was then size-fractionated by chromatography on a 6 ml Sephadex® G50 column in 30mM NaOH and 1 mM EDTA to remove small molecular weight contaminants.

The resulting size-fractionated cDNA generated from the sorted CTLL 19.4 cells was then hybridized with an excess of mRNA from the unsorted parental CTLL cells by ethanol-precipitating the cDNA from CTLL 19.4 cells with 30 µg of polyA<sup>+</sup> mRNA isolated from unsorted CTLL cells, resuspending in 16 µl of 0.25 M NaPO<sub>4</sub>, pH 6.8, 0.2% SDS, 2 mM EDTA and incubating for 20 hours at 68°C. The cDNAs from the sorted CTLL 19.4 cells that are complementary to mRNAs from the unsorted CTLL cells form double stranded cDNA/mRNA hybrids, which can then be separated from the single stranded cDNA based on their different binding affinities on hydroxyapatite. The mixture was diluted with 30 volumes of 0.02 M NaPO<sub>4</sub>, pH 6.8; bound to hydroxyapatite at room temperature, and single-stranded cDNA was then eluted from the resin with 0.12 M NaPO<sub>4</sub>, pH 6.8, at 60°C, as described by Sims et al., *Nature* 312:541, 1984. Phosphate buffer was then removed by centrifugation over 2 ml Sephadex® G50 spin columns in water. This hybrid subtraction procedure removes a majority of common sequences between CTLL 19.4 and unsorted CTLL cells, and leaves a single-stranded cDNA pool enriched for radiolabeled IL-4 receptor cDNA which can be used to probe a cDNA library (as described below).

## Example 7

### Synthesis of cDNA library and plaque screening

A cDNA library was constructed from polyadenylated mRNA isolated from CTLL 19.4 cells using standard techniques (Gubler, et al., *Gene* 25:263, 1983; Ausubel et al., eds., *Current Protocols in Molecular Biology*, Vol. 1, 1987). After reverse transcription using oligo dT as primer, the single-stranded cDNA was rendered double-stranded with DNA polymerase I, blunt-ended with T4 DNA polymerase, methylated with *EcoR*I methylase to protect *EcoR*I cleavage sites within the cDNA, and ligated to *EcoR*I linkers. The resulting constructs were digested with *EcoR*I to remove all but one copy of the linkers at each end of the cDNA, and ligated to an equimolar concentration of *EcoR*I cut and dephosphorylated λZAP® arms and the resulting ligation mix was packaged *in vitro* (Gigapack®) according to the manufacturer's instructions. Other suitable methods and reagents for generating cDNA libraries in λ phage vectors are described by Huynh et al., *DNA Cloning Techniques: A Practical Approach*, IRL Press, Oxford (1984); Meissner et al., *Proc. Natl. Acad. Sci. USA* 84:4171 (1987), and Ausubel et al., *supra*. λZAP® is a phage λ cloning vector similar to λgt11 (U.S. Patent 4,788,135) containing plasmid sequences from pUC19 (Norrander et al., *Gene* 26:101, 1987), a polylinker site located in a lacZ gene fragment, and an f1 phage origin of replication permitting recovery of ssDNA when host bacteria are superinfected with f1 helper phage. DNA is excised in the form of a plasmid comprising the foregoing elements, designated Bluescript®. Gigapack® is a sonicated *E. coli* extract used to package λ phage DNA. λZAP®, Bluescript®, and Gigapack® are registered trademarks of Stratagene, San Diego, CA, USA.

The radiolabeled hybrid-subtracted cDNA from Example 6 was then used as a probe to screen the cDNA library. The amplified library was plated on BB4 cells at a density of 25,000 plaques on each of 20 150 mm plates and incubated overnight at 37°C. All manipulations of λZAP® and excision of the Bluescript® plasmid were as described by Short et al., (*Nucl. Acids Res.* 16:7583, 1988) and Stratagene product literature. Duplicate plaque lift filters were incubated with hybrid-subtracted cDNA probes from Example 6 in hybridization buffer containing 50% formamide, 5 X SSC, 5 X Denhardt's reagent and 10% dextran sulfate at 42°C for 48 hours as described by Wahl et al., *Proc. Natl. Acad. Sci. USA* 76:3683, 1979. Filters were then washed at 68°C in 0.2 x SSC. Sixteen positive plaques were purified for further analysis.

Bluescript® plasmids containing the cDNA inserts were excised from the phage as described by the manufacturer and transformed into *E. coli*. Plasmid DNA was isolated from individual colonies, digested with *EcoR*I to release the cDNA inserts and electrophoresed on standard 1% agarose gels. Four duplicate gels were blotted onto nylon filters to produce identical Southern blots for analysis with various probes which were (1) radiolabeled cDNA from unsorted CTLL cells, (2) radiolabeled cDNA from CTLL 19.4 sorted cells, (3) hybrid subtracted cDNA from CTLL 19.4 sorted cells, and (4) hybrid subtracted cDNA from CTLL 19.4 sorted cells after a second round of hybridization to poly A<sup>+</sup> mRNA from an IL-4 receptor negative mouse cell line (LBRM 33 1A5B6). These probes were increasingly enriched for cDNA copies of mRNA specific for the sorted cell line CTLL 19.4. Of the 16 positive plaques isolated from the library,

four clones (11A, 14, 16 and 18) showed a parallel increase in signal strength with enrichment of the probe.

Restriction mapping (shown in Figure 1) and DNA sequencing of the isolated CTLL clones indicated the existence of at least two distinct mRNA populations. Both mRNA types have homologous open reading frames over most of the coding region yet diverge at the 3' end, thus encoding homologous proteins with different COOH-terminal sequences. DNA sequence from inside the open reading frames of both clones code for protein sequence that is identical to protein sequence derived from sequencing of the purified IL-4 receptor described in more detail in Example 5. Clone 16 and clone 18 were used as the prototypes for these two distinct message types. Clone 16 contains an open reading frame that encodes a 258-amino acid polypeptide which includes amino acids -25 to 233 of Figure 2A. Clone 18 encodes a 230-amino acid polypeptide, the N-terminal 224 amino acids of which are identical to the N-terminus of clone 16 but diverge at the 3' end with nucleotides CCAAGTAATGAAAATCTG which encode the C-terminal 6 amino acids, Pro-Ser-Asn-Glu-Asn-Leu, followed by a termination codon TGA. Both clones were expressed in a mammalian expression system, as described in Example 8.

### Example 8

#### Expression of IL-4R in mammalian cells

**A. Expression in COS-7 Cells.** A eukaryotic expression vector pCAV/NOT, shown in Figure 3, was derived from the mammalian high expression vector pDC201, described by Sims et al., *Science* 241:585, 1988). pDC201 is a derivative of pMLSV, previously described by Cosman et al., *Nature* 312:768, 1984. pCAV/NOT is designed to express cDNA sequences inserted at its multiple cloning site (MCS) when transfected into mammalian cells and includes the following components: SV40 (hatched box) contains SV40 sequences from coordinates 5171-270 including the origin of replication, enhancer sequences and early and late promoters. The fragment is oriented so that the direction of transcription from the early promoter is as shown by the arrow. CMV contains the promoter and enhancer regions from human cytomegalovirus (nucleotides -671 to +7 from the sequence published by Boshart et al., *Cell* 41:521-530, 1985). The tripartite leader (stippled box) contains the first exon and part of the intron between the first and second exons of the adenovirus-2 tripartite leader, the second exon and part of the third exon of the tripartite leader and a multiple cloning site (MCS) containing sites for *Xho*I, *Kpn*I, *Sma*I, *Not*I and *Bgl*II. pA (hatched box) contains SV40 sequences from 4127-4100 and 2770-2533 that include the polyadenylation and termination signals for early transcription. Clockwise from pA are adenovirus-2 sequences 10532-11156 containing the VA1 and VAII genes (designated by a black bar), followed by pBR322 sequences (solid line) from 4363-2486 and 1094-375 containing the ampicillin resistance gene and origin of replication. The resulting expression vector was designated pCAV/NOT.

Inserts in clone 16 and clone 18 were both released from Bluescript® plasmid by digestion with *Asp*718 and *Not*I. The 3.5 kb insert from clone 16 was then ligated directly into the expression vector pCAV/NOT also cut at the *Asp*718 and *Not*I sites in the polylinker region. The insert from clone 18 was blunt-ended with T4 polymerase followed by ligation into the vector pCAV/NOT cut with *Sma*I and dephosphorylated.

Plasmid DNA from both IL-4 receptor expression plasmids were used to transfect a sub-confluent layer of monkey COS-7 cells using DEAE-dextran followed by chloroquine treatment, as described by Luthman et al. (*Nucl. Acids Res.* 11:1295, 1983) and McCutchan et al. (*J. Natl. Cancer Inst.* 41:351, 1968). The cells were then grown in culture for three days to permit transient expression of the inserted sequences. After three days, cell culture supernatants and the cell monolayers were assayed (as described in Example 1) and IL-4 binding was confirmed.

**B. Expression in CHO Cells.** IL-4R was also expressed in the mammalian CHO cell line by first ligating an *Asp*718/*Not*I restriction fragment of clone 18 into the pCAV/NOT vector as described in Example 8. The pCAV/NOT vector containing the insert from clone 18 was then co-transfected using a standard calcium phosphate method into CHO cells with the dihydrofolate reductase (DHFR) cDNA selectable marker under the control of the SV40 early promoter. The DHFR sequence enables methotrexate selection for mammalian cells harboring the plasmid. DHFR sequence amplification events in such cells were selected using elevated methotrexate concentrations. In this way, the contiguous DNA sequences are also amplified and thus enhanced expression is achieved. Mass cell cultures of the transfectants secreted active soluble IL-4R at approximately 100 ng/ml.

**C. Expression in HeLa Cells.** IL-4R was expressed in the human HeLa-EBNA cell line 653-6, which constitutively expresses EBV nuclear antigen-1 driven from the CMV immediate-early enhancer/promoter. The expression vector used was pHAV-EO-NEO, described by Dower et al., *J. Immunol.* 142:4314, 1989), a derivative of pDC201, which contains the EBV origin of replication and allows high level expression in the 653-6 cell line. pHAV-EO-NEO is derived from pDC201 by replacing the adenovirus major late promoter with synthetic sequences from HIV-1 extending from -148 to +78 relative to the cap site of the viral mRNA, and including the HIV-1 *tat* gene under the control of the SV40 early promoter. It also contains a *Bgl*II-*Sma*I fragment containing the neomycin resistance gene of pSV2NEO (Southern & Berg, *J. Mol. Appl. Genet.* 1:332, 1982) inserted into the *Bgl*II and *Hpa*I sites and subcloning downstream of the *Sa*I cloning site. The resulting vector permits selection of transfected cells for neomycin resistance.



A 760 bp IL-4R fragment was released from the Bluescript® plasmid by digesting with *Eco*NI and *Sst*I restriction enzymes. This fragment of clone 18 corresponds to nucleotides 1-672 of Figure 2A, with the addition of a 5' terminal nucleotide sequence of GTGCAGGCACCTTTTGTGTCCCA, a TGA stop codon which follows nucleotide 672 of Figure 2A, and a 3' terminal nucleotide sequence of CTGAGTGACCTGGGGGCTGCGGTGGTGAGGAGAGCT. This fragment was then blunt-ended using T4 polymerase and subcloned into the *Sa*II site of pHAV-EO-NEO. The resulting plasmid was then transfected into the 653-6 cell line by a modified polybrene transfection method as described by Dower et al. (*J. Immunol.* 142:4314, 1989) with the exception that the cells were trypsinized at 2 days post-transfection and split at a ratio of 1:8 into media containing G418 (Gibco Co.) at a concentration of 1 mg/ml. Culture media were changed twice weekly until neomycin-resistant colonies were established. Colonies were then either picked individually using cloning rings, or pooled together, to generate several different cell lines. These cell lines were maintained under drug selection at a G418 concentration of 250 µg/ml. When the cells reached confluency supernatants were taken and tested in the inhibition assay of Example 1B. Cell lines produced from 100 ng/ml to 600 ng/ml of soluble IL-4R protein.

### Example 9

#### Expression of IL-4R in yeast cells

For expression of mIL-4R, a yeast expression vector derived from pXY120 was constructed as follows. pXY120 is identical to pYαHuGM (ATCC 53157), except that it contains no cDNA insert and includes a polylinker/multiple cloning site with an *Nco*I site. This vector includes DNA sequences from the following sources: (1) a large *Sph*I (nucleotide 562) to *Eco*RI (nucleotide 4361) fragment excised from plasmid pBR322 (ATCC 37017), including the origin of replication and the ampicillin resistance marker for selection in *E. coli*; (2) *S. cerevisiae* DNA including the TRP-1 marker, 2µ origin of replication, ADH2 promoter; and (3) DNA encoding an 85 amino acid signal peptide derived from the gene encoding the secreted peptide α-factor (See Kurjan et al., U.S. Patent 4,546,082). An *Asp* 718 restriction site was introduced at position 237 in the α-factor signal peptide to facilitate fusion to heterologous genes. This was achieved by changing the thymidine residue at nucleotide 241 to a cytosine residue by oligonucleotide-directed *in vitro* mutagenesis as described by Craik, *BioTechniques*, January 1985, pp.12-19. A synthetic oligonucleotide containing multiple cloning sites and having the following sequence was inserted from the *Asp*718 site at amino acid 79 near the 3' end of the α-factor signal peptide to a *Spe*I site in the 2µ sequence:

```

Asp718                               StuI   NcoI           BamHI/SmaI       SpeI
GTACCTTTGGATAAAAGAGACTACAAGGACGACGATGACAAGAGGCCTCCATGGATCCCCGGGACA
GAAACCTATTTCTCTGATGTTCTCTGCTACTGTTCTCCGGAGGTACCTAGGGGGCCCTGTGATC
                                     |<-----Polylinker----->|

```

pBC120 also varies from pYαHuGM by the presence of a 514 bp DNA fragment derived from the single-stranded phage f1 containing the origin of replication and intergenic region, which has been inserted at the *Nru*I site in the pBR322 sequence. The presence of an f1 origin of replication permits generation of single-stranded DNA copies of the vector when transformed into appropriate strains of *E. coli* and superinfected with bacteriophage f1, which facilitates DNA sequencing of the vector and provides a basis for *in vitro* mutagenesis. To insert a cDNA, pXY120 is digested with *Asp* 718 which cleaves near the 3' end of the α-factor leader peptide (nucleotide 237) and, for example, *Bam*HI which cleaves in the polylinker. The large vector fragment is then purified and ligated to a DNA fragment encoding the protein to be expressed.

To create a secretion vector for expressing mIL-4R, a cDNA fragment encoding mIL-4R was excised from the Bluescript® plasmid of Example 8 by digestion with *Ppu*mI and *Bg*II to release an 831 bp fragment from the *Ppu*mI site (see FIGURE ) to an *Bg*II site located 3' to the open reading frame containing the mIL-4R sequence minus the first two 5' codons encoding Ile and Lys. pXY120 was digested with *Asp* 718 near the 3' end of the α-factor leader and *Bam*HI. The vector fragment was ligated to the *Ppu*mI/*Bg*II mIL-4R cDNA fragment and the following fragment created by annealing a pair of synthetic oligonucleotides to recreate the last 6 amino acids of the α-factor leader and the first two amino acids of mature mIL-4R.

$\alpha$ -factor processing  $\longrightarrow$   
 GTA CCT CTA GAT AAA AGA ATC AAG  
 GA GAT CTA TTT TCT TAG TTC CAG  
 Val Pro Leu Asp Lys Arg Ile Lys  
 $\longleftarrow$  mIL-4R

The oligonucleotide also included a change from the nucleotide sequence TGG ATA to CTA GAT which introduces a *Xba*I restriction site, without altering the encoded amino acid sequence.

The foregoing expression vector was then purified and employed to transform a diploid yeast strain of *S. cerevisiae* (XV2181) by standard techniques, such as those disclosed in EPA 165,654, selecting for tryptophan prototrophs. The resulting transformants were cultured for expression of a secreted mIL-4R protein. Cultures to be assayed for biological activity were grown in 20-50 ml of YPD medium (1% yeast extract, 2% peptone, 1% glucose) at 37°C to a cell density of  $1.5 \times 10^8$  cells/ml. To separate cells from medium, cells were removed by centrifugation and the medium filtered through a 0.45  $\mu$  cellulose acetate filter prior to assay. Supernatants produced by the transformed yeast strain, or crude extracts prepared from disrupted yeast cells transformed the plasmid, were assayed to verify expression of a biologically active protein.

#### Example 10.

##### Isolation of full-length and truncated forms of murine IL-4 receptor cDNAs from unsorted 7B9 cells

Polyadenylated RNA was isolated from 7B9 cells, an antigen-dependent helper T cell clone derived from C57BL/6 mice, and used to construct a cDNA library in  $\lambda$ ZAP (Stratagene, San Diego), as described in example 7. The  $\lambda$ ZAP library was amplified once and a total of 300,000 plaques were screened as described in Example 7, with the exception that the probe was a randomly primed  $^{32}$ P-labeled 700 bp *Eco*RI fragment isolated from CTLL 19.4 clone 16. Thirteen clones were isolated and characterized by restriction analysis.

Nucleic acid sequence analysis of clone 7B9-2 revealed that it contains a polyadenylated tail, a putative polyadenylation signal, and an open reading frame of 810 amino acids (shown in Fig. 2), the first 258 of which are identical to those encoded by CTLL 19.4 clone 16, including the 25 amino acid putative signal peptide sequence. The 7B9-2 cDNA was subcloned into the eukaryotic expression vector, pCAV/NOT, and the resulting plasmid was transfected into COS-7 cells as described in Example 8. COS-7 transfectants were analyzed as set forth in Example 12.

A second cDNA form, similar to clone 18 in the CTLL 19.4 library, was isolated from the 7B9 library and subjected to sequence analysis. This cDNA, clone 7B9-4, is 376 bp shorter than clone 7B9-2 at the 5' end, and lacks the first 47 amino acids encoded by 7B9-2, but encodes the remaining N-terminal amino acids 23-199 (in Fig. 2). At position 200, clone 7B9-4 (like clone 18 from CTLL 19.4) has a 114 bp insert which changes the amino acid sequence to Pro Ser Asn Glu Asn Leu followed by a termination codon. The 114 bp inserts, found in both clone 7B9-4 and CTLL 19.4 clone 18 are identical in nucleic acid sequence. The fact that this cDNA form, which produces a secreted form of the IL-4 receptor when expressed in COS-7 cells, was isolated from these two different cell lines indicates that it is neither a cloning artifact nor a mutant form peculiar to the sorted CTLL cells.

#### Example 11

##### Isolation of human IL-4 receptor cDNAs from PBL and T22 libraries by cross-species hybridization

Polyadenylated RNA was isolated from pooled human peripheral blood lymphocytes (PBL) that were obtained by standard Ficoll purification and were cultured in IL-2 for six days followed by stimulation with PMA and Con-A for eight hours. An oligo dT primed cDNA library was constructed in  $\lambda$ gt10 using techniques described in example 7. A probe was produced by synthesizing an unlabeled RNA transcript of the 7B9-4 cDNA insert using T7 RNA polymerase, followed by  $^{32}$ P-labeled cDNA synthesis with reverse transcriptase using random primers (Boehringer-Mannheim). This murine single-stranded cDNA probe was used to screen 50,000 plaques from the human cDNA library in 50% formamide/0.4 M NaCl at 42°C, followed by washing in 2 X SSC at 55°C. Three positive plaques were purified, and the *Eco*RI inserts subcloned into the Bluescript® plasmid vector. Nucleic acid sequencing of a portion of clone PBL-1, a 3.4 kb cDNA, indicated the clone was approximately 67% homologous to the corresponding sequence of the murine IL-4 receptor. However, an insert of 68 bp, containing a termination codon and bearing no homology to the mouse IL-4 receptor clones, was found 45 amino acids downstream of the predicted N-terminus of the mature protein, suggesting that clone PBL-1 encodes a non-functional truncated form of the receptor. Nine additional human PBL

clones were obtained by screening the same library (under stringent conditions) with a  $^{32}\text{P}$ -labeled random-primed probe made from the clone PBL-1 (the 3.4 kb *EcoRI* cDNA insert). Two of these clones, PBL-11 and PBL-5, span the 5' region that contains the 68 bp insert in PBL-1, but lack the 68 bp insert and do not extend fully 3', as evidenced by their size, thus precluding functional analysis by mammalian expression. In order to obtain a construct expressible in COS-7 cells, the 5' *NotI*-*HincII* fragment of clones PBL-11 and PBL-5 were separately ligated to the 3' *HincII*-*BamHI* end of clone PBL-1, and subcloned into the pCAV/NOT expression vector cut with *NotI* and *BglII* described in Example 8. These chimeric human IL-4R cDNAs containing PBL-11/PBL-1 and PBL-5/PBL-1 DNA sequences have been termed clones A5 and B4, respectively, as further described in Example 12. These constructs were transfected into COS-7 cells, and assayed for IL-4 binding in a plate binding assay substantially as described in Sims et al. (*Science* 241:585, 1988). Both composite constructs encoded protein which exhibited IL-4 binding activity. The nucleotide sequence and predicted amino acid sequence of the composite A5 construct correspond to the sequence information set forth in Figures 4A-4C, with the exception that a GTC codon encodes the amino acid Val at position 50, instead of Ile. No other clones that were sequenced contained this change. The consensus codon from clones PBL-1, PBL-5 and T22-8, however, is ATC and encodes Ile<sup>50</sup>, as set forth in Figure 4A. The nucleotide and predicted amino acid sequence of the composite B4 construct also shows that the 25 amino acid leader sequence of PBL-11 is replaced with the sequence Met-Gln-Lys-Asp-Ala-Arg-Arg-Glu-Gly-Asn.

Constructs expressing a soluble form of the human IL-4 receptor were made by excising a 5'-terminal 0.8 kb *SmaI*-*DraIII* fragment from PBL-5 and the corresponding 0.8 kb *Asp718-DraIII* fragment from PBL-11, of which the *DraIII* overhangs were blunt-ended with T4 polymerase. The PBL-5 and PBL-11 fragments were separately subcloned into CAV/NOT cut with *SmaI* or *Asp 718* plus *SmaI*, respectively; these are called soluble hIL-4R-5 and soluble hIL-4R-11, respectively. In both constructs the final IL-4 receptor amino acid Thr<sup>194</sup> codon is followed by the vector-encoding amino acids GlyGlnArgProLeuGlnIleTyrAla before terminating.

A second library made from a CD4<sup>+</sup>/CD8<sup>-</sup> human T cell clone, T22, (Acres et al., *J. Immunol.* 138:2132, 1987) was screened (using duplicate filters) with two different probes synthesized as described above. The first probe was obtained from a 220 bp *PvuII* fragment from the 5' end of clone PBL-1 and the second probe was obtained from a 300 bp *PvuII*-*EcoRI* fragment from the 3' end of the clone PBL-1. Five additional cDNA clones were identified using these two probes. Two of these clones span the 5' region containing the 68 bp insert, but neither contain the insert. The third of these clones T22-8, was approximately 3.6 kb in size and contained in an open reading frame of 825 amino acids, including a 25 amino acid leader sequence, a 207 amino acid mature external domain, a 24 amino acid transmembrane region and a 569 amino acid cytoplasmic domain. The sequence of clone T22-8 is set forth in Figures 4A-4C. Figures 5A-5B compare the predicted human IL-4R amino acid sequence with the predicted murine IL-4R sequence and show approximately 53% sequence identity between the two proteins.

A third soluble human IL-4 receptor construct was made as follows. cDNA clone T22-8 was cleaved at the *DraIII* site in the Thr<sup>194</sup> codon, and repaired with synthetic oligonucleotides to regenerate Thr<sup>194</sup> and Lys<sup>195</sup> codons, followed by a termination codon, and a *NotI* restriction site. A 0.68 kb *StyI*-*NotI* restriction fragment of this clone was then blunt-ended at the *StyI* site and subcloned into a *SmaI*-*NotI* digested pCAV/NOT vector. This cDNA expression vector was designated hIL-4R-8.

### Example 12

#### Analysis and purification of IL-4 receptor in COS transfectants

Equilibrium binding studies were conducted for COS cells transfected with murine IL-4 receptor clones 16 and 18 from the CTLL 19.4 library. In all cases analysis of the data in the Scatchard coordinate system (Scatchard, *Ann. N.Y. Acad. Sci.* 51:660-672, 1949) yielded a straight line, indicating a single class of high-affinity receptors for murine IL-4. For COS pCAV-16 cells the calculated apparent  $K_a$  was  $3.6 \times 10^9 \text{ M}^{-1}$  with  $5.9 \times 10^5$  specific binding sites per cell. A similar apparent  $K_a$  was calculated for COS pCAV-18 cells at  $1.5 \times 10^9 \text{ M}^{-1}$  but receptor number expressed at the cell surface was  $4.2 \times 10^4$ . Equilibrium binding studies performed on COS cells transfected with IL-4R DNA clones isolated from the 7B9 cell library also showed high affinity binding of the receptor to IL-4. Specifically, studies using COS cells transfected with pCAV-7B9-2 demonstrated that the full length murine IL-4 receptor bound  $^{125}\text{I}$ -IL-4 with an apparent  $K_a$  of about  $1.4 \times 10^{10} \text{ M}^{-1}$  with  $4.5 \times 10^4$  specific binding sites per cell. The apparent  $K_a$  of CAV-7B9-4 IL-4R was calculated to be about  $1.7 \times 10^9 \text{ M}^{-1}$ . Although absolute values for  $K_a$  and binding sites per cell varied between transfections, the binding affinities were generally similar ( $1 \times 10^9 - 1 \times 10^{10} \text{ M}^{-1}$ ) and matched well with previously published affinity constants for IL-4 binding.

Inhibition of  $^{125}\text{I}$ -mIL-4 binding to CTLL cells by conditioned media from COS cells transfected with plasmid pCAV, pCAV-18, or pCAV-7B9-4 was used to determine if these cDNAs encoded functional soluble receptor molecules. Approximately 1.5  $\mu\text{l}$  of COS pCAV-18 conditioned media in a final assay volume of 150  $\mu\text{l}$  gives approximately 50% inhibition of  $^{125}\text{I}$ -IL-4 binding to the IL-4 receptor on CTLL cells.  $^{125}\text{I}$ -IL-4 receptor competing activity is not detected in

control pCAV transfected COS supernatants. From quantitative analysis of the dilution of pCAV-18 supernatant required to inhibit  $^{125}\text{I}$ -IL-4 binding by 50%, it is estimated that approximately 60-100 ng/ml of soluble IL-4 receptor has been secreted by COS cells when harvested three days after transfection. Similar results were obtained utilizing supernatants from COS cells transfected with pCAV-7B9-4.

5 Conditioned medium from COS cells transfected with pCAV-18 or pCAV-7B9-4 (see Example 8) and grown in DMEM containing 3% FBS was harvested three days after transfection. Supernatants were centrifuged at 3,000 cpm for 10 minutes, and frozen until needed. Two hundred ml of conditioned media was loaded onto a column containing 4 ml of mIL-4 Affigel prepared as described above. The column was washed extensively with PBS and IL-4 receptor eluted with 0.1 M glycine, 0.15 M NaCl pH 3.0. Immediately following elution, samples were neutralized with 80  $\mu\text{l}$  of 1 M Hepes pH 7.4. Samples were tested for their ability to inhibit binding of  $^{125}\text{I}$ -mIL-4 to CTLL cells as set forth in Example 1B. Additionally samples were tested for purity by analysis on SDS-PAGE and silver staining as previously described. Alternative methods for testing functional soluble receptor activity or IL-4 binding inhibition include solid-phase binding assays, as described in Example 1C, or other similar cell free assays which may utilize either radioiodinated or colorimetrically developed IL-4 binding, such as RIA or ELISA. The protein analyzed by SDS-PAGE under reducing conditions has a molecular weight of approximately 37,500, and appears approximately 90% pure by silver stain analysis of gels.

Purified recombinant soluble murine IL-4 receptor protein may also be tested for its ability to inhibit IL-4 induced  $^3\text{H}$ -thymidine incorporation in CTLL cells. Pursuant to such methods, soluble IL-4 receptor has been found to block IL-4 stimulated proliferation, but does not affect IL-2 driven mitogenic response.

20 Molecular weight estimates were performed on mIL-4 receptor clones transfected into COS cells. Utilizing M2 monoclonal antibody prepared against murine CTLL 19.4 cells (see Example 13), IL-4 receptor is immunoprecipitated from COS cells transfected with CAV-16, CAV-7B9-2 and CAV-7B9-4 and labeled with  $^{35}\text{S}$ -cysteine and  $^{35}\text{S}$ -methionine. Cell associated receptor from CAV-7B9-4 shows molecular weight heterogeneity ranging from 32-39 kDa. Secreted CAV-7B9-4 receptor has molecular weight between 36 and 41 kDa. Cell associated receptor from CAV-16 transfected COS cells is about 40-41 kDa. This is significantly smaller than molecular weight estimations from crosslinking studies described by Park et al., *J. Exp. Med.* 166:476, 1987; *J. Cell. Biol.*, Suppl. 12A, 1988. Immunoprecipitation of COS CAV-7B9-2 cell-associated receptor showed a molecular weight of 130-140 kDa, similar to the estimates of Park et al., *J. Cell. Biol.*, Suppl. 12A, 1988, estimated to be the full length IL-4 receptor. Similar molecular weight estimates of cell-associated CAV-16 and CAV-7B9-2 IL-4 receptor have also been made based on cross-linking  $^{125}\text{I}$ -IL-4 to COS cells transfected with these cDNAs. Heterogeneity of molecular weight of the individual clones can be partially attributed to glycosylation. This data, together with DNA sequence analysis, suggests that the 7B9-2 cDNA encodes the full length cell-surface IL-4 receptor, whereas both 7B9-4 and clone 18 represent soluble forms of murine IL-4 receptor.

Receptor characterization studies were also done on COS cells transfected with hIL-4R containing expression plasmids. The two chimeric human IL-4R molecules A5 and B4 (defined in Example 11) were transfected into COS cells and equilibrium binding studies undertaken. The COS monkey cell itself has receptors capable of binding hIL-4; therefore the binding calculations performed on COS cells transfected with and overexpressing hIL-4R cDNAs represent background binding from endogenous monkey IL-4R molecules subtracted from the total binding. COS cells transfected with hIL-4R A5 had  $5.3 \times 10^4$  hIL-4 binding sites with a calculated  $K_d$  of  $3.48 \times 10^9 \text{ M}^{-1}$ . Similarly, the hIL-4R B4 expressed in COS cells bound  $^{125}\text{I}$ -hIL-4 with an affinity of  $3.94 \times 10^9 \text{ M}^{-1}$  exhibiting  $3.2 \times 10^4$  receptors per cell.

40 Molecular weight estimates of human IL-4R expressed in COS cells were also performed. COS cells transfected with clones A5 or B4 in pCAV/NOT were labeled with  $^{35}\text{S}$ -cysteine/ methionine and lysed. Human IL-4R was affinity purified from the resulting lysates with hIL-4-coupled Affigel® (as described in Example 4). The hIL-4R A5 and B4 eluted from this affinity support migrated at about 140,000 daltons on SDS-PAGE, agreeing well with previous estimates of hIL-4R molecular weight by cross-linking (Park et al., *J. Exp. Med.* 166:476, 1987), as well as with estimates of full-length mIL-4R presented here.

Because no soluble human IL-4R cDNA has thus far been found occurring naturally, as was the case for the murine receptor (clones 18 and 7B9-4), a truncated form was constructed as described in Example 11. Following expression in COS cells, supernatants were harvested three days after transfection with soluble hIL-4R-11 and soluble hIL-4R-5 and tested for inhibition of  $^{125}\text{I}$ -hIL-4 binding to the human B cell line Raji. Supernatants from two of the soluble hIL-4R-11 and one of the soluble hIL-4R-5 transfected plates contained 29-149 ng/ml of IL-4R competing activity into the medium. In addition, the truncated protein could be detected in  $^{35}\text{S}$ -methionine/cysteine-labeled COS cell transfectants by affinity purification on hIL-4-coupled Affigel® as approximately a 44 kDa protein by SDS-PAGE. Supernatants COS cells transfected with hIL-4R-8 (encoding soluble truncated IL-4R) when concentrated 25-fold, inhibited human IL-4 binding to Raji cells, and contained approximately 16 ng/ml of competing activity.

**Example 13**Preparation of monoclonal antibodies to IL-4R

Preparations of purified recombinant IL-4 receptor, for example, human or murine IL-4 receptor, transfected COS cells expressing high levels of IL-4 receptor or CTLL 19.4 cells are employed to generate monoclonal antibodies against IL-4 receptor using conventional techniques, such as those disclosed in U.S. Patent 4,411,993. Such antibodies are likely to be useful in interfering with IL-4 binding to IL-4 receptors, for example, in ameliorating toxic or other undesired effects of IL-4.

To immunize rats, IL-4 receptor bearing CTLL 19.4 cells were used as immunogen emulsified in complete Freund's adjuvant and injected in amounts ranging from 10-100 µl subcutaneously into Lewis rats. Three weeks later, the immunized animals were boosted with additional immunogen emulsified in incomplete Freund's adjuvant and boosted every three weeks thereafter. Serum sample are periodically taken by retro-orbital bleeding or tail-tip excision for testing by dot-blot assay, ELISA (enzyme-linked immunosorbent assay), or inhibition of binding of <sup>125</sup>I-IL-4 to extracts of CTLL cells (as described in Example 1). Other assay procedures are also suitable. Following detection of an appropriate antibody titer, positive animals were given a final intravenous injection of antigen in saline. Three to four days later, the animals were sacrificed, splenocytes harvested, and fused to the murine myeloma cell line AG8653. Hybridoma cell lines generated by this procedure were plated in multiple microtiter plates in a HAT selective medium (hypoxanthine, aminopterin, and thymidine) to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

Hybridoma clones thus generated were screened for reactivity with IL-4 receptor. Initial screening of hybridoma supernatants utilized an antibody capture and binding of partially purified <sup>125</sup>I-mIL-4 receptor. Two of over 400 hybridomas screened were positive by this method. These two monoclonal antibodies, M1 and M2, were tested by a modified antibody capture to detect blocking antibody. Only M1 was able to inhibit <sup>125</sup>I-rmIL-4 binding to intact CTLL cells. Both antibodies are capable of immunoprecipitating native mIL-4R protein from CTLL cells or COS-7 cells transfected with IL-4R clones labelled with <sup>35</sup>S-cysteine/methionine. M1 and M2 were then injected into the peritoneal cavities of nude mice to produce ascites containing high concentrations (>1 mg/ml) of anti-IL-4R monoclonal antibody. The resulting monoclonal antibody was purified by ammonium sulfate precipitation followed by gel exclusion chromatography, and/or affinity chromatography based on binding of antibody to Protein G.

**Example 14**Use of soluble IL-4R to suppress immune response *in vivo*

Experiments were conducted to determine the effect of soluble IL-4R on allogeneic host versus graft (HVG) response *in vivo* using a popliteal lymph node assay. In this model mice are injected in the footpad with irradiated, allogeneic spleen cells. Irradiated, syngeneic cells are then injected into the contralateral pad. An alloreactive response occurs in the pad receiving the allogeneic cells, the extent of which can be measured by the relative increase in size and weight of the popliteal lymph node draining the site of antigen deposition.

On day 0 three BALB/C mice were injected in the footpad with irradiated, allogeneic spleen cells from c57BL/6 mice and in the contralateral footpad with irradiated, syngeneic spleen cells. On days -1, 0 and +1 three mice were injected (intravenously on days -1 and 0, and subcutaneously on day +1) with 100 ng of purified soluble IL-4R (sIL-4R) in phosphate buffered saline, three mice were injected intravenously with 1 µg of sIL-4R, three mice were injected with 2 µg of sIL-4R and three mice were injected with MSA (control). The mean difference in weight of the lymph nodes from the sites of allogeneic and syngeneic spleen cells was approximately 2.5 mg for the mice treated with MSA, 1 mg for the mice treated with 100 ng of sIL-4R, and 0.5 mg for mice treated with 1 µg sIL-4R. No detectable difference in weight of lymph nodes was ascertainable for the mice treated with 2 µg sIL-4R. Thus, IL-4R significantly ( $p < 0.5$  in all groups, using a two-tailed T test) suppressed the *in vivo* lymphoproliferative response in a dose dependent fashion relative to control mice.

**Claims**

**Claims for the following Contracting States : AT, BE, CH, LI, DE, FR, GB, IT, LU, NL, SE**

1. An isolated DNA sequence encoding a polypeptide capable of binding mammalian IL-4, wherein said DNA sequence is selected from the group consisting of:

(a) cDNA clones comprising a nucleotide sequence selected from the sequence presented as nucleotides -75 to 2355 of Figures 2A-2C, nucleotides 1 to 2355 of Figures 2A-2C, nucleotides -75 to 2400 of Figures 4A-4C, and nucleotides 1 to 2400 of Figures 4A-4C;

(b) DNA sequences capable of hybridisation to a cDNA of (a) under moderately stringent conditions, and which encode a polypeptide capable of binding mammalian IL-4; and

(c) DNA sequences that are degenerate as a result of the genetic code to a DNA sequence defined in (a) or (b), and which encode a polypeptide capable of binding mammalian IL-4.

2. A DNA sequence according to claim 1, wherein said DNA sequence comprises a nucleotide sequence selected from the group consisting of nucleotides -75 to 2355 of Figures 2A-2C, nucleotides 1 to 2355 of Figures 2A-2C, nucleotides -75 to 2400 of Figures 4A-4C, and nucleotides 1 to 2400 of Figures 4A-4C.

3. A DNA sequence according to claim 1, wherein said DNA sequence comprises a nucleotide sequence selected from the group consisting of nucleotides -75 to 621 of Figure 4A, and nucleotides 1 to 621 of Figure 4A.

4. A DNA sequence according to claim 1, which encodes an amino acid sequence that is greater than 80% similar to an amino acid sequence selected from residues -25 to 800, 1 to 800, -25 to 207, or 1 to 207, depicted in Figures 4A-4C.

5. A DNA sequence according to claim 4, which encodes a soluble receptor capable of binding human IL-4 and comprising an amino acid sequence consisting essentially of amino acid residues -25 to 207 or 1 to 207 depicted in Figure 4A.

6. A DNA sequence according to claim 1, which encodes an amino acid sequence consisting essentially of amino acid residues -25 to 800 or 1 to 800 depicted in Figures 4A-4C.

7. A DNA sequence according to claim 1, which encodes an IL-4 receptor polypeptide comprising an amino acid sequence selected from the sequence of amino acid residues 1 to 800 depicted in Figures 4A-4C, 1 to 207 depicted in Figure 4A, 1 to 785 depicted in Figures 2A-2C, 1 to 208 depicted in Figure 2A, or analogs thereof having a biological activity of a mammalian IL-4 receptor.

8. An isolated DNA sequence which is:

a) a fragment of the nucleotide sequence presented as nucleotides 1 to 2355 of Figures 2A-2C; and

b) a fragment of the nucleotide sequence presented as nucleotides 1 to 2400 of Figures 4A-4C;

wherein said fragment encodes a polypeptide that possesses a biological activity of a mammalian IL-4 receptor.

9. An isolated DNA sequence which is:

a) a DNA fragment containing at least about 60 consecutive nucleotides of the sequence presented as nucleotides 1 to 2355 of Figures 2A-2C; or

b) a DNA fragment containing at least about 60 consecutive nucleotides of the sequence presented as nucleotides 1 to 2400 of Figures 4A-4C.

10. A recombinant expression vector comprising a DNA sequence according to any of claims 1 to 9.

11. A process for preparing a polypeptide capable of binding mammalian IL-4, comprising culturing a suitable host cell comprising a vector according to claim 10 under conditions promoting expression of said polypeptide.

12. A process for preparing a polypeptide capable of binding human IL-4, comprising culturing a suitable host cell comprising a vector according to claim 10 under conditions promoting expression of said polypeptide.

13. A purified polypeptide capable of binding mammalian IL-4, wherein said polypeptide is encoded by a DNA according

to any of claims 1 to 7.

14. A polypeptide according to claim 13, consisting essentially of murine IL-4 receptor or human IL-4 receptor.

15. A polypeptide according to claim 13, which comprises an amino acid sequence selected from the sequence of amino acid residues 1 to 800 depicted in Figures 4A-4C, 1 to 207 depicted in Figure 4A, 1 to 785 depicted in Figures 2A-2C, 1 to 208 depicted in Figure 2A, or which is a fragment or analog thereof having a biological activity of mammalian IL-4 receptor.

16. A polypeptide according to claim 14 which is a human IL-4 receptor in the form of a glycoprotein having a molecular weight of between about 110,000 and 150,000  $M_r$  by SDS-PAGE and a binding affinity ( $K_a$ ) for human IL-4 of from  $1-8 \times 10^9 M^{-1}$ .

17. A polypeptide according to claim 14 which has an N terminal amino acid sequence Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp.

18. A polypeptide according to claim 13 wherein the transmembrane region and cytoplasmic domain of the native receptor have been deleted.

19. A polypeptide according to claim 15, wherein said polypeptide comprises an amino acid sequence that is greater than 80% similar to a sequence selected from residues 1-800 depicted in Figures 4A to 4C and residues 1-207 depicted in Figure 4A.

20. A polypeptide according to claim 19 which comprises an amino acid sequence consisting essentially of residues 1-207 depicted in Figure 4A.

21. A polypeptide according to claim 19 capable of binding human IL-4, wherein said polypeptide comprises an amino acid sequence consisting essentially of residues 1-800 depicted in Figures 4A to 4C.

22. A purified polypeptide selected from the group consisting of:

a) a fragment of the polypeptide having the sequence of amino acids 1 to 785 of Figures 2A-2C; and

b) a fragment of the polypeptide having the sequence of amino acids 1 to 800 of Figures 4A-4C;

wherein said fragment possesses a biological activity of the IL-4 receptor.

23. A purified polypeptide selected from the group consisting of:

a) a polypeptide comprising at least about 20 consecutive residues of the sequence presented as amino acids 1 to 785 of Figures 2A-2C; and

b) a polypeptide comprising at least about 20 consecutive residues of the sequence presented as amino acids 1 to 800 of Figures 4A-4C.

24. A pharmaceutical composition for regulating immune responses in a mammal, comprising an effective amount of a polypeptide according to any of claims 13 to 23 and a suitable diluent or carrier.

25. A composition according to claim 24 having a specific binding activity of at least about 0.01 nanomole IL-4/nanomole of said polypeptide.

26. A composition according to claim 24, wherein said polypeptide binds human IL-4 and is in the form of a glycoprotein having a binding affinity ( $K_a$ ) for human IL-4 of about  $1-8 \times 10^9 M^{-1}$ , and also having the N-terminal amino acid sequence Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp.

27. A composition according to claim 24, wherein said polypeptide comprises an amino acid sequence consisting essentially of amino acids 1 to 207 depicted in Figure 4A.



28. The use of a polypeptide according to any of claims 13 to 23 in a binding assay for detection of IL-4 or IL-4 receptor molecules or the interaction thereof.
29. A polypeptide according to any of claims 13 to 23, for use in human or veterinary medicine.
30. The use of a polypeptide according to any of claims 13 to 23, in the preparation of a medicament for regulating immune responses in a mammal.
31. The use of claim 30, wherein the polypeptide and the mammal to be treated are human.
32. Antibodies that are immunoreactive with a polypeptide according to any of claims 13 to 23.
33. A antibody according to claim 32, wherein said antibody is a monoclonal antibody.
34. A antibody according to claim 33, wherein said monoclonal antibody is immunoreactive with a human IL-4 receptor polypeptide.
35. The use of an antibody according to any of claims 32 to 34 in the preparation of a medicament for ameliorating toxic or other undesired effects of IL-4.
36. A host cell transfected with a vector as claimed in claim 10.
37. RNA substantially complementary to the DNA as claimed in any of claims 1 to 9.
38. A fusion protein comprising a polypeptide sequence coupled to a polypeptide as claimed in any of claims 13 to 23.
39. A fusion protein according to claim 38 for use in human or veterinary medicine.
40. The use of a fusion protein according to claim 38 in the preparation of a medicament for regulating an immune response in a mammal.
41. The use of a fusion protein according to claim 40 wherein the fusion protein comprises a polypeptide sequence capable of binding human IL-4 and wherein the mammal is a human.

**Claims for the following Contracting State : ES**

1. A process comprising the step of isolating a DNA sequence encoding a polypeptide capable of binding mammalian IL-4, wherein said DNA sequence is selected from the group consisting of:
  - (a) cDNA clones comprising a nucleotide sequence selected from the sequence presented as nucleotides -75 to 2355 of Figures 2A-2C, nucleotides 1 to 2355 of Figures 2A-2C, nucleotides -75 to 2400 of Figures 4A-4C, and nucleotides 1 to 2400 of Figures 4A-4C;
  - (b) DNA sequences capable of hybridisation to a cDNA of (a) under moderately stringent conditions, and which encode a polypeptide capable of binding mammalian IL-4; and
  - (c) DNA sequences that are degenerate as a result of the genetic code to a DNA sequence defined in (a) or (b), and which encode a polypeptide capable of binding mammalian IL-4.
2. A process according to claim 1, wherein said DNA sequence comprises a nucleotide sequence selected from the group consisting of nucleotides -75 to 2355 of Figures 2A-2C, nucleotides 1 to 2355 of Figures 2A-2C, nucleotides -75 to 2400 of Figures 4A-4C, and nucleotides 1 to 2400 of Figures 4A-4C.
3. A process according to claim 1, wherein said DNA sequence comprises a nucleotide sequence selected from the group consisting of nucleotides -75 to 621 of Figure 4A, and nucleotides 1 to 621 of Figure 4A.
4. A process according to claim 1, wherein said DNA sequence encodes an amino acid sequence that is greater than

80% similar to an amino acid sequence selected from residues -25 to 800, 1 to 800, -25 to 207, or 1 to 207, depicted in Figures 4A-4C.

- 5 5. A process according to claim 4, wherein said DNA sequence encodes a soluble receptor capable of binding human IL-4 and comprising an amino acid sequence consisting essentially of amino acid residues -25 to 207 or 1 to 207 depicted in Figure 4A.
- 10 6. A process according to claim 1, wherein said DNA sequence encodes an amino acid sequence consisting essentially of amino acid residues -25 to 800 or 1 to 800 depicted in Figures 4A-4C.
- 15 7. A process according to claim 1, wherein said DNA sequence encodes an IL-4 receptor polypeptide comprising an amino acid sequence selected from the sequence of amino acid residues 1 to 800 depicted in Figures 4A-4C, 1 to 207 depicted in Figure 4A, 1 to 785 depicted in Figures 2A-2C, 1 to 208 depicted in Figure 2A, or an analog thereof having a biological activity of a mammalian IL-4 receptor.
- 20 8. A process comprising isolating a DNA sequence wherein the DNA sequence is:
  - a) a fragment of the nucleotide sequence presented as nucleotides 1 to 2355 of Figures 2A-2C; and
  - 20 b) a fragment of the nucleotide sequence presented as nucleotides 1 to 2400 of Figures 4A-4C;wherein said fragment encodes a polypeptide that possesses a biological activity of a mammalian IL-4 receptor.
- 25 9. A process comprising isolating a DNA sequence, wherein the DNA sequence is:
  - a) a DNA fragment containing at least about 60 consecutive nucleotides of the sequence presented as nucleotides 1 to 2355 of Figures 2A-2C; or
  - 30 b) a DNA fragment containing at least about 60 consecutive nucleotides of the sequence presented as nucleotides 1 to 2400 of Figures 4A-4C.
- 35 10. A process comprising forming a recombinant expression vector comprising a DNA sequence as described in any of claims 1 to 9.
- 40 11. A process for preparing a polypeptide capable of binding mammalian IL-4, comprising culturing a suitable host cell comprising a vector as described in claim 10 under conditions promoting expression of said polypeptide.
- 45 12. A process for preparing a polypeptide capable of binding human IL-4, comprising culturing a suitable host cell comprising a vector as described in claim 10 under conditions promoting expression of said polypeptide.
- 50 13. A process comprising purifying a polypeptide capable of binding mammalian IL-4, wherein said polypeptide is encoded by a DNA sequence as described in any of claims 1 to 7.
- 55 14. A process according to claim 13, wherein said polypeptide consists essentially of murine IL-4 receptor or human IL-4 receptor.
15. A process according to claim 13, wherein said polypeptide comprises an amino acid sequence selected from the sequence of amino acid residues 1 to 800 depicted in Figures 4A-4C, 1 to 207 depicted in Figure 4A, 1 to 785 depicted in Figures 2A-2C, 1 to 208 depicted in Figure 2A, or is a fragment or analog thereof having a biological activity of mammalian IL-4 receptor.
16. A process according to claim 14 wherein said polypeptide is a human IL-4 receptor in the form of a glycoprotein having a molecular weight of between about 110,000 and 150,000 M<sub>r</sub> by SDS-PAGE and a binding affinity (K<sub>a</sub>) for human IL-4 of from 1-8 x 10<sup>9</sup>M<sup>-1</sup>.
17. A process according to claim 14 wherein said polypeptide has an N terminal amino acid sequence Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp.

18. A process according to claim 13 wherein said polypeptide does not have the transmembrane region and cytoplasmic domain of the native receptor.
19. A process according to claim 15, wherein said polypeptide comprises an amino acid sequence that is greater than 80% similar to a sequence selected from residues 1-800 depicted in Figures 4A to 4C and residues 1-207 depicted in Figure 4A.
20. A process according to claim 19 wherein said polypeptide comprises an amino acid sequence consisting essentially of residues 1-207 depicted in Figure 4A.
21. A process according to claim 19 wherein said polypeptide is capable of binding human IL-4, and comprises an amino acid sequence consisting essentially of residues 1-800 depicted in Figures 4A to 4C.
22. A process comprising purifying a polypeptide selected from the group consisting of:
  - a) a fragment of the polypeptide having the sequence of amino acids 1 to 785 of Figures 2A-2C; and
  - b) a fragment of the polypeptide having the sequence of amino acids 1 to 800 of Figures 4A-4C;wherein said fragment possesses a biological activity of the IL-4 receptor.
23. A process comprising purifying a polypeptide wherein the polypeptide is selected from the group consisting of:
  - a) a polypeptide comprising at least about 20 consecutive residues of the sequence presented as amino acids 1 to 785 of Figures 2A-2C; and
  - b) a polypeptide comprising at least about 20 consecutive residues of the sequence presented as amino acids 1 to 800 of Figures 4A-4C.
24. A process comprising forming a pharmaceutical composition for regulating immune responses in a mammal, comprising an effective amount of a polypeptide as described in any of claims 13 to 23 and a suitable diluent or carrier.
25. A process according to claim 24, wherein there is a specific binding activity of at least about 0.01 nanomole IL-4/nanomole of said polypeptide.
26. A process according to claim 24, wherein said polypeptide binds human IL-4 and is in the form of a glycoprotein having a binding affinity ( $K_a$ ) for human IL-4 of about  $1-8 \times 10^9 \text{ M}^{-1}$ , and also having the N-terminal amino acid sequence Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp.
27. A process according to claim 24, wherein said polypeptide comprises an amino acid sequence consisting essentially of amino acids 1 to 207 depicted in Figure 4A.
28. The use of a polypeptide as described in any of claims 13 to 23 in a binding assay for detection of IL-4 or IL-4 receptor molecules or the interaction thereof.
29. A polypeptide as described in any of claims 13 to 23, for use in human or veterinary medicine.
30. The use of a polypeptide as described in any of claims 13 to 23, in the preparation of a medicament for regulating immune responses in a mammal.
31. The use of claim 30, wherein the polypeptide and the mammal to be treated are human.
32. A process comprising providing antibodies that are immunoreactive with a polypeptide according to any of claims 13 to 23.
33. A process according to claim 32, wherein said antibodies are monoclonal antibodies.
34. A process according to claim 33, wherein said monoclonal antibodies are immunoreactive with a human IL-4 re-

ceptor polypeptide.

35. The use of an antibody as described in any of claims 32 to 34 in the preparation of a medicament for ameliorating toxic or other undesired effects of IL-4.
36. A host cell transfected with a vector as described in claim 10.
37. A process comprising providing RNA substantially complementary to the DNA as described in any of claims 1 to 9.
38. A process comprising providing a fusion protein comprising a polypeptide sequence coupled to a polypeptide as described in any of claims 13 to 23.
39. A fusion protein as described in claim 38 for use in human or veterinary medicine.
40. The use of a fusion protein as described in claim 38 in the preparation of a medicament for regulating an immune response in a mammal.
41. The use of a fusion protein as described in claim 40 wherein the fusion protein comprises a polypeptide sequence capable of binding human IL-4 and wherein the mammal is a human.

**Claims for the following Contracting State : GR**

1. An isolated DNA sequence encoding a polypeptide capable of binding mammalian IL-4, wherein said DNA sequence is selected from the group consisting of:
  - (a) cDNA clones comprising a nucleotide sequence selected from the sequence presented as nucleotides -75 to 2355 of Figures 2A-2C, nucleotides 1 to 2355 of Figures 2A-2C, nucleotides -75 to 2400 of Figures 4A-4C, and nucleotides 1 to 2400 of Figures 4A-4C;
  - (b) DNA sequences capable of hybridisation to a cDNA of (a) under moderately stringent conditions, and which encode a polypeptide capable of binding mammalian IL-4; and
  - (c) DNA sequences that are degenerate as a result of the genetic code to a DNA sequence defined in (a) or (b), and which encode a polypeptide capable of binding mammalian IL-4.
2. A DNA sequence according to claim 1, wherein said DNA sequence comprises a nucleotide sequence selected from the group consisting of nucleotides -75 to 2355 of Figures 2A-2C, nucleotides 1 to 2355 of Figures 2A-2C, nucleotides -75 to 2400 of Figures 4A-4C, and nucleotides 1 to 2400 of Figures 4A-4C.
3. A DNA sequence according to claim 1, wherein said DNA sequence comprises a nucleotide sequence selected from the group consisting of nucleotides -75 to 621 of Figure 4A, and nucleotides 1 to 621 of Figure 4A.
4. A DNA sequence according to claim 1, which encodes an amino acid sequence that is greater than 80% similar to an amino acid sequence selected from residues -25 to 800, 1 to 800, -25 to 207, or 1 to 207, depicted in Figures 4A-4C.
5. A DNA sequence according to claim 4, which encodes a soluble receptor capable of binding human IL-4 and comprising an amino acid sequence consisting essentially of amino acid residues -25 to 207 or 1 to 207 depicted in Figure 4A.
6. A DNA sequence according to claim 1, which encodes an amino acid sequence consisting essentially of amino acid residues -25 to 800 or 1 to 800 depicted in Figures 4A-4C.
7. A DNA sequence according to claim 1, which encodes an IL-4 receptor polypeptide comprising an amino acid sequence selected from the sequence of amino acid residues 1 to 800 depicted in Figures 4A-4C, 1 to 207 depicted in Figure 4A, 1 to 785 depicted in Figures 2A-2C, 1 to 208 depicted in Figure 2A, or analogs thereof having a biological activity of a mammalian IL-4 receptor.

8. An isolated DNA sequence which is:

a) a fragment of the nucleotide sequence presented as nucleotides 1 to 2355 of Figures 2A-2C; and

b) a fragment of the nucleotide sequence presented as nucleotides 1 to 2400 of Figures 4A-4C;

wherein said fragment encodes a polypeptide that possesses a biological activity of a mammalian IL-4 receptor.

9. An isolated DNA sequence which is:

a) a DNA fragment containing at least about 60 consecutive nucleotides of the sequence presented as nucleotides 1 to 2355 of Figures 2A-2C; or

b) a DNA fragment containing at least about 60 consecutive nucleotides of the sequence presented as nucleotides 1 to 2400 of Figures 4A-4C.

10. A recombinant expression vector comprising a DNA sequence according to any of claims 1 to 9.

11. A process for preparing a polypeptide capable of binding mammalian IL-4, comprising culturing a suitable host cell comprising a vector according to claim 10 under conditions promoting expression of said polypeptide.

12. A process for preparing a polypeptide capable of binding human IL-4, comprising culturing a suitable host cell comprising a vector according to claim 10 under conditions promoting expression of said polypeptide.

13. A process comprising purifying a polypeptide capable of binding mammalian IL-4, wherein said polypeptide is encoded by a DNA according to any of claims 1 to 7.

14. A process according to claim 13, wherein said polypeptide consists essentially of murine IL-4 receptor or human IL-4 receptor.

15. A process according to claim 13, wherein said polypeptide comprises an amino acid sequence selected from the sequence of amino acid residues 1 to 800 depicted in Figures 4A-4C, 1 to 207 depicted in Figure 4A, 1 to 785 depicted in Figures 2A-2C, 1 to 208 depicted in Figure 2A, or is a fragment or analog thereof having a biological activity of mammalian IL-4 receptor.

16. A process according to claim 14 wherein said polypeptide is a human IL-4 receptor in the form of a glycoprotein having a molecular weight of between about 110,000 and 150,000 M<sub>r</sub> by SDS-PAGE and a binding affinity (K<sub>a</sub>) for human IL-4 of from 1-8 x 10<sup>9</sup>M<sup>-1</sup>.

17. A process according to claim 14 wherein said polypeptide has an N terminal amino acid sequence Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp.

18. A process according to claim 13 wherein the transmembrane region and cytoplasmic domain of the native receptor are not present in said polypeptide.

19. A process according to claim 15, wherein said polypeptide comprises an amino acid sequence that is greater than 80% similar to a sequence selected from residues 1-800 depicted in Figures 4A to 4C and residues 1-207 depicted in Figure 4A.

20. A process according to claim 19 wherein said polypeptide comprises an amino acid sequence consisting essentially of residues 1-207 depicted in Figure 4A.

21. A process according to claim 19 wherein said polypeptide is capable of binding human IL-4 and comprises an amino acid sequence consisting essentially of residues 1-800 depicted in Figures 4A to 4C.

22. A process comprising purifying a polypeptide selected from the group consisting of:

a) a fragment of the polypeptide having the sequence of amino acids 1 to 785 of Figures 2A-2C; and

b) a fragment of the polypeptide having the sequence of amino acids 1 to 800 of Figures 4A-4C;

wherein said fragment possesses a biological activity of the IL-4 receptor.

23. A process comprising purifying a polypeptide selected from the group consisting of:

a) a polypeptide comprising at least about 20 consecutive residues of the sequence presented as amino acids 1 to 785 of Figures 2A-2C; and

b) a polypeptide comprising at least about 20 consecutive residues of the sequence presented as amino acids 1 to 800 of Figures 4A-4C.

24. A process comprising forming a pharmaceutical composition for regulating immune responses in a mammal, comprising an effective amount of a polypeptide as described in any of claims 13 to 23 and a suitable diluent or carrier.

25. A process according to claim 24 wherein there is a specific binding activity of at least about 0.01 nanomole IL-4/nanomole of said polypeptide.

26. A process according to claim 24, wherein said polypeptide binds human IL-4 and is in the form of a glycoprotein having a binding affinity ( $K_a$ ) for human IL-4 of about  $1-8 \times 10^9 \text{ M}^{-1}$ , and also having the N-terminal amino acid sequence Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp.

27. A process according to claim 24, wherein said polypeptide comprises an amino acid sequence consisting essentially of amino acids 1 to 207 depicted in Figure 4A.

28. The use of a polypeptide as described in any of claims 13 to 23 in a binding assay for detection of IL-4 or IL-4 receptor molecules or the interaction thereof.

29. A polypeptide as described in any of claims 13 to 23, for use in human or veterinary medicine.

30. The use of a polypeptide as described in any of claims 13 to 23, in the preparation of a medicament for regulating immune responses in a mammal.

31. The use of claim 30, wherein the polypeptide and the mammal to be treated are human.

32. A process comprising providing antibodies that are immunoreactive with a polypeptide as described in any of claims 13 to 23.

33. A process according to claim 32, wherein said antibodies are monoclonal antibodies.

34. A process according to claim 33, wherein said monoclonal antibodies are immunoreactive with a human IL-4 receptor polypeptide.

35. The use of antibodies as described in any of claims 32 to 34 in the preparation of a medicament for ameliorating toxic or other undesired effects of IL-4.

36. A host cell transfected with a vector as described in claim 10.

37. A process comprising providing RNA substantially complementary to the DNA as described in any of claims 1 to 9.

38. A process comprising providing a fusion protein comprising a polypeptide sequence coupled to a polypeptide as described in any of claims 13 to 23.

39. A fusion protein as described in claim 38 for use in human or veterinary medicine.

40. The use of a fusion protein as described in claim 38 in the preparation of a medicament for regulating an immune response in a mammal.

41. The use of a fusion protein as described in claim 40 wherein the fusion protein comprises a polypeptide sequence capable of binding human IL-4 and wherein the mammal is a human.

5 **Patentansprüche**

**Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, LI, DE, FR, GB, IT, LU, NL, SE**

- 10 1. Isolierte DNA-Sequenz, die für ein Polypeptid kodiert, das fähig ist, Säuger IL-4 zu binden, wobei die DNA-Sequenz aus der Gruppe ausgewählt ist, bestehend aus:
- 15 (a) cDNA-Klonen, die eine Nucleotid-Sequenz enthalten, ausgewählt aus der Sequenz, dargestellt als Nucleotide -75 bis 2355 der Fig. 2A-2C, Nucleotide 1 bis 2355 der Fig. 2A-2C, Nucleotide -75 bis 2400 der Fig. 4A-4C und Nucleotide 1 bis 2400 der Fig. 4A-4C;
- (b) DNA-Sequenzen, die fähig sind, mit einer cDNA von (a) unter moderat stringenten Bedingungen zu hybridisieren und die für ein Polypeptid kodieren, das fähig ist, Säuger IL-4 zu binden; und
- 20 (c) DNA-Sequenzen, die als Ergebnis des genetischen Codes zu einer DNA-Sequenz degeneriert sind, wie definiert in (a) oder (b), und die für ein Polypeptid kodieren, das fähig ist, Säuger IL-4 zu binden.
2. DNA-Sequenz gemäß Anspruch 1, wobei die DNA-Sequenz eine Nucleotid-Sequenz enthält, die ausgewählt ist aus der Gruppe, bestehend aus den Nucleotiden -75 bis 2355 der Fig. 2A-2C, den Nucleotiden 1 bis 2355 der Fig. 2A-2C, den Nucleotiden -75 bis 2400 der Fig. 4A-4C und den Nucleotiden 1 bis 2400 der Fig. 4A-4C.
- 25 3. DNA-Sequenz gemäß Anspruch 1, wobei die DNA-Sequenz eine Nucleotid-Sequenz enthält, die ausgewählt ist aus der Gruppe, bestehend aus den Nucleotiden -75 bis 621 der Fig. 4A, und den Nucleotiden 1 bis 621 der Fig. 4A.
- 30 4. DNA-Sequenz gemäß Anspruch 1, die für eine Aminosäure-Sequenz kodiert, die eine mehr als 80%ige Ähnlichkeit zu einer Aminosäure-Sequenz aufweist, die ausgewählt ist aus den Resten -25 bis 800, 1 bis 800, -25 bis 207 oder 1 bis 207, wie dargestellt in den Fig. 4A-4C.
- 35 5. DNA-Sequenz gemäß Anspruch 4, die für einen löslichen Rezeptor kodiert, der fähig ist, menschliches IL-4 zu binden und eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Aminosäureresten -25 bis 207 oder 1 bis 207 besteht, wie dargestellt in Fig. 4A.
6. DNA-Sequenz gemäß Anspruch 1, die für eine Aminosäure-Sequenz kodiert, die im wesentlichen aus den Aminosäureresten -25 bis 800 oder 1 bis 800 besteht, wie dargestellt in den Fig. 4A-4C.
- 40 7. DNA-Sequenz gemäß Anspruch 1, die für ein IL-4 Rezeptorpolypeptid kodiert, das eine Aminosäure-Sequenz enthält, die ausgewählt ist aus der Sequenz der Aminosäurereste 1 bis 800, wie dargestellt in den Fig. 4A-4C, 1 bis 207, wie dargestellt in Fig. 4A, 1 bis 785, wie dargestellt in den Fig. 2A-2C, 1 bis 208, wie dargestellt in Fig. 2A oder Analogen davon mit einer biologischen Aktivität eines Säuger IL-4 Rezeptors.
- 45 8. Isolierte DNA-Sequenz, die:
- a) ein Fragment der Nucleotid-Sequenz, dargestellt als Nucleotide 1 bis 2355 der Fig. 2A-2C, ist; und
- 50 b) ein Fragment der Nucleotid-Sequenz, dargestellt als Nucleotide 1 bis 2400 der Fig. 4A-4C ist;
- wobei das Fragment für eine Polypeptid kodiert, das eine biologische Aktivität eines Säuger IL-4 Rezeptors aufweist.
- 55 9. Isolierte DNA-Sequenz, die
- a) ein DNA-Fragment ist, das mindestens ungefähr 60 aufeinanderfolgende Nucleotide der Sequenz enthält, dargestellt als Nucleotide 1 bis 2355 der Fig. 2A-2C; oder



b) ein DNA-Fragment ist, das mindestens ungefähr 60 aufeinanderfolgende Nucleotide der Sequenz enthält, dargestellt als Nucleotide 1 bis 2400 der Fig. 4A-4C.

10. Rekombinanter Expressionsvektor, der eine DNA-Sequenz gemäß einem oder mehreren der Ansprüche 1 bis 9 enthält.

11. Verfahren für die Herstellung eines Polypeptids, das fähig ist, Säuger IL-4 zu binden, das den Schritt der Kultivierung einer geeigneten Wirtszelle enthält, die einen Vektor gemäß Anspruch 10 enthält unter Bedingungen, die die Expression des Polypeptids unterstützen.

12. Verfahren für die Herstellung eines Polypeptids, das fähig ist, menschliches IL-4 zu binden, das den Schritt der Kultivierung einer geeigneten Wirtszelle enthält, die einen Vektor gemäß Anspruch 10 enthält unter Bedingungen, die die Expression des Polypeptids unterstützen.

13. Gereinigtes Polypeptid, das fähig ist zur Bindung von Säuger IL-4, wobei das Polypeptid durch eine DNA gemäß einem oder mehreren der Ansprüche 1 bis 7 kodiert wird.

14. Polypeptid gemäß Anspruch 13, das im wesentlichen aus murinem IL-4 Rezeptor oder menschlichem IL-4 Rezeptor besteht.

15. Polypeptid gemäß Anspruch 13, das eine Aminosäure-Sequenz enthält, die ausgewählt ist aus der Sequenz der Aminosäurereste 1 bis 800, wie dargestellt in Fig. 4A-4C, 1 bis 207, wie dargestellt in Fig. 4A, 1 bis 785, wie dargestellt in den Fig. 2A-2C, 1 bis 208, wie dargestellt in Fig. 2A oder das ein Fragment oder ein Analog davon ist mit einer biologischen Aktivität des Säuger IL-4 Rezeptors.

16. Polypeptid gemäß Anspruch 14, das ein menschlicher IL-4 Rezeptor in Form eines Glycoproteins mit einem Molekulargewicht von zwischen ungefähr 110.000 und 150.000 M<sub>r</sub> durch SDS-PAGE ist und einer Bindungsaffinität ( $K_d$ ) für menschliches IL-4 von  $1-8 \times 10^9 \text{ M}^{-1}$ .

17. Polypeptid gemäß Anspruch 14, das eine N-terminale Aminosäure-Sequenz Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp aufweist.

18. Polypeptid gemäß Anspruch 13, wobei die transmembrane Region und die Cytoplasmadomäne des nativen Rezeptors deletiert wurden.

19. Polypeptid gemäß Anspruch 15, wobei das Polypeptid eine Aminosäure-Sequenz enthält, die eine mehr als 80%ige Ähnlichkeit mit einer Sequenz aufweist, die aus den Resten 1 bis 800, wie dargestellt in den Fig. 4A-4C und den Resten 1 bis 207, wie dargestellt in Fig. 4A ausgewählt ist.

20. Polypeptid gemäß Anspruch 19, das eine Aminosäure-Sequenz aufweist, die im wesentlichen aus den Resten 1 bis 207, wie dargestellt in Fig. 4A, besteht.

21. Polypeptid gemäß Anspruch 19, das fähig ist zur Bindung von menschlichem IL-4, wobei das Polypeptid eine Aminosäure-Sequenz umfaßt, die im wesentlichen aus den Resten 1 bis 800, wie dargestellt in den Fig. 4A-4C, besteht.

22. Gereinigtes Polypeptid, ausgewählt aus der Gruppe, bestehend aus:

a) einem Fragment des Polypeptids mit der Sequenz der Aminosäuren 1 bis 785 der Fig. 2A-2C; und

b) einem Fragment des Polypeptids mit der Aminosäure-Sequenz 1 bis 800 der Fig. 4A-4C;

wobei das Fragment eine biologische Aktivität des IL-4 Rezeptors aufweist.

23. Gereinigtes Polypeptid, ausgewählt aus der Gruppe, bestehend aus:

a) einem Polypeptid, das mindestens ungefähr 20 aufeinanderfolgende Reste der Sequenz aufweist, dargestellt als Aminosäuren 1 bis 785 der Fig. 2A-2C; und

b) einem Polypeptid, das mindestens ungefähr 20 aufeinanderfolgende Reste der Sequenz enthält, dargestellt als Aminosäuren 1 bis 800 der Fig. 4A-4C.

24. Pharmazeutische Zusammensetzung für die Regulierung der Immunantworten in einem Säugetier, die eine wirksame Menge eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 enthält und ein geeignetes Verdünnungsmittel oder einen Träger enthält.

25. Zusammensetzung gemäß Anspruch 24, mit einer spezifischen Bindungsaktivität von mindestens ungefähr 0,01 Nanomol IL-4/Nanomol des Polypeptids.

26. Zusammensetzung gemäß Anspruch 24, wobei das Polypeptid menschliches IL-4 bindet und in Form eines Glycoproteins mit einer Bindungsaffinität ( $K_d$ ) für menschliches IL-4 von ungefähr  $1-8 \times 10^9 \text{ M}^{-1}$  vorliegt und die N-terminale Aminosäure-Sequenz Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp aufweist.

27. Zusammensetzung gemäß Anspruch 24, wobei das Polypeptid eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Aminosäuren 1 bis 207, wie dargestellt in Fig. 4A, besteht.

28. Verwendung eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 in einem Bindungsassay für die Detektion von IL-4 oder IL-4-Rezeptormolekülen oder deren Interaktionen.

29. Polypeptid gemäß einem oder mehreren der Ansprüche 13 bis 23 zur Verwendung in der Human- oder Veterinärmedizin.

30. Verwendung eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 für die Herstellung eines Medikaments für die Regulierung der Immunantworten in einem Säuger.

31. Verwendung gemäß Anspruch 30, wobei das Polypeptid und der zu behandelnde Säuger menschlich sind.

32. Antikörper, die immunreaktiv mit einem Polypeptid gemäß einem oder mehreren der Ansprüche 13 bis 23 sind.

33. Antikörper gemäß Anspruch 32, wobei der Antikörper ein monoklonaler Antikörper ist.

34. Antikörper gemäß Anspruch 33, worin der monoklonale Antikörper immunreaktiv mit einem menschlichen IL-4 Rezeptorpolypeptid ist.

35. Verwendung eines Antikörpers gemäß einem oder mehreren der Ansprüche 32 bis 34 für die Herstellung eines Medikaments zum Ausgleich von toxischen oder anderen ungewünschten Wirkungen von IL-4.

36. Wirtszelle, die mit einem Vektor gemäß Anspruch 10 transfiziert ist.

37. RNA, die im wesentlichen komplementär zu der DNA gemäß einem oder mehreren der Ansprüche 1 bis 9 ist.

38. Fusionsprotein, das eine Polypeptid-Sequenz enthält, gekoppelt an ein Polypeptid gemäß einem oder mehreren der Ansprüche 13 bis 23.

39. Fusionsprotein gemäß Anspruch 38, zur Verwendung in Human- oder Veterinärmedizin.

40. Verwendung eines Fusionsproteins gemäß Anspruch 38 für die Herstellung eines Medikaments für die Regulierung einer Immunantwort in einem Säuger.

41. Verwendung eines Fusionsproteins gemäß Anspruch 40, wobei das Fusionsprotein eine Polypeptid-Sequenz enthält, die fähig ist, humanes IL-4 zu binden, wobei der Säuger menschlich ist.

#### Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren, das den Schritt der Isolierung einer DNA-Sequenz enthält, die für ein Polypeptid kodiert, das fähig ist,

Säuger IL-4 zu binden, wobei die DNA-Sequenz aus der Gruppe ausgewählt ist, bestehend aus:

a) cDNA-Klonen, die eine Nucleotid-Sequenz enthalten, ausgewählt aus der Sequenz, dargestellt als Nucleotide -75 bis 2355 der Fig. 2A-2C, Nucleotide 1 bis 2355 der Fig. 2A-2C, Nucleotide -75 bis 2400 der Fig. 4A-4C und Nucleotide 1 bis 2400 der Fig. 4A-4C;

(b) DNA-Sequenzen, die fähig sind, mit einer cDNA von (a) unter moderat stringenten Bedingungen zu hybridisieren und die für ein Polypeptid kodieren, das fähig ist, Säuger IL-4 zu binden; und

(c) DNA-Sequenzen, die als Ergebnis des genetischen Codes zu einer DNA-Sequenz degeneriert sind, wie definiert in (a) oder (b), und die für ein Polypeptid kodieren, das fähig ist, Säuger IL-4 zu binden.

2. Verfahren gemäß Anspruch 1, wobei die DNA-Sequenz eine Nucleotid-Sequenz enthält, die ausgewählt ist aus der Gruppe, bestehend aus den Nucleotiden -75 bis 2355 der Fig. 2A-2C, den Nucleotiden 1 bis 2355 der Fig. 2A-2C, den Nucleotiden -75 bis 2400 der Fig. 4A-4C und den Nucleotiden 1 bis 2400 der Fig. 4A-4C.

3. Verfahren gemäß Anspruch 1, wobei die DNA-Sequenz eine Nucleotid-Sequenz enthält, die ausgewählt ist aus der Gruppe, bestehend aus den Nucleotiden -75 bis 621 der Fig. 4A, und den Nucleotiden 1 bis 621 der Fig. 4A.

4. Verfahren gemäß Anspruch 1, wobei die DNA-Sequenz für eine Aminosäure-Sequenz kodiert, die eine mehr als 80%ige Ähnlichkeit zu einer Aminosäure-Sequenz aufweist, die ausgewählt ist aus den Resten -25 bis 800, 1 bis 800, -25 bis 207 oder 1 bis 207, wie dargestellt in den Fig. 4A-4C.

5. Verfahren gemäß Anspruch 4, wobei die DNA-Sequenz für einen löslichen Rezeptor kodiert, der fähig ist, menschliches IL-4 zu binden und eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Aminosäureresten -25 bis 207 oder 1 bis 207 besteht, wie dargestellt in Fig. 4A.

6. Verfahren gemäß Anspruch 1, wobei die DNA-Sequenz für eine Aminosäure-Sequenz kodiert, die im wesentlichen aus den Aminosäureresten -25 bis 800 oder 1 bis 800 besteht, wie dargestellt in den Fig. 4A-4C.

7. Verfahren gemäß Anspruch 1, wobei die DNA-Sequenz für ein IL-4 Rezeptorpolypeptid kodiert, das eine Aminosäure-Sequenz enthält, die ausgewählt ist aus der Sequenz der Aminosäurereste 1 bis 800, wie dargestellt in den Fig. 4A-4C, 1 bis 207, wie dargestellt in Fig. 4A, 1 bis 785, wie dargestellt in den Fig. 2A-2C, 1 bis 208, wie dargestellt in Fig. 2A oder einem Analog davon mit einer biologischen Aktivität eines Säuger IL-4 Rezeptors.

8. Verfahren, das den Schritt der Isolierung einer DNA-Sequenz enthält, wobei die DNA-Sequenz:

a) ein Fragment der Nucleotid-Sequenz, dargestellt als Nucleotide 1 bis 2355 der Fig. 2A-2C, ist; und

b) ein Fragment der Nucleotid-Sequenz, dargestellt als Nucleotide 1 bis 2400 der Fig. 4A-4C ist;

wobei das Fragment für eine Polypeptid kodiert, das eine biologische Aktivität eines Säuger IL-4 Rezeptors aufweist.

9. Verfahren, das den Schritt der Isolierung einer DNA-Sequenz enthält, wobei die DNA-Sequenz:

a) ein DNA-Fragment ist, das mindestens ungefähr 60 aufeinanderfolgende Nucleotide der Sequenz enthält, dargestellt als Nucleotide 1 bis 2355 der Fig. 2A-2C; oder

b) ein DNA-Fragment ist, das mindestens ungefähr 60 aufeinanderfolgende Nucleotide der Sequenz enthält, dargestellt als Nucleotide 1 bis 2400 der Fig. 4A-4C.

10. Verfahren, das den Schritt enthält der Bildung eines rekombinanten Expressionsvektors, der eine DNA-Sequenz enthält, wie beschrieben in einem oder mehreren der Ansprüche 1 bis 9.

11. Verfahren für die Herstellung eines Polypeptids, das fähig ist, Säuger IL-4 zu binden, das den Schritt der Kultivierung einer geeigneten Wirtszelle enthält, die einen Vektor gemäß Anspruch 10 enthält unter Bedingungen, die die Expression des Polypeptids unterstützen.

12. Verfahren für die Herstellung eines Polypeptids, das fähig ist, menschliches IL-4 zu binden, das den Schritt der Kultivierung einer geeigneten Wirtszelle enthält, die einen Vektor gemäß Anspruch 10 enthält unter Bedingungen, die die Expression des Polypeptids unterstützen.
- 5 13. Verfahren, enthaltend den Schritt der Reinigung eines Polypeptids, das fähig ist zur Bindung von Säuger IL-4, wobei das Polypeptid durch eine DNA gemäß einem oder mehreren der Ansprüche 1 bis 7 kodiert wird.
14. Verfahren gemäß Anspruch 13, wobei das Polypeptid im wesentlichen aus murinem IL-4 Rezeptor oder menschlichem IL-4 Rezeptor besteht.
- 10 15. Verfahren gemäß Anspruch 13, wobei das Polypeptid eine Aminosäure-Sequenz enthält, die ausgewählt ist aus der Sequenz der Aminosäurereste 1 bis 800, wie dargestellt in Fig. 4A-4C, 1 bis 207, wie dargestellt in Fig. 4A, 1 bis 785, wie dargestellt in den Fig. 2A-2C, 1 bis 208, wie dargestellt in Fig. 2A oder das ein Fragment oder ein Analog davon ist mit einer biologischen Aktivität des Säuger IL-4 Rezeptors.
- 15 16. Verfahren gemäß Anspruch 14, wobei das Polypeptid ein menschlicher IL-4 Rezeptor in Form eines Glycoproteins mit einem Molekulargewicht von zwischen ungefähr 110.000 und 150.000 M<sub>r</sub> durch SDS-PAGE ist und einer Bindungsaffinität ( $K_a$ ) für menschliches IL-4 von  $1-8 \times 10^9 M^{-1}$ .
- 20 17. Verfahren gemäß Anspruch 14, wobei das Polypeptid eine N-terminale Aminosäure-Sequenz Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp aufweist.
18. Verfahren gemäß Anspruch 13, wobei das Polypeptid nicht die transmembrane Region und die Cytoplasmadomäne des nativen Rezeptors aufweist.
- 25 19. Verfahren gemäß Anspruch 15, wobei das Polypeptid eine Aminosäure-Sequenz aufweist, die eine mehr als 80%ige Ähnlichkeit mit einer Sequenz aufweist, die aus den Resten 1 bis 800, wie dargestellt in den Fig. 4A-4C und den Resten 1 bis 207, wie dargestellt in Fig. 4A ausgewählt ist.
- 30 20. Verfahren gemäß Anspruch 19, wobei das Polypeptid eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Resten 1 bis 207, wie dargestellt in Fig. 4A, besteht.
21. Verfahren gemäß Anspruch 19, wobei das Polypeptid fähig zur Bindung von menschlichem IL-4 ist und eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Resten 1 bis 800, wie dargestellt in den Fig. 4A-4C, besteht.
- 35 22. Verfahren, das den Schritt der Reinigung eines Polypeptids enthält, ausgewählt aus der Gruppe, bestehend aus:
  - a) einem Fragment des Polypeptids mit der Sequenz der Aminosäuren 1 bis 785 der Fig. 2A-2C; und
  - 40 b) einem Fragment des Polypeptids mit der Aminosäure-Sequenz 1 bis 800 der Fig. 4A-4C;wobei das Fragment eine biologische Aktivität des IL-4 Rezeptors aufweist.
23. Verfahren, das den Schritt der Reinigung eines Polypeptids enthält, wobei das Polypeptid ausgewählt ist aus der Gruppe, bestehend aus:
  - 45 a) einem Polypeptid, das mindestens ungefähr 20 aufeinanderfolgende Reste der Sequenz aufweist, dargestellt als Aminosäuren 1 bis 785 der Fig. 2A-2C; und
  - 50 b) einem Polypeptid, das mindestens ungefähr 20 aufeinanderfolgende Reste der Sequenz enthält, dargestellt als Aminosäuren 1 bis 800 der Fig. 4A-4C.
24. Verfahren, das den Schritt aufweist, der Bildung einer pharmazeutischen Zusammensetzung für die Regulierung der Immunantworten in einem Säugetier, die eine wirksame Menge eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 enthält und ein geeignetes Verdünnungsmittel oder einen Träger.
- 55 25. Verfahren gemäß Anspruch 24, mit einer spezifischen Bindungsaktivität von mindestens ungefähr 0,01 Nanomol IL-4/Nanomol des Polypeptids.

26. Verfahren gemäß Anspruch 24, wobei das Polypeptid menschliches IL-4 bindet und in Form eines Glycoproteins mit einer Bindungsaffinität ( $K_d$ ) für menschliches IL-4 von ungefähr  $1-8 \times 10^9 \text{ M}^{-1}$  vorliegt und die N-terminale Aminosäure-Sequenz Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp aufweist.
27. Verfahren gemäß Anspruch 24, wobei das Polypeptid eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Aminosäuren 1 bis 207, wie dargestellt in Fig. 4A, besteht.
28. Verwendung eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 in einem Bindungsassay für die Detektion von IL-4 oder IL-4-Rezeptormolekülen oder deren Interaktionen.
29. Polypeptid gemäß einem oder mehreren der Ansprüche 13 bis 23 zur Verwendung in der Human- oder Veterinärmedizin.
30. Verwendung eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 für die Herstellung eines Medikaments für die Regulierung der Immunantworten in einem Säuger.
31. Verwendung gemäß Anspruch 30, wobei das Polypeptid und der zu behandelnde Säuger menschlich sind.
32. Verfahren, das den Schritt enthält, Antikörper zur Verfügung zu stellen, die immunreaktiv mit einem Polypeptid gemäß einem oder mehreren der Ansprüche 13 bis 23 sind.
33. Verfahren gemäß Anspruch 32, wobei die Antikörper monoklonale Antikörper sind.
34. Verfahren gemäß Anspruch 33, worin die monoklonalen Antikörper immunreaktiv mit einem menschlichen IL-4 Rezeptorpolypeptid sind.
35. Verwendung eines Antikörpers gemäß einem oder mehreren der Ansprüche 32 bis 34 für die Herstellung eines Medikaments zum Ausgleich von toxischen oder anderen ungewünschten Wirkungen von IL-4.
36. Wirtszelle, die mit einem Vektor gemäß Anspruch 10 transfiziert ist.
37. Verfahren, das den Schritt aufweist, RNA zur Verfügung zu stellen, die im wesentlichen komplementär zu der DNA, wie beschrieben in einem oder mehreren der Ansprüche 1 bis 9, ist.
38. Verfahren, das den Schritt aufweist, ein Fusionsprotein zur Verfügung zu stellen, das eine Polypeptid-Sequenz enthält, die mit einem Polypeptid, wie beschrieben in einem oder mehreren der Ansprüche 13 bis 23, gekoppelt ist.
39. Fusionsprotein gemäß Anspruch 38, zur Verwendung in Human- oder Veterinärmedizin.
40. Verwendung eines Fusionsproteins gemäß Anspruch 38 für die Herstellung eines Medikaments für die Regulierung einer Immunantwort in einem Säuger.
41. Verwendung eines Fusionsproteins gemäß Anspruch 40, wobei das Fusionsprotein eine Polypeptid-Sequenz enthält, die fähig ist, humanes IL-4 zu binden, wobei der Säuger menschlich ist.

**Patentansprüche für folgenden Vertragsstaat : GR**

1. Isolierte DNA-Sequenz, die für ein Polypeptid kodiert, das fähig ist, Säuger IL-4 zu binden, wobei die DNA-Sequenz aus der Gruppe ausgewählt ist, bestehend aus:
  - (a) cDNA-Klonen, die eine Nucleotid-Sequenz enthalten, ausgewählt aus der Sequenz, dargestellt als Nucleotide -75 bis 2355 der Fig. 2A-2C, Nucleotide 1 bis 2355 der Fig. 2A-2C, Nucleotide -75 bis 2400 der Fig. 4A-4C und Nucleotide 1 bis 2400 der Fig. 4A-4C;
  - (b) DNA-Sequenzen, die fähig sind, mit einer cDNA von (a) unter moderat stringenten Bedingungen zu hybridisieren und die ein Polypeptid kodieren, das fähig ist, Säuger IL-4 zu binden; und

(c) DNA-Sequenzen, die als Ergebnis des genetischen Codes zu einer DNA-Sequenz degeneriert sind, wie definiert in (a) oder (b), und die für ein Polypeptid kodieren, das fähig ist, Säuger IL-4 zu binden.

2. DNA-Sequenz gemäß Anspruch 1, wobei die DNA-Sequenz eine Nucleotid-Sequenz enthält, die ausgewählt ist aus der Gruppe, bestehend aus den Nucleotiden -75 bis 2355 der Fig. 2A-2C, den Nucleotiden 1 bis 2355 der Fig. 2A-2C, den Nucleotiden -75 bis 2400 der Fig. 4A-4C und den Nucleotiden 1 bis 2400 der Fig. 4A-4C.
3. DNA-Sequenz gemäß Anspruch 1, wobei die DNA-Sequenz eine Nucleotid-Sequenz enthält, die ausgewählt ist aus der Gruppe, bestehend aus den Nucleotiden -75 bis 621 der Fig. 4A, und den Nucleotiden 1 bis 621 der Fig. 4A.
4. DNA-Sequenz gemäß Anspruch 1, die für eine Aminosäure-Sequenz kodiert, die eine mehr als 80%ige Ähnlichkeit zu einer Aminosäure-Sequenz aufweist, die ausgewählt ist aus den Resten -25 bis 800, 1 bis 800, -25 bis 207 oder 1 bis 207, wie dargestellt in den Fig. 4A-4C.
5. DNA-Sequenz gemäß Anspruch 4, die für einen löslichen Rezeptor kodiert, der fähig ist, menschliches IL-4 zu binden und eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Aminosäureresten -25 bis 207 oder 1 bis 207 besteht, wie dargestellt in Fig. 4A.
6. DNA-Sequenz gemäß Anspruch 1, die für eine Aminosäure-Sequenz kodiert, die im wesentlichen aus den Aminosäureresten -25 bis 800 oder 1 bis 800 besteht, wie dargestellt in den Fig. 4A-4C.
7. DNA-Sequenz gemäß Anspruch 1, die für ein IL-4 Rezeptorpolypeptid kodiert, das eine Aminosäure-Sequenz enthält, die ausgewählt ist aus der Sequenz der Aminosäurereste 1 bis 800, wie dargestellt in den Fig. 4A-4C, 1 bis 207, wie dargestellt in Fig. 4A, 1 bis 785, wie dargestellt in den Fig. 2A-2C, 1 bis 208, wie dargestellt in Fig. 2A oder Analogen davon mit einer biologischen Aktivität eines Säuger IL-4 Rezeptors.
8. Isolierte DNA-Sequenz, die:
  - a) ein Fragment der Nucleotid-Sequenz, dargestellt als Nucleotide 1 bis 2355 der Fig. 2A-2C, ist; und
  - b) ein Fragment der Nucleotid-Sequenz, dargestellt als Nucleotide 1 bis 2400 der Fig. 4A-4C ist;wobei das Fragment für eine Polypeptid kodiert, das eine biologische Aktivität eines Säuger IL-4 Rezeptors aufweist.
9. Isolierte DNA-Sequenz, die
  - a) ein DNA-Fragment ist, das mindestens ungefähr 60 aufeinanderfolgende Nucleotide der Sequenz enthält, dargestellt als Nucleotide 1 bis 2355 der Fig. 2A-2C; oder
  - b) ein DNA-Fragment ist, das mindestens ungefähr 60 aufeinanderfolgende Nucleotide der Sequenz enthält, dargestellt als Nucleotide 1 bis 2400 der Fig. 4A-4C.
10. Rekombinanter Expressionsvektor, der eine DNA-Sequenz gemäß einem oder mehreren der Ansprüche 1 bis 9 enthält.
11. Verfahren für die Herstellung eines Polypeptids, das fähig ist, Säuger IL-4 zu binden, das den Schritt der Kultivierung einer geeigneten Wirtszelle enthält, die einen Vektor gemäß Anspruch 10 enthält unter Bedingungen, die die Expression des Polypeptids unterstützen.
12. Verfahren für die Herstellung eines Polypeptids, das fähig ist, menschliches IL-4 zu binden, das den Schritt der Kultivierung einer geeigneten Wirtszelle enthält, die einen Vektor gemäß Anspruch 10 enthält unter Bedingungen, die die Expression des Polypeptids unterstützen.
13. Verfahren, enthaltend den Schritt der Reinigung eines Polypeptids, das fähig ist zur Bindung von Säuger IL-4, wobei das Polypeptid durch eine DNA gemäß einem oder mehreren der Ansprüche 1 bis 7 kodiert wird.
14. Verfahren gemäß Anspruch 13, wobei das Polypeptid im wesentlichen aus murinem IL-4 Rezeptor oder mensch-

lichem IL-4 Rezeptor besteht.

15. Verfahren gemäß Anspruch 13, wobei das Polypeptid eine Aminosäure-Sequenz enthält, die ausgewählt ist aus der Sequenz der Aminosäurereste 1 bis 800, wie dargestellt in Fig. 4A-4C, 1 bis 207, wie dargestellt in Fig. 4A, 1 bis 785, wie dargestellt in den Fig. 2A-2C, 1 bis 208, wie dargestellt in Fig. 2A oder das ein Fragment oder ein Analog davon ist mit einer biologischen Aktivität des Säuger IL-4 Rezeptors.
16. Verfahren gemäß Anspruch 14, wobei das Polypeptid ein menschlicher IL-4 Rezeptor in Form eines Glycoproteins mit einem Molekulargewicht von zwischen ungefähr 110.000 und 150.000 M<sub>r</sub> durch SDS-PAGE ist und einer Bindungsaffinität ( $K_d$ ) für menschliches IL-4 von  $1-8 \times 10^9 M^{-1}$ .
17. Verfahren gemäß Anspruch 14, wobei das Polypeptid eine N-terminale Aminosäure-Sequenz Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp aufweist.
18. Verfahren gemäß Anspruch 13, wobei das Polypeptid nicht die transmembrane Region und die Cytoplasmadomäne des nativen Rezeptors aufweist.
19. Verfahren gemäß Anspruch 15, wobei das Polypeptid eine Aminosäure-Sequenz aufweist, die eine mehr als 80%ige Ähnlichkeit mit einer Sequenz aufweist, die aus den Resten 1 bis 800, wie dargestellt in den Fig. 4A-4C und den Resten 1 bis 207, wie dargestellt in Fig. 4A ausgewählt ist.
20. Verfahren gemäß Anspruch 19, wobei das Polypeptid eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Resten 1 bis 207, wie dargestellt in Fig. 4A, besteht.
21. Verfahren gemäß Anspruch 19, wobei das Polypeptid fähig zur Bindung von menschlichem IL-4 ist und eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Resten 1 bis 800, wie dargestellt in den Fig. 4A-4C, besteht.
22. Verfahren, das den Schritt der Reingigung eines Polypeptids enthält, ausgewählt aus der Gruppe, bestehend aus:
  - a) einem Fragment des Polypeptids mit der Sequenz der Aminosäure 1 bis 785 der Fig. 2A-2C; und
  - b) einem Fragment des Polypeptids mit der Aminosäure-Sequenz 1 bis 800 der Fig. 4A-4C;wobei das Fragment eine biologische Aktivität des IL-4 Rezeptors aufweist.
23. Verfahren, das den Schritt der Reinigung eines Polypeptids enthält, wobei das Polypeptid ausgewählt ist aus der Gruppe, bestehend aus:
  - a) einem Polypeptid, das mindestens ungefähr 20 aufeinanderfolgende Reste der Sequenz aufweist, dargestellt als Aminosäuren 1 bis 785 der Fig. 2A-2C; und
  - b) einem Polypeptid, das mindestens ungefähr 20 aufeinanderfolgende Reste der Sequenz enthält, dargestellt als Aminosäuren 1 bis 800 der Fig. 4A-4C.
24. Verfahren, das den Schritt aufweist, der Bildung einer pharmazeutischen Zusammensetzung für die Regulierung der Immunantworten in einem Säugetier, die eine wirksame Menge eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 enthält und ein geeignetes Verdünnungsmittel oder einen Träger.
25. Verfahren gemäß Anspruch 24, mit einer spezifischen Bindungsaktivität von mindestens ungefähr 0,01 Nanomol IL-4/Nanomol des Polypeptids.
26. Verfahren gemäß Anspruch 24, wobei das Polypeptid menschliches IL-4 bindet und in Form eines Glycoproteins mit einer Bindungsaffinität ( $K_d$ ) für menschliches IL-4 von ungefähr  $1-8 \times 10^9 M^{-1}$  vorliegt und die N-terminale Aminosäure-Sequenz Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Glu-Trp aufweist.
27. Verfahren gemäß Anspruch 24, wobei das Polypeptid eine Aminosäure-Sequenz enthält, die im wesentlichen aus den Aminosäuren 1 bis 207, wie dargestellt in Fig. 4A, besteht.



28. Verwendung eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 in einem Bindungsassay für die Detektion von IL-4 oder IL-4-Rezeptormolekülen oder deren Interaktionen.
29. Polypeptid gemäß einem oder mehreren der Ansprüche 13 bis 23 zur Verwendung in der Human- oder Veterinärmedizin.
30. Verwendung eines Polypeptids gemäß einem oder mehreren der Ansprüche 13 bis 23 für die Herstellung eines Medikaments für die Regulierung der Immunantworten in einem Säuger.
31. Verwendung gemäß Anspruch 30, wobei das Polypeptid und der zu behandelnde Säuger menschlich sind.
32. Verfahren, das den Schritt enthält, Antikörper zur Verfügung zu stellen, die immunreaktiv mit einem Polypeptid gemäß einem oder mehreren der Ansprüche 13 bis 23 sind.
33. Verfahren gemäß Anspruch 32, wobei die Antikörper monoklonale Antikörper sind.
34. Verfahren gemäß Anspruch 33, worin die monoklonalen Antikörper immunreaktiv mit einem menschlichen IL-4 Rezeptorpolypeptid sind.
35. Verwendung eines Antikörpers gemäß einem oder mehreren der Ansprüche 32 bis 34 für die Herstellung eines Medikaments zum Ausgleich von toxischen oder anderen ungewünschten Wirkungen von IL-4.
36. Wirtszelle, die mit einem Vektor gemäß Anspruch 10 transfiziert ist.
37. Verfahren, das den Schritt aufweist, RNA zur Verfügung zu stellen, die im wesentlichen komplementär zu der DNA, wie beschrieben in einem oder mehreren der Ansprüche 1 bis 9, ist.
38. Verfahren, das den Schritt aufweist, ein Fusionsprotein zur Verfügung zu stellen, das eine Polypeptid-Sequenz enthält, die mit einem Polypeptid, wie beschrieben in einem oder mehreren der Ansprüche 13 bis 23, gekoppelt ist.
39. Fusionsprotein gemäß Anspruch 38, zur Verwendung in Human- oder Veterinärmedizin.
40. Verwendung eines Fusionsproteins gemäß Anspruch 38 für die Herstellung eines Medikaments für die Regulierung einer Immunantwort in einem Säuger.
41. Verwendung eines Fusionsproteins gemäß Anspruch 40, wobei das Fusionsprotein eine Polypeptid-Sequenz enthält, die fähig ist, humanes IL-4 zu binden, wobei der Säuger menschlich ist.

## Revendications

**Revendications pour les Etats contractants suivants : AT, BE, CH, LI, DE, FR, GB, IT, LU, NL, SE**

1. Séquence d'ADN isolée codant pour un polypeptide capable de lier l'IL-4 mammifère, dans laquelle ladite séquence d'ADN est choisie dans le groupe constitué :
  - (a) de clones d'ADNc comprenant une séquence nucléotidique choisie parmi la séquence présentée comme une suite des nucléotides -75 à 2355 des Figures 2A-2C, des nucléotides 1 à 2355 des Figures 2A-2C, des nucléotides -75 à 2400 des Figures 4A-4C, et des nucléotides 1 à 2400 des Figures 4A-4C;
  - (b) de séquences d'ADN capables de s'hybrider à un ADNc de (a) dans des conditions moyennement strictes, et qui codent pour un polypeptide capable de lier l'IL-4 mammifère; et
  - (c) de séquences d'ADN qui, de par la nature du code génétique, sont dégénérées en une séquence d'ADN définie en (a) ou en (b), et qui codent pour un polypeptide capable de lier l'IL-4 mammifère.
2. Séquence d'ADN selon la revendication 1, dans laquelle ladite séquence d'ADN comprend une séquence nucléotidique choisie dans le groupe constitué des nucléotides -75 à 2355 des Figures 2A-2C, des nucléotides 1 à 2355 des Figures 2A-2C, des nucléotides -75 à 2400 des Figures 4A-4C, et des nucléotides 1 à 2400 des Figures 4A-4C.

3. Séquence d'ADN selon la revendication 1, dans laquelle ladite séquence d'ADN comprend une séquence nucléotidique choisie dans le groupe constitué des nucléotides -75 à 621 de la Figure 4A, et des nucléotides 1 à 621 de la Figure 4A.
- 5 4. Séquence d'ADN selon la revendication 1, qui code pour une séquence d'acides aminés présentant un degré d'homologie supérieur à 80% à une séquence d'acides aminés choisie parmi les résidus -25 à 800, 1 à 800, -25 à 207, ou 1 à 207 décrits aux Figures 4A-4C.
- 10 5. Séquence d'ADN selon la revendication 4, qui code pour un récepteur soluble capable de lier l'IL-4 humaine et comprenant une séquence d'acides aminés constituée essentiellement des résidus d'acides aminés -25 à 207 ou 1 à 207 décrits à la Figure 4A.
- 15 6. Séquence d'ADN selon la revendication 1, qui code pour une séquence d'acides aminés constituée essentiellement des résidus d'acides aminés -25 à 800 ou 1 à 800 décrits aux Figures 4A-4C.
- 20 7. Séquence d'ADN selon la revendication 1, qui code pour un polypeptide récepteur d'IL-4 comprenant une séquence d'acides aminés choisie parmi la séquence de résidus d'acides aminés 1 à 800 décrits aux Figures 4A-4C, 1 à 207 décrits à la Figure 4A, 1 à 785 décrits aux Figures 2A-2C, 1 à 208 décrits à la Figure 2A, ou les analogues de celles-ci ayant une activité biologique d'un récepteur d'IL-4 mammifère.
- 25 8. Séquence d'ADN isolée qui est :
  - a) un fragment de la séquence nucléotidique présentée comme une suite des nucléotides 1 à 2355 des Figures 2A-2C; et
  - b) un fragment de la séquence nucléotidique présentée comme une suite des nucléotides 1 à 2400 des Figures 4A-4C;dans laquelle ledit fragment code pour un polypeptide qui possède une activité biologique d'un récepteur d'IL-4 mammifère.
- 30 9. Séquence d'ADN isolée qui est :
  - a) un fragment d'ADN contenant au moins environ 60 nucléotides consécutifs de la séquence présentée comme une suite des nucléotides 1 à 2355 des Figures 2A-2C; ou
  - 35 b) un fragment d'ADN contenant au moins environ 60 nucléotides consécutifs de la séquence présentée comme une suite des nucléotides 1 à 2400 des Figures 4A-4C.
- 40 10. Vecteur d'expression recombinant comprenant une séquence d'ADN selon l'une quelconque des revendications 1 à 9.
- 45 11. Procédé de préparation d'un polypeptide capable de lier l'IL-4 mammifère, comprenant la mise en culture d'une cellule hôte convenable comprenant un vecteur selon la revendication 10 dans des conditions favorables à l'expression dudit polypeptide.
- 50 12. Procédé de préparation d'un polypeptide capable de lier l'IL-4 humaine, comprenant la mise en culture d'une cellule hôte convenable comprenant un vecteur selon la revendication 10 dans des conditions favorables à l'expression dudit polypeptide.
- 55 13. Polypeptide purifié capable de lier l'IL-4 mammifère, dans lequel ledit polypeptide est encodé par un ADN selon l'une quelconque des revendications 1 à 7.
14. Polypeptide selon la revendication 13, constitué essentiellement du récepteur d'IL-4 murine ou du récepteur d'IL-4 humaine.
15. Polypeptide selon la revendication 13, qui comprend une séquence d'acides aminés choisie parmi la séquence de résidus d'acides aminés 1 à 800 décrits aux Figures 4A-4C, 1 à 207 décrits à la Figure 4A, 1 à 785 décrits aux Figures 2A-2C, 1 à 208 décrits à la Figure 2A, ou qui est un fragment ou un analogue de celle-ci ayant une activité biologique d'un récepteur d'IL-4 mammifère.

16. Polypeptide selon la revendication 14, qui est un récepteur d'IL-4 humaine sous forme d'une glycoprotéine ayant un poids moléculaire  $M_r$  compris entre 110 000 et 150 000 par SDS-PAGE et une affinité de liaison ( $K_a$ ) pour l'IL-4 humaine de  $1 \text{ à } 8 \times 10^9 \text{ M}^{-1}$ .
- 5 17. Polypeptide selon la revendication 14, qui possède une séquence d'acides aminés N-terminale Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Gly-Trp.
18. Polypeptide selon la revendication 13, dans lequel la région transmembranaire et le domaine cytoplasmique du récepteur natif ont été supprimés.
- 10 19. Polypeptide selon la revendication 15, dans lequel ledit polypeptide comprend une séquence d'acides aminés qui présente un degré d'homologie supérieur à 80% à une séquence choisie parmi les résidus 1 à 800 décrits aux Figures 4A à 4C et les résidus 1 à 207 décrits à la Figure 4A.
- 15 20. Polypeptide selon la revendication 19, qui comprend une séquence d'acides aminés constituée essentiellement des résidus 1 à 207 décrits à la Figure 4A.
21. Polypeptide selon la revendication 19, capable de lier l'IL-4 humain, dans lequel ledit polypeptide comprend une séquence d'acides aminés constituée essentiellement des résidus 1 à 800 décrits aux Figures 4A à 4C.
- 20 22. Polypeptide purifié choisi dans le groupe constitué :
  - a) d'un fragment du polypeptide ayant la séquence d'acides aminés 1 à 785 des Figures 2A-2C; et
  - b) d'un fragment du polypeptide ayant la séquence d'acides aminés 1 à 800 des Figures 4A-4C;- 25 dans lequel ledit fragment possède une activité biologique du récepteur d'IL-4.
- 23. Polypeptide purifié choisi dans le groupe constitué :
  - a) d'un polypeptide comprenant au moins environ 20 résidus consécutifs de la séquence présentée comme une suite des acides aminés 1 à 785 des Figures 2A-2C; et
  - b) d'un polypeptide comprenant au moins environ 20 résidus consécutifs de la séquence présentée comme une suite des acides aminés 1 à 800 des Figures 4A-4C.
- 30 24. Composition pharmaceutique pour réguler des réponses immunes chez un mammifère, comprenant une quantité efficace d'un polypeptide selon l'une quelconque des revendications 13 à 23 et un diluant ou véhicule approprié.
- 35 25. Composition selon la revendication 24 ayant une activité de liaison spécifique d'environ au moins 0,01 nanomole d'IL-4/nanomole dudit polypeptide.
- 40 26. Composition selon la revendication 24, dans laquelle ledit polypeptide lie l'IL-4 humaine et se présente sous forme d'une glycoprotéine ayant une affinité de liaison ( $K_a$ ) pour l'IL-4 humaine de  $1 \text{ à } 8 \times 10^9 \text{ M}^{-1}$  environ, et dotée également de la séquence d'acides aminés N-terminale Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Gly-Trp.
- 45 27. Composition selon la revendication 24, dans laquelle ledit polypeptide comprend une séquence d'acides aminés constituée essentiellement des acides aminés 1 à 207 décrits à la Figure 4A.
- 50 28. Utilisation d'un polypeptide selon l'une quelconque des revendications 13 à 23 dans un essai de fixation en vue de détecter des molécules d'IL-4 ou de récepteur d'IL-4 ou leur interaction.
- 29. Polypeptide selon l'une quelconque des revendications 13 à 23, pour utilisation en médecine humaine ou vétérinaire.
- 55 30. Utilisation d'un polypeptide selon l'une quelconque des revendications 13 à 23, dans la préparation d'un médicament destiné à réguler des réponses immunes chez un mammifère.
- 31. Utilisation selon la revendication 30, dans laquelle le polypeptide et le mammifère à traiter sont d'origine humaine.

32. Anticorps qui sont immunoréactifs vis-à-vis d'un polypeptide selon l'une quelconque des revendications 13 à 23.
33. Anticorps selon la revendication 32, dans lequel ledit anticorps est un anticorps monoclonal.
- 5 34. Anticorps selon la revendication 33, dans lequel ledit anticorps monoclonal est immunoréactif vis-à-vis d'un polypeptide récepteur d'IL-4 humaine.
35. Utilisation d'un anticorps selon l'une quelconque des revendications 32 à 34 dans la préparation d'un médicament destiné à atténuer les effets toxiques ou autres effets indésirables de l'IL-4.
- 10 36. Cellule hôte transfectée par un vecteur selon la revendication 10.
37. ARN essentiellement complémentaire à l'ADN selon l'une quelconque des revendications 1 à 9.
- 15 38. Protéine de fusion comprenant une séquence polypeptidique couplée à un polypeptide selon l'une quelconque des revendications 13 à 23.
39. Protéine de fusion selon la revendication 38 pour utilisation en médecine humaine ou vétérinaire.
- 20 40. Utilisation d'une protéine de fusion selon la revendication 38 dans la préparation d'un médicament destiné à réguler une réponse immune chez un mammifère.
41. Utilisation d'une protéine de fusion selon la revendication 40, dans laquelle la protéine de fusion comprend une séquence polypeptidique capable de lier l'IL-4 humaine et dans laquelle le mammifère est un être humain.
- 25

#### Revendications pour l'Etat contractant suivant : ES

- 30 1. Procédé comprenant l'étape d'isolement d'une séquence d'ADN codant pour un polypeptide capable de lier l'IL-4 mammifère, dans lequel ladite séquence d'ADN est choisie dans le groupe constitué:
  - (a) de clones d'ADNc comprenant une séquence nucléotidique choisie parmi la séquence présentée comme une suite des nucléotides -75 à 2355 des Figures 2A-2C, des nucléotides 1 à 2355 des Figures 2A-2C, des nucléotides -75 à 2400 des Figures 4A-4C, et des nucléotides 1 à 2400 des Figures 4A-4C;
  - 35 (b) de séquences d'ADN capables de s'hybrider à un ADNc de (a) dans des conditions moyennement strictes, et qui codent pour un polypeptide capable de lier l'IL-4 mammifère; et
  - (c) de séquences d'ADN qui, de par la nature du code génétique, sont dégénérées en une séquence d'ADN définie en (a) ou en (b), et qui codent pour un polypeptide capable de lier l'IL-4 mammifère.
- 40 2. Procédé selon la revendication 1, dans lequel ladite séquence d'ADN comprend une séquence nucléotidique choisie dans le groupe constitué des nucléotides -75 à 2355 des Figures 2A-2C, des nucléotides 1 à 2355 des Figures 2A-2C, des nucléotides -75 à 2400 des Figures 4A-4C, et des nucléotides 1 à 2400 des Figures 4A-4C.
- 45 3. Procédé selon la revendication 1, dans lequel ladite séquence d'ADN comprend une séquence nucléotidique choisie dans le groupe constitué des nucléotides -75 à 621 de la Figure 4A, et des nucléotides 1 à 621 de la Figure 4A.
4. Procédé selon la revendication 1, dans lequel ladite séquence d'ADN code pour une séquence d'acides aminés qui présente un degré d'homologie supérieur à 80% à une séquence d'acides aminés choisie parmi les résidus -25 à 800, 1 à 800, -25 à 207, ou 1 à 207 décrits aux Figures 4A-4C.
- 50 5. Procédé selon la revendication 4, dans lequel ladite séquence d'ADN code pour un récepteur soluble capable de lier l'IL-4 humaine et comprenant une séquence d'acides aminés constituée essentiellement des résidus d'acides aminés -25 à 207 ou 1 à 207 décrits à la Figure 4A.
- 55 6. Procédé selon la revendication 1, dans lequel ladite séquence d'ADN code pour une séquence d'acides aminés constituée essentiellement des résidus d'acides aminés -25 à 800 ou 1 à 800 décrits aux Figures 4A-4C.
7. Procédé selon la revendication 1, dans lequel ladite séquence d'ADN code pour un polypeptide récepteur d'IL-4

comprenant une séquence d'acides aminés choisie parmi la séquence de résidus d'acides aminés 1 à 800 décrits aux Figures 4A-4C, 1 à 207 décrits à la Figure 4A, 1 à 785 décrits aux Figures 2A-2C, 1 à 208 décrits à la Figure 2A, ou les analogues de celles-ci ayant une activité biologique d'un récepteur d'IL-4 mammifère.

- 5 8. Procédé comprenant l'isolement d'une séquence d'ADN dans laquelle ladite séquence d'ADN est :
  - a) un fragment de la séquence nucléotidique présentée comme une suite des nucléotides 1 à 2355 des Figures 2A-2C; et
  - 10 b) un fragment de la séquence nucléotidique présentée comme une suite des nucléotides 1 à 2400 des Figures 4A-4C;dans laquelle ledit fragment code pour un polypeptide qui possède une activité biologique d'un récepteur d'IL-4 mammifère.
- 15 9. Procédé comprenant l'isolement d'une séquence d'ADN dans laquelle ladite séquence d'ADN est :
  - a) un fragment d'ADN contenant au moins environ 60 nucléotides consécutifs de la séquence présentée comme une suite des nucléotides 1 à 2355 des Figures 2A-2C; ou
  - 20 b) un fragment d'ADN contenant au moins environ 60 nucléotides consécutifs de la séquence présentée comme une suite des nucléotides 1 à 2400 des Figures 4A-4C.
10. Procédé comprenant la construction d'un vecteur d'expression recombinant comprenant une séquence d'ADN telle que décrite dans l'une quelconque des revendications 1 à 9.
- 25 11. Procédé de préparation d'un polypeptide capable de lier l'IL-4 mammifère, comprenant la mise en culture d'une cellule hôte convenable comprenant un vecteur tel que décrit dans la revendication 10 dans des conditions favorables à l'expression dudit polypeptide.
- 30 12. Procédé de préparation d'un polypeptide capable de lier l'IL-4 humaine, comprenant la mise en culture d'une cellule hôte convenable comprenant un vecteur tel que décrit dans la revendication 10 dans des conditions favorables à l'expression dudit polypeptide.
- 35 13. Procédé comprenant la purification d'un polypeptide capable de lier l'IL-4 mammifère, dans lequel ledit polypeptide est encodé par une séquence d'ADN telle que décrite dans l'une quelconque des revendications 1 à 7.
- 40 14. Procédé selon la revendication 13, dans lequel ledit polypeptide est constitué essentiellement du récepteur d'IL-4 murine ou du récepteur d'IL-4 humaine.
- 45 15. Procédé selon la revendication 13, dans lequel ledit polypeptide comprend une séquence d'acides aminés choisie parmi la séquence de résidus d'acides aminés 1 à 800 décrits aux Figures 4A-4C, 1 à 207 décrits à la Figure 4A, 1 à 785 décrits aux Figures 2A-2C, 1 à 208 décrits à la Figure 2A, ou qui est un fragment ou un analogue de celles-ci ayant une activité biologique d'un récepteur d'IL-4 mammifère.
16. Procédé selon la revendication 14, dans lequel ledit polypeptide est un récepteur d'IL-4 humaine sous forme d'une glycoprotéine ayant un poids moléculaire  $M_r$  compris entre 110 000 et 150 000 par SDS-PAGE et une affinité de liaison ( $K_a$ ) pour l'IL-4 humaine de  $1 \text{ à } 8 \times 10^9 \text{ M}^{-1}$ .
17. Procédé selon la revendication 14, dans lequel ledit polypeptide possède une séquence d'acides aminés N-terminale Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Gly-Trp.
- 50 18. Procédé selon la revendication 13, dans lequel ledit polypeptide ne possède pas la région transmembranaire et le domaine cytoplasmique du récepteur natif.
- 55 19. Procédé selon la revendication 15, dans lequel ledit polypeptide comprend une séquence d'acides aminés qui présente un degré d'homologie supérieur à 80% à une séquence choisie parmi les résidus 1 à 800 décrits aux Figures 4A à 4C et les résidus 1 à 207 décrits à la Figure 4A.
20. Procédé selon la revendication 19, dans lequel ledit polypeptide comprend une séquence d'acides aminés cons-

tituée essentiellement des résidus 1 à 207 décrits à la Figure 4A.

21. Procédé selon la revendication 19, dans lequel ledit polypeptide est capable de lier l'IL-4 humaine, et comprend une séquence d'acides aminés constituée essentiellement des résidus 1 à 800 décrits aux Figures 4A à 4C.

22. Procédé comprenant la purification d'un polypeptide choisi dans le groupe constitué :

- a) d'un fragment du polypeptide ayant la séquence d'acides aminés 1 à 785 des Figures 2A-2C; et
- b) d'un fragment du polypeptide ayant la séquence d'acides aminés 1 à 800 des Figures 4A-4C;

dans lequel ledit fragment possède une activité biologique du récepteur d'IL-4.

23. Procédé comprenant la purification d'un polypeptide, dans lequel le polypeptide est choisi dans le groupe constitué :

- a) d'un polypeptide comprenant au moins environ 20 résidus consécutifs de la séquence présentée comme une suite des acides aminés 1 à 785 des Figures 2A-2C; et
- b) d'un polypeptide comprenant au moins environ 20 résidus consécutifs de la séquence présentée comme une suite des acides aminés 1 à 800 des Figures 4A-4C.

24. Procédé comprenant l'obtention d'une composition pharmaceutique pour réguler des réponses immunes chez un mammifère, comprenant une quantité efficace d'un polypeptide tel que décrit dans l'une quelconque des revendications 13 à 23 et un diluant ou véhicule approprié.

25. Procédé selon la revendication 24, dans lequel l'activité de liaison spécifique est d'environ au moins 0,01 nanomole d'IL-4/nanomole dudit polypeptide.

26. Procédé selon la revendication 24, dans lequel ledit polypeptide lie l'IL-4 humaine et se présente sous forme d'une glycoprotéine ayant une affinité de liaison ( $K_d$ ) pour l'IL-4 humaine de 1 à  $8 \times 10^9 \text{ M}^{-1}$  environ, et dotée également de la séquence d'acides aminés N-terminale Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Gly-Trp.

27. Procédé selon la revendication 24, dans lequel ledit polypeptide comprend une séquence d'acides aminés constituée essentiellement des acides aminés 1 à 207 décrits à la Figure 4A.

28. Utilisation d'un polypeptide selon l'une quelconque des revendications 13 à 23 dans un essai de fixation en vue de détecter des molécules d'IL-4 ou de récepteur d'IL-4 ou leur interaction.

29. Polypeptide tel que décrit dans l'une quelconque des revendications 13 à 23, pour utilisation en médecine humaine ou vétérinaire.

30. Utilisation d'un polypeptide tel que décrit dans l'une quelconque des revendications 13 à 23, dans la préparation d'un médicament destiné à réguler les réponses immunes chez un mammifère.

31. Utilisation selon la revendication 30, dans laquelle le polypeptide et le mammifère à traiter sont d'origine humaine.

32. Procédé comprenant l'obtention d'anticorps qui sont immunoréactifs vis-à-vis d'un polypeptide selon l'une quelconque des revendications 13 à 23.

33. Procédé selon la revendication 32, dans lequel lesdits anticorps sont des anticorps monoclonaux.

34. Procédé selon la revendication 33, dans lequel lesdits anticorps monoclonaux sont immunoréactifs vis-à-vis d'un polypeptide récepteur d'IL-4 humaine.

35. Utilisation d'un anticorps tel que décrit dans l'une quelconque des revendications 32 à 34 dans la préparation d'un médicament destiné à atténuer les effets toxiques ou autres effets indésirables de l'IL-4.

36. Cellule hôte transfectée par un vecteur tel que décrit dans la revendication 10.

37. Procédé comprenant l'obtention d'ARN essentiellement complémentaire à l'ADN tel que décrit dans l'une quelconque des revendications 1 à 9.

38. Procédé comprenant l'obtention d'une protéine de fusion comprenant une séquence polypeptidique couplée à un polypeptide tel que décrit dans l'une quelconque des revendications 13 à 23.

39. Protéine de fusion telle que décrite dans la revendication 38 pour utilisation en médecine humaine ou vétérinaire.

40. Utilisation d'une protéine de fusion telle que décrite dans la revendication 38 dans la préparation d'un médicament destiné à réguler une réponse immune chez un mammifère.

41. Utilisation d'une protéine de fusion telle que décrite dans la revendication 40, dans laquelle la protéine de fusion comprend une séquence polypeptidique capable de lier l'IL-4 humaine et dans laquelle le mammifère est un être humain.

#### Revendications pour l'Etat contractant suivant : GR

1. Séquence d'ADN isolée codant pour un polypeptide capable de lier l'IL-4 mammifère, dans laquelle ladite séquence d'ADN est choisie dans le groupe constitué :

(a) de clones d'ADNc comprenant une séquence nucléotidique choisie parmi la séquence présentée comme une suite des nucléotides -75 à 2355 des Figures 2A-2C, des nucléotides 1 à 2355 des Figures 2A-2C, des nucléotides -75 à 2400 des Figures 4A-4C, et des nucléotides 1 à 2400 des Figures 4A-4C;

(b) de séquences d'ADN capables de s'hybrider à un ADNc de (a) dans des conditions moyennement strictes, et qui codent pour un polypeptide capable de lier l'IL-4 mammifère; et

(c) de séquences d'ADN qui, de par la nature du code génétique, sont dégénérées en une séquence d'ADN définie en (a) ou en (b), et qui codent pour un polypeptide capable de lier l'IL-4 mammifère.

2. Séquence d'ADN selon la revendication 1, dans laquelle ladite séquence d'ADN comprend une séquence nucléotidique choisie dans le groupe constitué des nucléotides -75 à 2355 des Figures 2A-2C, des nucléotides 1 à 2355 des Figures 2A-2C, des nucléotides -75 à 2400 des Figures 4A-4C, et des nucléotides 1 à 2400 des Figures 4A-4C.

3. Séquence d'ADN selon la revendication 1, dans laquelle ladite séquence d'ADN comprend une séquence nucléotidique choisie dans le groupe constitué des nucléotides -75 à 621 de la Figure 4A, et des nucléotides 1 à 621 de la Figure 4A.

4. Séquence d'ADN selon la revendication 1, qui code pour une séquence d'acides aminés présentant un degré d'homologie supérieur à 80% à une séquence d'acides aminés choisie parmi les résidus -25 à 800, 1 à 800, -25 à 207, ou à 207 décrits aux Figures 4A-4C.

5. Séquence d'ADN selon la revendication 4, qui code pour un récepteur soluble capable de lier l'IL-4 humaine et comprenant une séquence d'acides aminés constituée essentiellement des résidus d'acides aminés -25 à 207 ou 1 à 207 décrits à la Figure 4A.

6. Séquence d'ADN selon la revendication 1, qui code pour une séquence d'acides aminés constituée essentiellement des résidus d'acides aminés -25 à 800 ou 1 à 800 décrits aux Figures 4A-4C.

7. Séquence d'ADN selon la revendication 1, qui code pour un polypeptide récepteur d'IL-4 comprenant une séquence d'acides aminés choisie parmi la séquence de résidus d'acides aminés 1 à 800 décrits aux Figures 4A-4C, 1 à 207 décrits à la Figure 4A, 1 à 785 décrits aux Figures 2A-2C, 1 à 208 décrits à la Figure 2A, ou les analogues de celles-ci ayant une activité biologique d'un récepteur d'IL-4 mammifère.

8. Séquence d'ADN isolée qui est :

a) un fragment de la séquence nucléotidique présentée comme une suite des nucléotides 1 à 2355 des Figures 2A-2C; et

b) un fragment de la séquence nucléotidique présentée comme une suite des nucléotides 1 à 2400 des Figures

4A-4C;

dans laquelle ledit fragment code pour un polypeptide qui possède une activité biologique d'un récepteur d'IL-4 mammifère.

9. Séquence d'ADN isolée qui est :

- a) un fragment d'ADN contenant au moins environ 60 nucléotides consécutifs de la séquence présentée comme une suite des nucléotides 1 à 2355 des Figures 2A-2C; ou
- b) un fragment d'ADN contenant au moins environ 60 nucléotides consécutifs de la séquence présentée comme une suite des nucléotides 1 à 2400 des Figures 4A-4C.

10. Vecteur d'expression recombinant comprenant une séquence d'ADN selon l'une quelconque des revendications 1 à 9.

11. Procédé de préparation d'un polypeptide capable de lier l'IL-4 mammifère, comprenant la mise en culture d'une cellule hôte convenable comprenant un vecteur selon la revendication 10 dans des conditions favorables à l'expression dudit polypeptide.

12. Procédé de préparation d'un polypeptide capable de lier l'IL-4 humaine, comprenant la mise en culture d'une cellule hôte convenable comprenant un vecteur selon la revendication 10 dans des conditions favorables à l'expression dudit polypeptide.

13. Procédé comprenant la purification d'un polypeptide capable de lier l'IL-4 mammifère, dans lequel ledit polypeptide est encodé par un ADN selon l'une quelconque des revendications 1 à 7.

14. Procédé selon la revendication 13, dans lequel ledit polypeptide est constitué essentiellement du récepteur d'IL-4 murine ou du récepteur d'IL-4 humaine.

15. Procédé selon la revendication 13, dans lequel ledit polypeptide comprend une séquence d'acides aminés choisie parmi la séquence de résidus d'acides aminés 1 à 800 décrits aux Figures 4A-4C, 1 à 207 décrits à la Figure 4A, 1 à 785 décrits aux Figures 2A-2C, 1 à 208 décrits à la Figure 2A, ou qui est un fragment ou un analogue de celles-ci ayant une activité biologique d'un récepteur d'IL-4 mammifère.

16. Procédé selon la revendication 14, dans lequel ledit polypeptide est un récepteur d'IL-4 humaine sous forme d'une glycoprotéine ayant un poids moléculaire  $M_r$  compris entre 110 000 et 150 000 par SDS-PAGE et une affinité de liaison ( $K_a$ ) pour l'IL-4 humaine de  $1 \text{ à } 8 \times 10^9 \text{ M}^{-1}$ .

17. Procédé selon la revendication 14, dans lequel ledit polypeptide possède une séquence d'acides aminés N-terminale Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Gly-Trp.

18. Procédé selon la revendication 13, dans lequel la région transmembranaire et le domaine cytoplasmique ne sont pas présents dans ledit polypeptide.

19. Procédé selon la revendication 15, dans lequel ledit polypeptide comprend une séquence d'acides aminés qui présente un degré d'homologie supérieur à 80% à une séquence choisie parmi les résidus 1 à 800 décrits aux Figures 4A à 4C et les résidus 1 à 207 décrits à la Figure 4A.

20. Procédé selon la revendication 19, dans lequel ledit polypeptide comprend une séquence d'acides aminés constituée essentiellement des résidus 1 à 207 décrits à la Figure 4A.

21. Procédé selon la revendication 19, dans lequel ledit polypeptide est capable de lier l'IL-4 humaine et comprend une séquence d'acides aminés constituée essentiellement des résidus 1 à 800 décrits aux Figures 4A à 4C.

22. Procédé comprenant la purification d'un polypeptide choisi dans le groupe constitué :

- a) d'un fragment du polypeptide ayant la séquence d'acides aminés 1 à 785 des Figures 2A-2C; et
- b) d'un fragment du polypeptide ayant la séquence d'acides aminés 1 à 800 des Figures 4A-4C;



dans lequel ledit fragment possède une activité biologique du récepteur d'IL-4.

23. Procédé comprenant la purification d'un polypeptide choisi dans le groupe constitué :

- a) d'un polypeptide comprenant au moins environ 20 résidus consécutifs de la séquence présentée comme une suite des acides aminés 1 à 785 des Figures 2A-2C; et
- b) d'un polypeptide comprenant au moins environ 20 résidus consécutifs de la séquence présentée comme une suite des acides aminés 1 à 800 des Figures 4A-4C.

24. Procédé comprenant l'obtention d'une composition pharmaceutique pour réguler des réponses immunes chez un mammifère, comprenant une quantité efficace d'un polypeptide tel que décrit dans l'une quelconque des revendications 13 à 23 et un diluant ou véhicule approprié.

25. Procédé selon la revendication 24, dans lequel l'activité de liaison spécifique est d'au moins 0,01 nanomole d'IL-4/nanomole dudit polypeptide environ.

26. Procédé selon la revendication 24, dans lequel ledit polypeptide lie l'IL-4 humaine et se présente sous forme d'une glycoprotéine ayant une affinité de liaison ( $K_a$ ) pour l'IL-4 humaine de  $1 \text{ à } 8 \times 10^9 \text{ M}^{-1}$  environ, et dotée également de la séquence d'acides aminés N-terminale Met-Lys-Val-Leu-Gln-Glu-Pro-Thr-Cys-Val-Ser-Asp-Tyr-Met-Ser-Ile-Ser-Thr-Cys-Gly-Trp.

27. Procédé selon la revendication 24, dans lequel ledit polypeptide comprend une séquence d'acides aminés constituée essentiellement des acides aminés 1 à 207 décrits à la Figure 4A.

28. Utilisation d'un polypeptide selon l'une quelconque des revendications 13 à 23 dans un essai de fixation en vue de détecter des molécules d'IL-4 ou de récepteur d'IL-4 ou leur interaction.

29. Polypeptide tel que décrit dans l'une quelconque des revendications 13 à 23, pour utilisation en médecine humaine ou vétérinaire.

30. Utilisation d'un polypeptide tel que décrit dans l'une quelconque des revendications 13 à 23, dans la préparation d'un médicament destiné à réguler les réponses immunes chez un mammifère.

31. Utilisation selon la revendication 30, dans laquelle le polypeptide et le mammifère à traiter sont d'origine humaine.

32. Procédé comprenant l'obtention d'anticorps qui sont immunoréactifs vis-à-vis d'un polypeptide tel que décrit dans l'une quelconque des revendications 13 à 23.

33. Procédé selon la revendication 32, dans lequel lesdits anticorps sont des anticorps monoclonaux.

34. Procédé selon la revendication 33, dans lequel lesdits anticorps monoclonaux sont immunoréactifs vis-à-vis d'un polypeptide récepteur d'IL-4 humaine.

35. Utilisation d'anticorps tels que décrits dans l'une quelconque des revendications 32 à 34 dans la préparation d'un médicament destiné à atténuer les effets toxiques ou autres effets indésirables de l'IL-4.

36. Cellule hôte transfectée par un vecteur tel que décrit dans la revendication 10.

37. Procédé comprenant l'obtention d'ARN essentiellement complémentaire à l'ADN tel que décrit dans l'une quelconque des revendications 1 à 9.

38. Procédé comprenant l'obtention d'une protéine de fusion comprenant une séquence polypeptidique couplée à un polypeptide selon l'une quelconque des revendications 13 à 23.

39. Protéine de fusion telle que décrite dans la revendication 38 pour utilisation en médecine humaine ou vétérinaire.

40. Utilisation d'une protéine de fusion telle que décrite dans la revendication 38 dans la préparation d'un médicament destiné à réguler une réponse immune chez un mammifère.

- 41.** Utilisation d'une protéine de fusion telle que décrite dans la revendication 40, dans laquelle la protéine de fusion comprend une séquence polypeptidique capable de lier l'IL-4 humaine et dans laquelle le mammifère est un être humain.

5

10

15

20

25

30

35


40

45

50

55

**FIGURE 1**



**FIGURE 2A**

|  |     |
|--|-----|
| ATG GGG CGG CTT TGC ACC AAG TTC CTG ACC TCT GTG GGC TGT CTG        | -31 |
| Met Gly Arg Leu Cys Thr Lys Phe Leu Thr Ser Val Gly Cys Leu        | -11 |
| ATT TTG CTG TTG GTG ACT GGA TCT GGG AGC ATC AAG GTC CTG GGT        | 15  |
| Ile Leu Leu Leu Val Thr Gly Ser Gly Ser <u>Ile</u> Lys Val Leu Gly | 5   |
| GAG CCC ACC TGC TTC TCT GAC TAC ATC CGC ACT TCC ACG TGT GAG        | 60  |
| Glu Pro Thr Cys Phe Ser Asp Tyr Ile Arg Thr Ser Thr Cys Glu        | 20  |
| TGG TTC CTG GAT AGC GCT GTG GAC TGC AGT TCT CAG CTC TGC CTA        | 105 |
| Trp Phe Leu Asp Ser Ala Val Asp Cys Ser Ser Gln Leu Cys Leu        | 35  |
| CAC TAC AGG CTG ATG TTC TTC GAG TTC TCT GAA AAC CTC ACA TGC        | 150 |
| His Tyr Arg Leu Met Phe Phe Glu Phe Ser Glu Asn Leu Thr Cys        | 50  |
| ATC CCG AGG AAC AGT GCC AGC ACT GTG TGT GTG TGC CAC ATG GAA        | 195 |
| Ile Pro Arg Asn Ser Ala Ser Thr Val Cys Val Cys His Met Glu        | 65  |
| ATG AAT AGG CCG GTC CAA TCA GAC AGA TAC CAG ATG GAA CTG TGG        | 240 |
| Met Asn Arg Pro Val Gln Ser Asp Arg Tyr Gln Met Glu Leu Trp        | 80  |
| GCT GAG CAC AGA CAG CTG TGG CAG GGC TCC TTC AGC CCC AGT GGT        | 285 |
| Ala Glu His Arg Gln Leu Trp Gln Gly Ser Phe Ser Pro Ser Gly        | 95  |
| AAT GTG AAG CCC CTA GCT CCA GAC AAC CTC ACA CTC CAC ACC AAT        | 330 |
| Asn Val Lys Pro Leu Ala Pro Asp Asn Leu Thr Leu His Thr Asn        | 110 |
| GTG TCC GAC GAA TGG CTG CTG ACC TGG AAT AAC CTG TAC CCA TCG        | 375 |
| Val Ser Asp Glu Trp Leu Leu Thr Trp Asn Asn Leu Tyr Pro Ser        | 125 |
| AAC AAC TTA CTG TAC AAA GAC CTC ATC TCC ATG GTC AAC ATC TCC        | 420 |
| Asn Asn Leu Leu Tyr Lys Asp Leu Ile Ser Met Val Asn Ile Ser        | 140 |
| AGA GAG GAC AAC CCT GCA GAA TTC ATA GTC TAT AAT GTG ACC TAC        | 465 |
| Arg Glu Asp Asn Pro Ala Glu Phe Ile Val Tyr Asn Val Thr Tyr        | 155 |
| AAG GAA CCC AGG CTG AGC TTC CCG ATC AAC ATC CTG ATG TCA GGG        | 510 |
| Lys Glu Pro Arg Leu Ser Phe Pro Ile Asn Ile Leu Met Ser Gly        | 170 |
| GTC TAC TAT ACG GCG CGT GTG AGG GTC AGA TCC CAG ATA CTC ACT        | 555 |
| Val Tyr Tyr Thr Ala Arg Val Arg Val Arg Ser Gln Ile Leu Thr        | 185 |
| GGC ACC TGG AGT GAG TGG AGT CCT AGC ATC ACG TGG TAC AAC CAC        | 600 |
| Gly Thr Trp Ser Glu Trp Ser Pro Ser Ile Thr Trp Tyr Asn His        | 200 |
| TTC CAG CTG CCC CTG ATA CAG CGC CTT CCA CTG GGG GTC ACC ATC        | 645 |
| Phe Gln Leu Pro Leu Ile Gln Arg <u>Leu Pro Leu Gly Val Thr Ile</u> | 215 |
| TCC TGC CTC TGC ATC CCG TTG TTT TGC CTG TTC TGT TAC TTC AGC        | 690 |
| <u>Ser Cys Leu Cys Ile Pro Leu Phe Cys Leu Phe Cys Tyr Phe Ser</u> | 230 |
| ATT ACC AAG ATT AAG AAG ATA TGG TGG GAC CAG ATT CCC ACC CCA        | 735 |
| <u>Ile Thr</u> Lys Ile Lys Lys Ile Trp Trp Asp Gln Ile Pro Thr Pro | 245 |

**FIGURE 2B**

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| GCA | CGC | AGT | CCC | TTG | GTG | GCC | ATC | ATC | ATT | CAG | GAT | GCA | CAG | GTG | 780  |
| Ala | Arg | Ser | Pro | Leu | Val | Ala | Ile | Ile | Ile | Gln | Asp | Ala | Gln | Val | 260  |
| CCC | CTC | TGG | GAT | AAG | CAG | ACC | CGA | AGC | CAG | GAG | TCA | ACC | AAG | TAC | 825  |
| Pro | Leu | Trp | Asp | Lys | Gln | Thr | Arg | Ser | Gln | Glu | Ser | Thr | Lys | Tyr | 275  |
| CCG | CAC | TGG | AAA | ACT | TGT | CTA | GAC | AAG | CTG | CTG | CCT | TGC | TTG | CTG | 870  |
| Pro | His | Trp | Lys | Thr | Cys | Leu | Asp | Lys | Leu | Leu | Pro | Cys | Leu | Leu | 290  |
| AAG | CAC | AGA | GTA | AAG | AAG | AAG | ACA | GAC | TTC | CCG | AAG | GCT | GCC | CCA | 915  |
| Lys | His | Arg | Val | Lys | Lys | Lys | Thr | Asp | Phe | Pro | Lys | Ala | Ala | Pro | 305  |
| ACC | AAG | TCT | CTC | CAG | AGT | CCT | GGA | AAG | GCA | GGC | TGG | TGT | CCC | ATG | 960  |
| Thr | Lys | Ser | Leu | Gln | Ser | Pro | Gly | Lys | Ala | Gly | Trp | Cys | Pro | Met | 320  |
| GAG | GTC | AGC | AGG | ACC | GTC | CTC | TGG | CCA | GAG | AAT | GTT | AGT | GTC | AGT | 1005 |
| Glu | Val | Ser | Arg | Thr | Val | Leu | Trp | Pro | Glu | Asn | Val | Ser | Val | Ser | 335  |
| GTG | GTG | CGC | TGT | ATG | GAG | CTG | TTT | GAG | GCC | CCA | GTA | CAG | AAT | GTG | 1050 |
| Val | Val | Arg | Cys | Met | Glu | Leu | Phe | Glu | Ala | Pro | Val | Gln | Asn | Val | 350  |
| GAG | GAG | GAA | GAA | GAT | GAG | ATA | GTC | AAA | GAG | GAC | CTG | AGC | ATG | TCA | 1095 |
| Glu | Glu | Glu | Glu | Asp | Glu | Ile | Val | Lys | Glu | Asp | Leu | Ser | Met | Ser | 365  |
| CCT | GAG | AAC | AGC | GGA | GGC | TGC | GGC | TTC | CAG | GAG | AGC | CAG | GCA | GAC | 1140 |
| Pro | Glu | Asn | Ser | Gly | Gly | Cys | Gly | Phe | Gln | Glu | Ser | Gln | Ala | Asp | 380  |
| ATC | ATG | GCT | CGG | CTC | ACT | GAG | AAC | CTG | TTT | TCC | GAC | TTG | TTG | GAG | 1185 |
| Ile | Met | Ala | Arg | Leu | Thr | Glu | Asn | Leu | Phe | Ser | Asp | Leu | Leu | Glu | 395  |
| GCT | GAG | AAT | GGG | GGC | CTT | GGC | CAG | TCA | GCC | TTG | GCA | GAG | TCA | TGC | 1230 |
| Ala | Glu | Asn | Gly | Gly | Leu | Gly | Gln | Ser | Ala | Leu | Ala | Glu | Ser | Cys | 410  |
| TCC | CCT | CTG | CCT | TCA | GGA | AGT | GGG | CAG | GCT | TCT | GTA | TCC | TGG | GCC | 1275 |
| Ser | Pro | Leu | Pro | Ser | Gly | Ser | Gly | Gln | Ala | Ser | Val | Ser | Trp | Ala | 425  |
| TGC | CTC | CCC | ATG | GGG | CCC | AGT | GAG | GAG | GCC | ACA | TGC | CAG | GTC | ACA | 1320 |
| Cys | Leu | Pro | Met | Gly | Pro | Ser | Glu | Glu | Ala | Thr | Cys | Gln | Val | Thr | 440  |
| GAG | CAG | CCT | TCA | CAC | CCA | GGC | CCT | CTT | TCA | GGC | AGC | CCA | GCC | CAG | 1365 |
| Glu | Gln | Pro | Ser | His | Pro | Gly | Pro | Leu | Ser | Gly | Ser | Pro | Ala | Gln | 455  |
| AGT | GCA | CCT | ACT | CTG | GCT | TGC | ACG | CAG | GTC | CCA | CTT | GTC | CTT | GCA | 1410 |
| Ser | Ala | Pro | Thr | Leu | Ala | Cys | Thr | Gln | Val | Pro | Leu | Val | Leu | Ala | 470  |
| GAC | AAT | CCT | GCC | TAC | CGG | AGT | TTT | AGT | GAC | TGC | TGT | AGC | CCG | GCC | 1455 |
| Asp | Asn | Pro | Ala | Tyr | Arg | Ser | Phe | Ser | Asp | Cys | Cys | Ser | Pro | Ala | 485  |
| CCA | AAT | CCT | GGA | GAG | CTG | GCT | CCA | GAG | CAG | CAG | CAG | GCT | GAT | CAT | 1500 |
| Pro | Asn | Pro | Gly | Glu | Leu | Ala | Pro | Glu | Gln | Gln | Gln | Ala | Asp | His | 500  |
| CTG | GAA | GAA | GAG | GAG | CCT | CCA | AGC | CCG | GCT | GAC | CCC | CAT | TCT | TCA | 1545 |
| Leu | Glu | Glu | Glu | Glu | Pro | Pro | Ser | Pro | Ala | Asp | Pro | His | Ser | Ser | 515  |

**FIGURE 2C**

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| GGG | CCA | CCA | ATG | CAG | CCA | GTG | GAG | AGC | TGG | GAG | CAG | ATC | CTT | CAC | 1590 |
| Gly | Pro | Pro | Met | Gln | Pro | Val | Glu | Ser | Trp | Glu | Gln | Ile | Leu | His | 530  |
| ATG | AGT | GTC | CTG | CAG | CAT | GGG | GCA | GCT | GCT | GGC | TCC | ACC | CCA | GCC | 1635 |
| Met | Ser | Val | Leu | Gln | His | Gly | Ala | Ala | Ala | Gly | Ser | Thr | Pro | Ala | 545  |
| CCT | GCC | GGT | GGC | TAC | CAG | GAG | TTT | GTG | CAG | GCA | GTG | AAG | CAG | GGT | 1680 |
| Pro | Ala | Gly | Gly | Tyr | Gln | Glu | Phe | Val | Gln | Ala | Val | Lys | Gln | Gly | 560  |
| GCC | GCC | CAG | GAT | CCT | GGG | GTG | CCT | GGT | GTC | AGG | CCT | TCT | GGA | GAC | 1725 |
| Ala | Ala | Gln | Asp | Pro | Gly | Val | Pro | Gly | Val | Arg | Pro | Ser | Gly | Asp | 575  |
| CCC | GGT | TAC | AAG | GCC | TTC | TCG | AGC | CTG | CTC | AGC | AGC | AAT | GGC | ATC | 1770 |
| Pro | Gly | Tyr | Lys | Ala | Phe | Ser | Ser | Leu | Leu | Ser | Ser | Asn | Gly | Ile | 590  |
| CGC | GGG | GAC | ACA | GCA | GCA | GCG | GGG | ACT | GAC | GAT | GGG | CAT | GGA | GGC | 1815 |
| Arg | Gly | Asp | Thr | Ala | Ala | Ala | Gly | Thr | Asp | Asp | Gly | His | Gly | Gly | 605  |
| TAC | AAG | CCC | TTC | CAG | AAT | CCT | GTT | CCT | AAC | CAG | TCC | CCT | AGC | TCC | 1860 |
| Tyr | Lys | Pro | Phe | Gln | Asn | Pro | Val | Pro | Asn | Gln | Ser | Pro | Ser | Ser | 620  |
| GTG | CCC | TTA | TTT | ACT | TTC | GGA | CTA | GAC | ACG | GAG | CTG | TCA | CCC | AGT | 1905 |
| Val | Pro | Leu | Phe | Thr | Phe | Gly | Leu | Asp | Thr | Glu | Leu | Ser | Pro | Ser | 635  |
| CCT | CTG | AAC | TCA | GAC | CCA | CCC | AAA | AGC | CCC | CCA | GAA | TGC | CTT | GGT | 1950 |
| Pro | Leu | Asn | Ser | Asp | Pro | Pro | Lys | Ser | Pro | Pro | Glu | Cys | Leu | Gly | 650  |
| CTG | GAG | CTG | GGG | CTC | AAA | GGA | GGT | GAC | TGG | GTG | AAG | GCC | CCT | CCT | 1995 |
| Leu | Glu | Leu | Gly | Leu | Lys | Gly | Gly | Asp | Trp | Val | Lys | Ala | Pro | Pro | 665  |
| CCT | GCA | GAT | GAG | GTG | CCC | AAG | CCC | TTT | GGG | GAT | GAC | CTG | GGC | TTT | 2040 |
| Pro | Ala | Asp | Glu | Val | Pro | Lys | Pro | Phe | Gly | Asp | Asp | Leu | Gly | Phe | 680  |
| GGT | ATT | GTG | TAC | TCG | TCC | CTC | ACT | TGC | CAC | TTG | TGT | GGC | CAC | CTG | 2085 |
| Gly | Ile | Val | Tyr | Ser | Ser | Leu | Thr | Cys | His | Leu | Cys | Gly | His | Leu | 695  |
| AAG | CAA | CAC | CAC | AGC | CAG | GAG | GAA | GGT | GGC | CAG | AGC | CCC | ATC | GTT | 2130 |
| Lys | Gln | His | His | Ser | Gln | Glu | Glu | Gly | Gly | Gln | Ser | Pro | Ile | Val | 710  |
| GCT | AGC | CCT | GGC | TGT | GGC | TGC | TGC | TAC | GAT | GAC | AGA | TCA | CCA | TCC | 2175 |
| Ala | Ser | Pro | Gly | Cys | Gly | Cys | Cys | Tyr | Asp | Asp | Arg | Ser | Pro | Ser | 725  |
| CTG | GGG | AGC | CTC | TCG | GGG | GCC | TTG | GAA | AGC | TGT | CCT | GAG | GGA | ATA | 2220 |
| Leu | Gly | Ser | Leu | Ser | Gly | Ala | Leu | Glu | Ser | Cys | Pro | Glu | Gly | Ile | 740  |
| CCA | CCA | GAA | GCC | AAC | CTC | ATG | TCA | GCA | CCC | AAG | ACA | CCC | TCA | AAC | 2265 |
| Pro | Pro | Glu | Ala | Asn | Leu | Met | Ser | Ala | Pro | Lys | Thr | Pro | Ser | Asn | 755  |
| TTG | TCA | GGG | GAG | GGC | AAG | GGC | CCT | GGT | CAC | TCT | CCT | GTT | CCC | AGC | 2310 |
| Leu | Ser | Gly | Glu | Gly | Lys | Gly | Pro | Gly | His | Ser | Pro | Val | Pro | Ser | 770  |
| CAG | ACG | ACC | GAG | GTG | CCT | GTG | GGC | GCC | CTG | GGC | ATT | GCT | GTT | TCT | 2355 |
| Gln | Thr | Thr | Glu | Val | Pro | Val | Gly | Ala | Leu | Gly | Ile | Ala | Val | Ser | 785  |




Fig. 3

**FIGURE 4A**

|            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| ATG        | GGG        | TGG        | CTT        | TGC        | TCT        | GGG        | CTC        | CTG        | TTC        | CCT        | GTG        | AGC        | TGC        | CTG        | -31 |
| Met        | Gly        | Trp        | Leu        | Cys        | Ser        | Gly        | Leu        | Leu        | Phe        | Pro        | Val        | Ser        | Cys        | Leu        | -11 |
| GTC        | CTG        | CTG        | CAG        | GTG        | GCA        | AGC        | TCT        | GGG        | AAC        | ATG        | AAG        | GTC        | TTG        | CAG        | 15  |
| Val        | Leu        | Leu        | Gln        | Val        | Ala        | Ser        | Ser        | Gly        | Asn        | Met        | Lys        | Val        | Leu        | Gln        | 5   |
| GAG        | CCC        | ACC        | TGC        | GTC        | TCC        | GAC        | TAC        | ATG        | AGC        | ATC        | TCT        | ACT        | TGC        | GAG        | 60  |
| Glu        | Pro        | Thr        | Cys        | Val        | Ser        | Asp        | Tyr        | Met        | Ser        | Ile        | Ser        | Thr        | Cys        | Glu        | 20  |
| TGG        | AAG        | ATG        | AAT        | GGT        | CCC        | ACC        | AAT        | TGC        | AGC        | ACC        | GAG        | CTC        | CGC        | CTG        | 105 |
| Trp        | Lys        | Met        | Asn        | Gly        | Pro        | Thr        | Asn        | Cys        | Ser        | Thr        | Glu        | Leu        | Arg        | Leu        | 35  |
| TTG        | TAC        | CAG        | CTG        | GTT        | TTT        | CTG        | CTC        | TCC        | GAA        | GCC        | CAC        | ACG        | TGT        | ATC        | 150 |
| Leu        | Tyr        | Gln        | Leu        | Val        | Phe        | Leu        | Leu        | Ser        | Glu        | Ala        | His        | Thr        | Cys        | Ile        | 50  |
| CCT        | GAG        | AAC        | AAC        | GGA        | GGC        | GCG        | GGG        | TGC        | GTG        | TGC        | CAC        | CTG        | CTC        | ATG        | 195 |
| Pro        | Glu        | Asn        | Asn        | Gly        | Gly        | Ala        | Gly        | Cys        | Val        | Cys        | His        | Leu        | Leu        | Met        | 65  |
| GAT        | GAC        | GTG        | GTC        | AGT        | GCG        | GAT        | AAC        | TAT        | ACA        | CTG        | GAC        | CTG        | TGG        | GCT        | 240 |
| Asp        | Asp        | Val        | Val        | Ser        | Ala        | Asp        | Asn        | Tyr        | Thr        | Leu        | Asp        | Leu        | Trp        | Ala        | 80  |
| GGG        | CAG        | CAG        | CTG        | CTG        | TGG        | AAG        | GGC        | TCC        | TTC        | AAG        | CCC        | AGC        | GAG        | CAT        | 285 |
| Gly        | Gln        | Gln        | Leu        | Leu        | Trp        | Lys        | Gly        | Ser        | Phe        | Lys        | Pro        | Ser        | Glu        | His        | 95  |
| GTG        | AAA        | CCC        | AGG        | GCC        | CCA        | GGA        | AAC        | CTG        | ACA        | GTT        | CAC        | ACC        | AAT        | GTC        | 330 |
| Val        | Lys        | Pro        | Arg        | Ala        | Pro        | Gly        | Asn        | Leu        | Thr        | Val        | His        | Thr        | Asn        | Val        | 110 |
| TCC        | GAC        | ACT        | CTG        | CTG        | CTG        | ACC        | TGG        | AGC        | AAC        | CCG        | TAT        | CCC        | CCT        | GAC        | 375 |
| Ser        | Asp        | Thr        | Leu        | Leu        | Leu        | Thr        | Trp        | Ser        | Asn        | Pro        | Tyr        | Pro        | Pro        | Asp        | 125 |
| AAT        | TAC        | CTG        | TAT        | AAT        | CAT        | CTC        | ACC        | TAT        | GCA        | GTC        | AAC        | ATT        | TGG        | AGT        | 420 |
| Asn        | Tyr        | Leu        | Tyr        | Asn        | His        | Leu        | Thr        | Tyr        | Ala        | Val        | Asn        | Ile        | Trp        | Ser        | 140 |
| GAA        | AAC        | GAC        | CCG        | GCA        | GAT        | TTC        | AGA        | ATC        | TAT        | AAC        | GTG        | ACC        | TAC        | CTA        | 465 |
| Glu        | Asn        | Asp        | Pro        | Ala        | Asp        | Phe        | Arg        | Ile        | Tyr        | Asn        | Val        | Thr        | Tyr        | Leu        | 155 |
| GAA        | CCC        | TCC        | CTC        | CGC        | ATC        | GCA        | GCC        | AGC        | ACC        | CTG        | AAG        | TCT        | GGG        | ATT        | 510 |
| Glu        | Pro        | Ser        | Leu        | Arg        | Ile        | Ala        | Ala        | Ser        | Thr        | Leu        | Lys        | Ser        | Gly        | Ile        | 170 |
| TCC        | TAC        | AGG        | GCA        | CGG        | GTG        | AGG        | GCC        | TGG        | GCT        | CAG        | TGC        | TAT        | AAC        | ACC        | 555 |
| Ser        | Tyr        | Arg        | Ala        | Arg        | Val        | Arg        | Ala        | Trp        | Ala        | Gln        | Cys        | Tyr        | Asn        | Thr        | 185 |
| ACC        | TGG        | AGT        | GAG        | TGG        | AGC        | CCC        | AGC        | ACC        | AAG        | TGG        | CAC        | AAC        | TCC        | TAC        | 600 |
| Thr        | Trp        | Ser        | Glu        | Trp        | Ser        | Pro        | Ser        | Thr        | Lys        | Trp        | His        | Asn        | Ser        | Tyr        | 200 |
| AGG        | GAG        | CCC        | TTC        | GAG        | CAG        | CAC        | CTC        | CTG        | CTG        | GGC        | GTC        | AGC        | GTT        | TCC        | 645 |
| Arg        | Glu        | Pro        | Phe        | Glu        | Gln        | His        | <u>Leu</u> | <u>Leu</u> | <u>Leu</u> | <u>Gly</u> | <u>Val</u> | <u>Ser</u> | <u>Val</u> | <u>Ser</u> | 215 |
| TGC        | ATT        | GTC        | ATC        | CTG        | GCC        | GTC        | TGC        | CTG        | TTG        | TGC        | TAT        | GTC        | AGC        | ATC        | 690 |
| <u>Cys</u> | <u>Ile</u> | <u>Val</u> | <u>Ile</u> | <u>Leu</u> | <u>Ala</u> | <u>Val</u> | <u>Cys</u> | <u>Leu</u> | <u>Leu</u> | <u>Cys</u> | <u>Tyr</u> | <u>Val</u> | <u>Ser</u> | <u>Ile</u> | 230 |
| ACC        | AAG        | ATT        | AAG        | AAA        | GAA        | TGG        | TGG        | GAT        | CAG        | ATT        | CCC        | AAC        | CCA        | GCC        | 735 |
| <u>Thr</u> | Lys        | Ile        | Lys        | Lys        | Glu        | Trp        | Trp        | Asp        | Gln        | Ile        | Pro        | Asn        | Pro        | Ala        | 245 |



FIGURE 4B

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| CGC | AGC | CGC | CTC | GTG | GCT | ATA | ATA | ATC | CAG | GAT | GCT | CAG | GGG | TCA | 780  |
| Arg | Ser | Arg | Leu | Val | Ala | Ile | Ile | Ile | Gln | Asp | Ala | Gln | Gly | Ser | 260  |
| CAG | TGG | GAG | AAG | CGG | TCC | CGA | GGC | CAG | GAA | CCA | GCC | AAG | TGC | CCA | 825  |
| Gln | Trp | Glu | Lys | Arg | Ser | Arg | Gly | Gln | Glu | Pro | Ala | Lys | Cys | Pro | 275  |
| CAC | TGG | AAG | AAT | TGT | CTT | ACC | AAG | CTC | TTG | CCC | TGT | TTT | CTG | GAG | 870  |
| His | Trp | Lys | Asn | Cys | Leu | Thr | Lys | Leu | Leu | Pro | Cys | Phe | Leu | Glu | 290  |
| CAC | AAC | ATG | AAA | AGG | GAT | GAA | GAT | CCT | CAC | AAG | GCT | GCC | AAA | GAG | 915  |
| His | Asn | Met | Lys | Arg | Asp | Glu | Asp | Pro | His | Lys | Ala | Ala | Lys | Glu | 305  |
| ATG | CCT | TTC | CAG | GGC | TCT | GGA | AAA | TCA | GCA | TGG | TGC | CCA | GTG | GAG | 960  |
| Met | Pro | Phe | Gln | Gly | Ser | Gly | Lys | Ser | Ala | Trp | Cys | Pro | Val | Glu | 320  |
| ATC | AGC | AAG | ACA | GTC | CTC | TGG | CCA | GAG | AGC | ATC | AGC | GTG | GTG | CGA | 1005 |
| Ile | Ser | Lys | Thr | Val | Leu | Trp | Pro | Glu | Ser | Ile | Ser | Val | Val | Arg | 335  |
| TGT | GTG | GAG | TTG | TTT | GAG | GCC | CCG | GTG | GAG | TGT | GAG | GAG | GAG | GAG | 1050 |
| Cys | Val | Glu | Leu | Phe | Glu | Ala | Pro | Val | Glu | Cys | Glu | Glu | Glu | Glu | 350  |
| GAG | GTA | GAG | GAA | GAA | AAA | GGG | AGC | TTC | TGT | GCA | TCG | CCT | GAG | AGC | 1095 |
| Glu | Val | Glu | Glu | Glu | Lys | Gly | Ser | Phe | Cys | Ala | Ser | Pro | Glu | Ser | 365  |
| AGC | AGG | GAT | GAC | TTC | CAG | GAG | GGA | AGG | GAG | GGC | ATT | GTG | GCC | CGG | 1140 |
| Ser | Arg | Asp | Asp | Phe | Gln | Glu | Gly | Arg | Glu | Gly | Ile | Val | Ala | Arg | 380  |
| CTA | ACA | GAG | AGC | CTG | TTC | CTG | GAC | CTG | CTC | GGA | GAG | GAG | AAT | GGG | 1185 |
| Leu | Thr | Glu | Ser | Leu | Phe | Leu | Asp | Leu | Leu | Gly | Glu | Glu | Asn | Gly | 395  |
| GGC | TTT | TGC | CAG | CAG | GAC | ATG | GGG | GAG | TCA | TGC | CTT | CTT | CCA | CCT | 1230 |
| Gly | Phe | Cys | Gln | Gln | Asp | Met | Gly | Glu | Ser | Cys | Leu | Leu | Pro | Pro | 410  |
| TCG | GGA | AGT | ACG | AGT | GCT | CAC | ATG | CCC | TGG | GAT | GAG | TTC | CCA | AGT | 1275 |
| Ser | Gly | Ser | Thr | Ser | Ala | His | Met | Pro | Trp | Asp | Glu | Phe | Pro | Ser | 425  |
| GCA | GGG | CCC | AAG | GAG | GCA | CCT | CCC | TGG | GGC | AAG | GAG | CAG | CCT | CTC | 1320 |
| Ala | Gly | Pro | Lys | Glu | Ala | Pro | Pro | Trp | Gly | Lys | Glu | Gln | Pro | Leu | 440  |
| CAC | CTG | GAG | CCA | AGT | CCT | CCT | GCC | AGC | CCG | ACC | CAG | AGT | CCA | GAC | 1365 |
| His | Leu | Glu | Pro | Ser | Pro | Pro | Ala | Ser | Pro | Thr | Gln | Ser | Pro | Asp | 455  |
| AAC | CTG | ACT | TGC | ACA | GAG | ACG | CCC | CTC | GTC | ATC | GCA | GGC | AAC | CCT | 1410 |
| Asn | Leu | Thr | Cys | Thr | Glu | Thr | Pro | Leu | Val | Ile | Ala | Gly | Asn | Pro | 470  |
| GCT | TAC | CGC | AGC | TTC | AGC | AAC | TCC | CTG | AGC | CAG | TCA | CCG | TGT | CCC | 1455 |
| Ala | Tyr | Arg | Ser | Phe | Ser | Asn | Ser | Leu | Ser | Gln | Ser | Pro | Cys | Pro | 485  |
| AGA | GAG | CTG | GGT | CCA | GAC | CCA | CTG | CTG | GCC | AGA | CAC | CTG | GAG | GAA | 1500 |
| Arg | Glu | Leu | Gly | Pro | Asp | Pro | Leu | Leu | Ala | Arg | His | Leu | Glu | Glu | 500  |
| GTA | GAA | CCC | GAG | ATG | CCC | TGT | GTC | CCC | CAG | CTC | TCT | GAG | CCA | ACC | 1545 |
| Val | Glu | Pro | Glu | Met | Pro | Cys | Val | Pro | Gln | Leu | Ser | Glu | Pro | Thr | 515  |

FIGURE 4C

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| ACT | GTG | CCC | CAA | CCT | GAG | CCA | GAA | ACC | TGG | GAG | CAG | ATC | CTC | CGC | 1590 |
| Thr | Val | Pro | Gln | Pro | Glu | Pro | Glu | Thr | Trp | Glu | Gln | Ile | Leu | Arg | 530  |
| CGA | AAT | GTC | CTC | CAG | CAT | GGG | GCA | GCT | GCA | GCC | CCC | GTC | TCG | GCC | 1635 |
| Arg | Asn | Val | Leu | Gln | His | Gly | Ala | Ala | Ala | Ala | Pro | Val | Ser | Ala | 545  |
| CCC | ACC | AGT | GGC | TAT | CAG | GAG | TTT | GTA | CAT | GCG | GTG | GAG | CAG | GGT | 1680 |
| Pro | Thr | Ser | Gly | Tyr | Gln | Glu | Phe | Val | His | Ala | Val | Glu | Gln | Gly | 560  |
| GGC | ACC | CAG | GCC | AGT | GCG | GTG | GTG | GGC | TTG | GGT | CCC | CCA | GGA | GAG | 1725 |
| Gly | Thr | Gln | Ala | Ser | Ala | Val | Val | Gly | Leu | Gly | Pro | Pro | Gly | Glu | 575  |
| GCT | GGT | TAC | AAG | GCC | TTC | TCA | AGC | CTG | CTT | GCC | AGC | AGT | GCT | GTG | 1770 |
| Ala | Gly | Tyr | Lys | Ala | Phe | Ser | Ser | Leu | Leu | Ala | Ser | Ser | Ala | Val | 590  |
| TCC | CCA | GAG | AAA | TGT | GGG | TTT | GGG | GCT | AGC | AGT | GGG | GAA | GAG | GGG | 1815 |
| Ser | Pro | Glu | Lys | Cys | Gly | Phe | Gly | Ala | Ser | Ser | Gly | Glu | Glu | Gly | 605  |
| TAT | AAG | CCT | TTC | CAA | GAC | CTC | ATT | CCT | GGC | TGC | CCT | GGG | GAC | CCT | 1860 |
| Tyr | Lys | Pro | Phe | Gln | Asp | Leu | Ile | Pro | Gly | Cys | Pro | Gly | Asp | Pro | 620  |
| GCC | CCA | GTC | CCT | GTC | CCC | TTG | TTC | ACC | TTT | GGA | CTG | GAC | AGG | GAG | 1905 |
| Ala | Pro | Val | Pro | Val | Pro | Leu | Phe | Thr | Phe | Gly | Leu | Asp | Arg | Glu | 635  |
| CCA | CCT | CGC | AGT | CCG | CAG | AGC | TCA | CAT | CTC | CCA | AGC | AGC | TCC | CCA | 1950 |
| Pro | Pro | Arg | Ser | Pro | Gln | Ser | Ser | His | Leu | Pro | Ser | Ser | Ser | Pro | 650  |
| GAG | CAC | CTG | GGT | CTG | GAG | CCG | GGG | GAA | AAG | GTA | GAG | GAC | ATG | CCA | 1995 |
| Glu | His | Leu | Gly | Leu | Glu | Pro | Gly | Glu | Lys | Val | Glu | Asp | Met | Pro | 665  |
| AAG | CCC | CCA | CTT | CCC | CAG | GAG | CAG | GCC | ACA | GAC | CCC | CTT | GTG | GAC | 2040 |
| Lys | Pro | Pro | Leu | Pro | Gln | Glu | Gln | Ala | Thr | Asp | Pro | Leu | Val | Asp | 680  |
| AGC | CTG | GGC | AGT | GGC | ATT | GTC | TAC | TCA | GCC | CTT | ACC | TGC | CAC | CTG | 2085 |
| Ser | Leu | Gly | Ser | Gly | Ile | Val | Tyr | Ser | Ala | Leu | Thr | Cys | His | Leu | 695  |
| TGC | GGC | CAC | CTG | AAA | CAG | TGT | CAT | GGC | CAG | GAG | GAT | GGT | GGC | CAG | 2130 |
| Cys | Gly | His | Leu | Lys | Gln | Cys | His | Gly | Gln | Glu | Asp | Gly | Gly | Gln | 710  |
| ACC | CCT | GTC | ATG | GCC | AGT | CCT | TGC | TGT | GGC | TGC | TGC | TGT | GGA | GAC | 2175 |
| Thr | Pro | Val | Met | Ala | Ser | Pro | Cys | Cys | Gly | Cys | Cys | Cys | Gly | Asp | 725  |
| AGG | TCC | TCG | CCC | CCT | ACA | ACC | CCC | CTG | AGG | GCC | CCA | GAC | CCC | TCT | 2220 |
| Arg | Ser | Ser | Pro | Pro | Thr | Thr | Pro | Leu | Arg | Ala | Pro | Asp | Pro | Ser | 740  |
| CCA | GGT | GGG | GTT | CCA | CTG | GAG | GCC | AGT | CTG | TGT | CCG | GCC | TCC | CTG | 2265 |
| Pro | Gly | Gly | Val | Pro | Leu | Glu | Ala | Ser | Leu | Cys | Pro | Ala | Ser | Leu | 755  |
| GCA | CCC | TCG | GGC | ATC | TCA | GAG | AAG | AGT | AAA | TCC | TCA | TCA | TCC | TTC | 2310 |
| Ala | Pro | Ser | Gly | Ile | Ser | Glu | Lys | Ser | Lys | Ser | Ser | Ser | Ser | Phe | 770  |
| CAT | CCT | GCC | CCT | GGC | AAT | GCT | CAG | AGC | TCA | AGC | CAG | ACC | CCC | AAA | 2355 |
| His | Pro | Ala | Pro | Gly | Asn | Ala | Gln | Ser | Ser | Ser | Gln | Thr | Pro | Lys | 785  |
| ATC | GTG | AAC | TTT | GTC | TCC | GTG | GGA | CCC | ACA | TAC | ATG | AGG | GTC | TCT | 2400 |
| Ile | Val | Asn | Phe | Val | Ser | Val | Gly | Pro | Thr | Tyr | Met | Arg | Val | Ser | 800  |

```

1  MGWLC SGL LFPV SCLV LLQV ASSGNMKVLQEPTCVSDYMSISTCEWK MNG 50
   || || | | | | | | | | | | | | | | | | | | | |
1  MGR LCTK FLTSV GCLILL LV TGSGS I KVLGEPTCFSDYIRTSTCEWFLDS 50

51 PTNCSTELRLLYQLVFL.LSEAHTCIPENNGGAGCVCHLLMDDVVSADNY 99
   || | | | | | | | | | | | | | | | | | | | |
51 AVDCSSQLCLHYRLMFFFESENLTICIPRNSASTVCVCHMEMNRPVQSDRY 100

100 TDLWAGQQLLWKGSFKPSEHV KPRAPGNLTVHTNVSDTLLLTWSNPYP 149
   || | | | | | | | | | | | | | | | | | | | |
101 QMELWAEHRQLWQGSFSPSGNVKPLAPDNLT LHTNVSD EWL LTWNNLYPS 150

150 DNYLYNHLYAVNIWSENDPA DFR IYNVTYLEPSLR IAASTL KSGISYRA 199
   | | | | | | | | | | | | | | | | | | | |
151 NNLLYKDLISMVNISREDNPAEFIVYNVTYKEPRLSFPINILMSGVYYTA 200

200 RVRAWAQCYNTTWSEWSPSTKWHNSYREFEQHLLGVSVSCIVILAVCL 249
   || | | | | | | | | | | | | | | | | | | | |
201 RVRVRSQILTGTWSEWSPSITWYNHFQLPLIQRLPLGVTISCLCIPFLCL 250

250 LCYVSITKIKKEWWDQIPNPARSRLVAIIQDAQGSQWEKRSRGQEPAC 299
   || | | | | | | | | | | | | | | | | | | | |
251 FCYFSITKIKKIWWDQIPTPARSPLVAIIQDAQVPLWDKQTRSQUESTKY 300

300 PHWKNC LTKLLPCFLEHNMKRDEDPHKA AKEMPFQ GSGKSAWCPVEISK 349
   || || | | | | | | | | | | | | | | | | | | | |
301 PHWKTCLDKLLPCLLKHRVKKKTDFPKAAPTKSLQSPGKAGWCPMEVSRT 350

350 VLWPE..SISVVRVELFEAPVECEEEEEVEEEKGSFCASPESSRD.DFQ 396
   || || | | | | | | | | | | | | | | | | | | | |
351 VLWPENVS SVVVRCELF EAPVQNV EEEDEIVKEDLSMSPENSGGCGFQ 400

397 EGREGIVARL TESLFLDLLGEENG GFCQQDMGESCLLP SSGSTSAHMPWD 446
   | | | | | | | | | | | | | | | | | | | |
401 ESQADIMARLTENLFSDLL EAENGGLGQSALAESCSPLPSGSGQASVSWA 450

447 EFPSAGPK EAPPWGKEQPLHLEPSPPASPTQSPDNLTCTETPLVIAGNPA 496
   | | | | | | | | | | | | | | | | | | | |
451 CLPMGPSEEATCQVTEQPSHGP.LSGSPAQSAPT LACTQVPLVLADNPA 499

497 YRSFSNSLSQSPCPRELGPDP LLARHLEEVEPEMPCVPQLSEPTTVPOPE 546
   || || | | | | | | | | | | | | | | | | | |
500 YRSFSDCCSPAPNPGELAPEQQQADHLEEEPPSPADPHSSGP...PMQP 546

547 PETWEQILRRNVLQHGA AAAPVSAPTSGYQEFVHAVEQGGTQASAVVGLG 596
   | | | | | | | | | | | | | | | | | | | |
547 VESWEQILHMSVLQHGA AAGSTPAPAGGYQEFVQAVKQGAAQDPGVPGVR 596

597 PPGEAGYKAFSSLLASSAVSPEKCGFGASSGEEGYKPFQDLIPGCPGDPA 646
   | | | | | | | | | | | | | | | | | | | |
597 PSGDPGYKAFSSLLSSNGIRGDTAAAGTDDGHGGYKPFQNPVP...NQS 642

```

**FIGURE 5B**

647 PVPVPLFTFGLDREPPRSPQSSHLPSSSPÉHLGLEPGEKVEDMPKPPLPQ 696  
 | | | | | | | | | | | | | | | | | | | | | |  
 643 PSSVPLFTFGLDTELSPSPLNSDPPKSPPECLGLELGLKGGDWVKAPPPA 692  
 697 EQATDPLVDSLGSIGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGC 746  
 | | | | | | | | | | | | | | | | | | | | | |  
 693 DQVPKPFGDDLGFIVYSSLTCHLCGHLKQHHSQEEGGQSPIVASPGCGC 742  
 747 CCGDRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSSFH 796  
 | | | | | | | | | | | | | | | | | | | | | |  
 743 CYDDRSPSLGSLSGALESCPEGIPPEANLMSAPKTPSNLSGEGK..... 786  
 797 PAPGNAQSSSQTPKIVNFVSVGPTYMRVS 825  
 | | | | | | | | | | | | | | | | | | | | | |  
 787 .GPGHSPVPSQTTE....VPVGALGIAVS 810